10-K
1
f10k2020_zonedproperties.htm
ANNUAL REPORT
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-K
(Mark
One)
☒ ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the fiscal year ended: December 31, 2020
or
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from ___________ to ___________
Commission
file number: 000-51640
ZONED
PROPERTIES, INC.
(Exact
name of registrant as specified in its charter)
Nevada
46-5198242
(State
or other jurisdiction of
incorporation or organization)
(I.R.S.
Employer
Identification No.)
14269
N. 87th Street, #205, Scottsdale, AZ
85260
(Address
of principal executive offices)
(Zip
Code)
Registrant’s
telephone number, including area code: (877) 360-8839
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
Trading
Symbol
Name
of each exchange on which registered
N/A
N/A
N/A
Securities
registered pursuant to Section 12(g) of the Exchange Act: Common stock, par value $0.001
Indicate
by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐
No ☒
Indicate
by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes ☒ No ☐
Indicate
by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer
☐
Accelerated
filer
☐
Non-accelerated
filer
☒
Smaller reporting
company
☒
Emerging growth
company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The
aggregate market value of the voting and non-voting common equity held by non-affiliates based upon the closing price of $0.131
per share of common stock as of June 30, 2020 (the last business day of the registrant’s most recently completed second
fiscal quarter), was $1,165,557.
Indicate
the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date:
12,141,548 shares of common stock are issued and outstanding as of March 30, 2021.
Documents
Incorporated by Reference
None
ZONED
PROPERTIES, INC.
TABLE
OF CONTENTS
Page
PART I
Item 1.
Business
1
Item 1A.
Risk Factors
10
Item 1B.
Unresolved Staff Comments
18
Item 2.
Properties
18
Item 3
Legal Proceedings
18
Item 4.
Mine Safety Disclosures
18
PART II
Item 5.
Market for Registrant’s
Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
19
Item 6.
Reserved
21
Item 7.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
21
Item 7A.
Quantitative and Qualitative Disclosures About
Market Risk
29
Item 8.
Financial Statements and Supplementary Data
30
Item 9.
Changes in and Disagreements with Accountants
on Accounting and Financial Disclosures
30
Item 9A.
Controls and Procedures
30
Item 9B.
Other Information
30
PART III
Item 10.
Directors, Executive Officers and Corporate
Governance
31
Item 11.
Executive Compensation
34
Item 12.
Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters
38
Item 13.
Certain Relationships and Related Transactions,
and Director Independence
39
Item 14.
Principal Accountant Fees and Services
40
PART IV
Item 15.
Exhibits and Financial Statement Schedules
41
Item 16.
Form 10-K Summary
43
Signatures
44
i
PART
I
ITEM
1. BUSINESS
The
following discussion should be read in conjunction with our consolidated financial statements and the related notes to the consolidated
financial statements that appear elsewhere in this annual report on Form 10-K.
As used in this annual report on Form 10-K
and unless otherwise indicated, the terms the terms “Zoned Properties”, “Company,” “we,” “us,”
or “our” refer to Zoned Properties, Inc. and its wholly owned subsidiaries, Gilbert Property Management, LLC, Green
Valley Group, LLC, Kingman Property Group, LLC, Chino Valley Properties, LLC, Zoned Oregon Properties, LLC, Zoned Colorado Properties,
LLC, Zoned Illinois Properties, LLC, Zoned Arizona Properties, LLC, Zoned Advisory Services, LLC and Zoned Properties Brokerage,
LLC, as the context may require.
Overview
Zoned
Properties, Inc. (“Zoned Properties” or the “Company”), was incorporated in the State of Nevada on August
25, 2003. The Company is a strategic real estate development firm whose primary mission is to provide specialized real estate
and sustainability services for clients in the regulated cannabis industry, positioning the company for real estate investments
and revenue growth . We intend to pioneer sustainable development for emerging industries, including the regulated cannabis
industry. We are an accredited member of the Better Business Bureau, the U.S. Green Building Council, and the Forbes Real Estate
Council. We focus on investing capital to acquire and develop commercial properties to be leased on a triple-net basis, and engaging
clients that face zoning, permitting, development, and operational challenges. We provide development strategies and advisory
services that could potentially have a major impact on cash flow and property value. We do not grow, harvest, sell or distribute
cannabis or any substances regulated under United States law such as the Controlled Substance Act of 1970, as amended (the “CSA”).
The
Company has the following wholly owned subsidiaries:
●
Gilbert Property
Management, LLC (“Gilbert”) was organized in the State of Arizona on February 10, 2014.
●
Chino Valley Properties,
LLC (“Chino Valley”) was organized in the State of Arizona on April 15, 2014.
●
Kingman Property
Group, LLC (“Kingman”) was organized in the State of Arizona on April 15, 2014.
●
Green Valley Group,
LLC (“Green Valley”) organized in the State of Arizona on April 15, 2014.
●
Zoned Oregon Properties,
LLC was organized in the State of Oregon on June 16, 2015.
●
Zoned Colorado Properties,
LLC (“Zoned Colorado”) was organized in the State of Colorado on September 17, 2015.
●
Zoned Illinois Properties, LLC was organized
in the State of Illinois on July 15, 2015.
●
Zoned Arizona Properties, LLC (“Zoned
Arizona”) was organized in the State of Arizona on June 2, 2017.
●
Zoned Advisory Services, LLC (“Zoned Advisory”)
was organized in the State of Arizona on July 27, 2018.
●
Zoned Properties Brokerage, LLC (“Zoned
Brokerage”) was organized in the State of Arizona on March 17, 2021.
In
March 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures
worldwide. The Company is monitoring this closely, and although operations have not been materially affected by the COVID-19 outbreak
to date, the ultimate duration and severity of the outbreak and its impact on the economic environment and our business is uncertain.
Currently, all of the properties in the Company’s portfolio are open to its Significant Tenants and their customers and
will remain open pursuant to state and local government requirements. The Company did not experience in 2020, and does not foresee
in 2021, any material changes to its operations from COVID-19. The Company’s tenants are continuing to generate revenue
at these properties and they have continued to make rental payments in full and on time and we believe the tenants’ liquidity
position is sufficient to cover its expected rental obligations. Accordingly, while the Company does not anticipate an impact
on its operations, it cannot estimate the duration of the pandemic and potential impact on its business if the properties must
close or if the tenants are otherwise unable or unwilling to make rental payments. In addition, a severe or prolonged economic
downturn could result in a variety of risks to the Company’s business, including weakened demand for its properties and
a decreased ability to raise additional capital when needed on acceptable terms, if at all.
Our
Business
Zoned
Properties is a strategic real estate development firm whose primary mission is to provide specialized real estate and sustainability
services for clients in the regulated cannabis industry, positioning the company for real estate investments and revenue growth .
We intend to pioneer sustainable development for emerging industries, including the regulated cannabis industry. We are an
accredited member of the Better Business Bureau, the U.S. Green Building Council, and the Forbes Real Estate Council. We focus
on investing capital to acquire and develop commercial properties to be leased on a triple-net basis, and engaging clients that
face zoning, permitting, development, and operational challenges. We provide development strategies and advisory services that
could potentially have a major impact on cash flow and property value. We do not grow, harvest, sell or distribute cannabis or
any substances regulated under United States law such as the CSA.
1
We
are in the process of developing and expanding multiple business divisions; including an advisory services division, a licensed
commercial real estate brokerage division, a real estate division focused on franchise services, a real estate division focused
on real estate data, and a nonprofit charitable organization to focus on community prosperity. Each of these operating divisions
are important elements of the overall business development strategy for long-term growth. We believe in the value of building
relationships with clients and local communities in order to position the Company for long-term portfolio and revenue growth backed
by sophisticated, safe, and sustainable assets and clients.
The
core of our business involves identifying and developing commercial properties that intend to operate within highly regulated
industries, including the regulated cannabis industry. Within highly regulated industries, local municipalities typically develop
strict regulations, including zoning and permitting requirements related to commercial real estate, that dictate the specific
locations and parameters under which regulated properties can operate. These regulations often include complex permitting processes
and can include non-standard codes governing each location; for example, restricting a regulated property or facility from operating
within a certain distance of any parks, schools, churches, or residential districts, or restricting a regulated property from
operating outside a defined set of hours of operation. When an organization can collaborate with local representatives, a proactive
set of rules and regulations can be established and followed to meet the needs of both the regulated operators and the local community.
The
Company currently maintains a portfolio of properties that we own, develop, and lease. We currently lease land and/or building
space at all five of the properties in our portfolio. Four of the properties are leased to licensed and regulated cannabis tenants
and are located in areas with established zoning and permitting procedures. Two of the leased properties are zoned and permitted
as licensed and regulated cannabis dispensaries, and two of the leased properties are zoned and permitted as licensed and regulated
cannabis cultivation facilities. Each regulated property may undergo a non-standard development process. Various development requirements
in this process may include initial property identification, zoning authorization, and permitting guidance in order to qualify
a commercial property for subsequent architectural design, utility installation, construction and development, property management,
facilities management systems, and security system installation.
There
are significant challenges that take place when zoning, permitting, and developing facilities that intend to operate within a
regulated industry, including the regulated cannabis industry. Each state and local jurisdiction may adopt specific zoning and
permitting regulations that may be unique compared to alternative jurisdictions. The Company has gained valuable knowledge and
developed best practices in this area by successfully completing four major projects in the state of Arizona, a highly regulated
market for the regulated cannabis industry. The Company intends to replicate this business model in other states as markets mature
and rules and regulations are established.
The
process for obtaining zoning authorizations and permitting for a regulated cannabis facility can take several months to complete.
The process primarily involves working directly with the local government representatives. Notwithstanding proper zoning and permitted
use, we may work with local zoning authorities in order to revise zoning codes and regulations. The Company has been involved
with local representatives for each of the properties currently held in our portfolio and on behalf of third-part client properties.
For example, the Company worked directly with local representatives in Tempe, Arizona to update the local zoning code that regulates
licensed cannabis facilities. The successfully adoption of these code amendments directly impact the continued development of
any licensed cannabis facilities that operate within municipal limits.
In
the event a property is not currently zoned or does not currently allow permitted use as a regulated cannabis facility, we may
work with local authorities to seek changes to existing zoning or permitted use. Our efforts may not be successful. For example,
our property located in Gilbert, Arizona has not been successfully zoned and permitted for a prospective regulated cannabis facility
nor has it been leased to a licensed cannabis operator. We may lease this property to a non-cannabis tenant in the interim or
divest our ownership of the property entirely.
The
Company has established a network of experts in the fields of real estate, design, construction, operations, and corporate social
responsibility in order to provide tenants and clients with comprehensive solutions to best meet their needs. We require our prospective
tenants and clients to go through extensive due diligence in order to meet the Company’s standards as sophisticated and
experienced operators.
Our
vision is to be recognized for setting the standard in sustainable development for emerging industries, while increasing community
prosperity and shareholder value. We believe that a focus on real estate and the sustainable development of properties will bring
value to the local communities in which we operate and to local stakeholders. While we intend to expand into a variety of emerging
industries, our current focus is on developing projects within the regulated cannabis industry.
We
are the sole member of nine limited liability companies: Zoned Advisory Services, LLC (“Zoned Advisory Services”),
Zoned Arizona Properties, LLC (“Zoned Arizona”), Gilbert Property Management LLC (“Gilbert Management”),
Green Valley Group LLC (“Green Valley Group”), Kingman Property Group LLC (“Kingman Property”), Chino
Valley Properties LLC (“Chino Valley Properties”), Zoned Colorado Properties LLC (“Zoned Colorado”), Zoned
Illinois Properties LLC (“Zoned Illinois”), and Zoned Oregon Properties LLC (“Zoned Oregon”). Five of
these entities own our properties: Zoned Arizona, Gilbert Management, Green Valley Group, Kingman Property, and Chino Valley Properties
have all acquired land and/or real property.
Multiple
state-licensed operators from across the United States have approached Zoned Properties for strategic partnership and/or advisory
services for development and prospective sale-lease back arrangements. We are continuously evaluating these projects as we seek
development partnerships, prospective sale-lease back arrangements, and explore financing terms with capital funding sources.
2
We
believe that we are well positioned to benefit from ancillary development opportunities that the regulated cannabis industry presents
without having to deal with the risk of directly cultivating, distributing, or dispensing the product, which is still illegal
under federal law.
Our
initial holdings and acquisition targets have been in the State of Arizona. Unlike many other states that have legalized and regulated
cannabis, Arizona’s program has some of the strictest regulations in the country and limits the number of dispensaries that
will be allowed to be open and operate within the state. While there are hundreds of dispensaries in Denver, Colorado, the entire
state of Arizona can have a maximum of 130 operating dispensaries under current legislation. Two of our properties in Arizona
(Kingman and Green Valley) are leased to licensed operators that have been awarded dispensary licenses. This limitation on the
number of dispensaries permitted to operate in Arizona under current legislation will limit our ability to purchase additional
property in Arizona for lease to dispensary operators.
Recent
Corporate History and Transactions
On
April 22, 2016, Zoned Colorado Properties, LLC (“Zoned Colorado”), a wholly owned subsidiary of the Company, entered
into a Contract to Buy and Sell Real Estate (the “Parachute Agreement”) with Parachute Development Corporation (“Seller”)
pursuant to which Zoned Colorado agreed to purchase, and Seller agreed to sell, property in Parachute, Colorado (the “Property”)
for a purchase price of $499,857. Of the total purchase price, $274,857, or 55%, was to be paid in cash at closing and $225,000,
or 45%, was to be financed by Seller at an interest rate of 6.5%, amortized over a five-year period, with a balloon payment at
the end of the fifth year. Pursuant to the terms of the Parachute Agreement, the parties cooperated in good faith to complete
due diligence during a period of 45 days following execution of the Parachute Agreement. The closing was subject to certain contingencies,
including that Zoned Colorado must obtain acceptable financing for the purchase and development of the Property, the grant of
a special use permit by the Town of Parachute, approval of a protected development deal or equivalent agreement by the Town of
Parachute, execution of a lease agreement by a prospective tenant and the prospective tenant’s obtaining a license to cultivate
on the Property. Pursuant to the terms of the Parachute Agreement, Zoned Colorado had a right of first refusal on eleven additional
lots owned by Seller in Parachute, Colorado. In April 2016, the Company paid a refundable deposit of $45,000 into escrow in connection
with the Parachute Agreement. In January 2021, the Parachute Agreement was mutually terminated and the refundable deposit of $45,000
was returned to the Company.
On
May 1, 2018, Zoned Arizona, Green Valley Group, Kingman Property, and Chino Valley Properties executed lease agreements with our
Significant Tenant at each of the respective properties. These locations generate rental revenue. The lease agreements have a
22-year term, expiring on April 30, 2040. Additionally, we own land located in Gilbert, Arizona that is leased as vacant land.
The
leases dated May 1, 2018, with Zoned Arizona, Green Valley Group, Kingman Property, and Chino Valley Properties each include a
Guarantee of Payment and Performance by Mr. Abrams and the tenant organizations.
Also
on May 1, 2018, the Company entered into that certain Confidential Advisory Services Agreement by and between the Company and
Broken Arrow Herbal Center, Inc. (“Broken Arrow”) (the “Broken Arrow CASA”), with a term expiring on April
30, 2040, unless earlier terminated as provided in the Broken Arrow CASA. Additionally, on May 1, 2018, the Company entered into
that certain Confidential Advisory Services Agreement by and between the Company and CJK, Inc. (“CJK”) (the “CJK
CASA”), with a term expiring on April 30, 2040, unless earlier terminated as provided in the CJK CASA. Each of the Broken
Arrow CASA and the CJK CASA may be terminated prior to the expiration of the respective term upon the occurrence of any of the
following: (a) by the Company for any reason at any time upon 30 calendar days’ written notice to the other party; (b) by
either party immediately upon the mutual agreement of the parties, evidenced by a writing signed by the parties; or (c) immediately
by either party in the event of an actual finding, by a court of competent jurisdiction, of fraud, gross negligence or willful
misconduct of the other party in connection with these agreements. Pursuant to the terms of the Broken Arrow CASA and CJK CASA,
Broken Arrow and CJK engaged the Company to perform certain advisory services in exchange for a fee equal to 10% of Broken Arrow’s
and CJK’s gross revenues (the “Revenue Fee”), commencing January 2019. The Revenue Fee was to be paid on a monthly
basis, no later than 30 calendar days following the end of the immediately preceding calendar month, and the amount of such monthly
payment of the Revenue Fee is equal to the product of (a) 10%, multiplied by (b) the gross revenues of Broken Arrow or CJK, as
the case may be, for such immediately preceding calendar month. Notwithstanding the foregoing, upon the filing of the federal
or state tax returns of Broken Arrow or CJK, as the case may be, (i) the advisory client shall calculate the Revenue Fee based
on the amount of the advisory client’s gross revenue reported on such federal or state tax returns, and (ii), if the amount
of such calculation is greater than the sum of all monthly Revenue Fees payable to the Company under the Broken Arrow CASA or
the CJK CASA, as the case may be, the applicable advisory client is required to pay to the Company the amount of such difference,
which amount is in addition to all monthly Revenue Fees due to the Company under the Broken Arrow CASA or the CJK CASA.
Through
December 31, 2018, each of Messrs. Abrams and Carra was a significant stockholder of the Company.
3
Effective
January 1, 2019, the Company, Christopher Carra, Alan Abrams, Clayton Abrams Revocable Trust (the “Clayton Abrams Trust”),
and Kyle Abrams Revocable Trust (the “Kyle Abrams Trust” and together with the Clayton Abrams Trust, the “Trusts”)
entered into a Stock Redemption Agreement (the “Stock Redemption Agreement”). Prior to entry into the Stock Redemption
Agreement, (i) Mr. Carra was the owner 2,028,335 shares of the Company’s common stock, representing approximately 11.6%
of the Company’s outstanding shares as of January 1, 2019, and (ii) Mr. Abrams, together with the Trusts (collectively,
the “Abrams Affiliates”), owned 3,611,669 shares of the Company’s common stock, representing approximately 20.7%
of the Company’s outstanding common stock as of January 1, 2019. Pursuant to SEC rules, each of Messrs. Carra and Abrams
was deemed to be a “related person” due solely to their status as significant stockholders of the Company. Pursuant
to the terms of the Stock Redemption Agreement, the parties agreed that the Company would redeem an aggregate of 5,640,004 owned
by Mr. Carra and the Abrams Affiliates (the “Stock Redemption”) such that Messrs. Carra and Abrams would no longer
be stockholders of the Company and would no longer be deemed to be “related persons” under SEC rules. In exchange
for the Stock Redemption, the parties agreed that:
●
The
Company and Broken Arrow, which was owned at the time of the transaction, in whole or in part, directly or indirectly, by
Messrs. Abrams and Carra, amended the Broken Arrow CASA to reduce the gross revenue fee payable by Broken Arrow from 10% of
gross revenue to 0% of gross revenue,
●
The
Company and CJK, which was owned at the time of the transaction, in whole or in part, directly or indirectly, by Messrs. Abrams
and Carra, amended the CJK CASA to reduce the gross revenue fee payable by CJK from 10% of gross revenue to 0% of gross revenue,
●
The
Company and Mr. Abrams amended the convertible debenture dated January 9, 2017 (the “Abrams Debenture”) to extend
the maturity date of the Abrams Debenture from January 9, 2022 until January 9, 2030, and
●
Chino
Valley and Broken Arrow amended the Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018
(the “Chino Valley Lease”) to increase the monthly base rent payable by Broken Arrow from $35,000 to $40,000.
Following
effectiveness of the Stock Redemption and the transactions set forth above:
●
Messrs.
Carra and Abrams no longer beneficially own any shares of the Company’s common stock. Accordingly, they are no longer
be significant stockholders of the Company or “related persons” under the SEC rules.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between Chino Valley and Broken Arrow
continues in full force and effect, except as amended by the Chino Valley Lease Amendment to increase the monthly base rent
payable by Broken Arrow from $35,000 to $40,000.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between Green Valley and Broken Arrow
continues in full force and effect.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement (concerning the Company’s Tempe, Arizona property)
dated May 1, 2018 between Zoned Arizona and CJK continues in full force and effect.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between Kingman and CJK continues in
full force and effect.
Chino
Valley
On
May 29, 2020, Chino Valley and Broken Arrow entered into a second amendment to the 2018 Chino Valley Lease, as amended (the “2020
Chino Valley Amendment”), effective May 31, 2020 (“Effective Date”). Pursuant to the terms of the 2020 Chino
Valley Amendment, among other things, the base rent was adjusted to $32,800 per month, and the base rent was abated from June
1, 2020 to July 31, 2020. Any increase in the rentable area of the leased premises will result in an increase in all amounts calculated
based on the same, including, without limitation, base rent. Pursuant to the terms of the 2020 Chino Valley Amendment, the parties
agreed that if there is any change in laws such that the dispensing, sale or cultivation of regulated cannabis upon the premises
is prohibited or materially and adversely affected as mutually and reasonably determined by Chino Valley and Broken Arrow, Broken
Arrow may terminate the 2018 Chino Valley Lease, as amended, by delivering written notice to Chino Valley, together with a termination
payment which shall be the sum of (i) any unpaid rent and interest, plus (ii) 5% of the base rent which would have been earned
after termination for the balance of the term. In addition, the parties agreed that from the period from the Effective Date to
June 30, 2022 (the “Improvement Period”), Broken Arrow will and/or Broken Arrow will cause its affiliate, CJK, to
invest a combined total of at least $8,000,000 of improvements (“Investment by Tenants”) in and to the property that
is the subject of the Chino Valley Lease and the property that is the subject of the Tempe Lease (discussed below, and collectively
referred to as the “Facilities”). If Broken Arrow and/or CJK fails to deliver to the Company receipted bills for hard
and soft costs of improvements to the Facilities totaling at least $8,000,000 on or before June 30, 2022, Broken Arrow will be
in default under the Chino Valley Lease and Tempe Lease, as amended.
Green
Valley
On
May 29, 2020, Green Valley and Broken Arrow entered into the First Amendment (the “Green Valley Amendment”) to the
Green Valley Lease, effective May 31, 2020. Pursuant to the terms of the Green Valley Amendment, among other things, the parties
agreed to abate the fixed base rent of $3,500 from June 1, 2020 to July 31, 2020. In addition, the Green Valley Amendment provides
that any increase in the rentable area of the leases premises will result in an increase in all amounts calculated based on the
same, including, without limitation, base rent. The parties also agreed that if there is any change in laws such that the dispensing,
sale or cultivation of cannabis upon the premises is prohibited or materially and adversely affected as mutually and reasonably
determined by Green Valley and Broken Arrow, Broken Arrow may terminate the Green Valley Lease by delivering written notice to
Green Valley, together with a termination payment which shall be the sum of (i) any unpaid rent and interest, plus (ii) 5% of
the base rent which would have been earned after termination for the balance of the term.
4
Tempe
On
May 29, 2020, Zoned Arizona and CJK entered into the First Amendment (the “Tempe Amendment”) to the Tempe Lease, effective
May 31, 2020. Pursuant to the terms of the Tempe Amendment, among other things, the base rent was increased to $49,200 per month,
and the base rent was abated from June 1, 2020 to July 31, 2020. Any increase in the rentable area of the leased premises will
result in an increase in all amounts calculated based on the same, including, without limitation, base rent. Pursuant to the terms
of the Tempe Amendment, the parties agreed that if there is any change in laws such that the dispensing, sale or cultivation of
cannabis upon the premises is prohibited or materially and adversely affected as mutually and reasonably determined by Zoned Arizona
and CJK, CJK may terminate the Tempe Lease by delivering written notice to Zoned Arizona, together with a termination payment
which shall be the sum of (i) any unpaid rent and interest, plus (ii) 5% of the base rent which would have been earned after termination
for the balance of the term. In addition, under the Tempe Amendment the parties agreed to an Investment by Tenant (as defined
above in the subheading Chino Valley ) to the property that is the subject of the Chino Valley Lease and the property that
is the subject of the Tempe Lease. If Broken Arrow and/or CJK fails to deliver to the Company receipted bills for hard and soft
costs of improvements to the Facilities totaling at least $8,000,000 on or before June 30, 2022, Broken Arrow and CJK will be
in default under the Chino Valley Lease and Tempe Lease, as amended.
Kingman
On
May 29, 2020, Kingman and CJK entered into the First Amendment (the “Kingman Amendment”) to the Kingman Lease, effective
May 31, 2020. Pursuant to the terms of the Kingman Amendment, among other things, the parties agreed to abate the $4,000 base
rent from June 1, 2020 to July 31, 2020. In addition, the Kingman Amendment provides that any increase in the rentable area of
the leases premises will result in an increase in all amounts calculated based on the same, including, without limitation, base
rent. The parties also agreed that if there is any change in laws such that the dispensing, sale or cultivation of cannabis upon
the premises is prohibited or materially and adversely affected as mutually and reasonably determined by Kingman and CJK, CJK
may terminate the Kingman Lease by delivering written notice to Kingman, together with a termination payment which shall be the
sum of (i) any unpaid rent and interest, plus (ii) 5% of the base rent which would have been earned after termination for the
balance of the term.
CJK
and Broken Arrow, together, operate under the company brand, “Hana Meds”, and are referred to as the Company’s
Significant Tenants.
During
the years ended December 31, 2020 and 2019, substantially all of the Company’s real estate properties are leased under triple-net
leases to tenants that are controlled by one entity (each, a “Significant Tenant” and collectively, the “Significant
Tenants”). For the years ended December 31, 2020 and 2019, rental and advisory revenue associated with the Significant Tenants
amounted to $1,176,666 and $1,146,654, which represents 96.8% and 91.0% of the Company’s total revenues, respectively. As
of December 31, 2020 and 2019, the Company had an asset concentration related to the Significant Tenants. As of December 31, 2020
and 2019, the Significant Tenants represented approximately 83.2% and 87.1% of the Company’s total assets, respectively.
KCB
Jade Holdings, LLC Investment
On
March 19, 2020, the Company made an initial investment of $100,000 into KCB Jade Holdings, LLC (“KCB”). In exchange
for the investment, KCB issued to the Company a convertible debenture (the “Original Debenture”) dated March 19, 2020
(the “Issuance Date”) in the original principal amount of $100,000. The Original Debenture bears interest at the rate
of 6.5% per annum and matures on March 19, 2025 (the “Maturity Date”).
Interest
on the outstanding principal sum of the Original Debenture commences accruing on the Issuance Date and is computed on the basis
of a 365-day year and the actual number of days elapsed, and shall be payable annually due by the first day of each calendar anniversary
following the Issuance Date.
KCB
may prepay the Original Debenture at any point after 18 months following the Issuance Date, in whole or in part. However, if KCB
elects to prepay the Original Debenture prior to the Maturity Date or prior to any conversion as provided in the Original Debenture
in whole or in part, the Company will be entitled to receive a number of KCB units, in addition to such prepayment amount, constituting
10% of the total outstanding units and 10% of the total percentage interest following such issuance and at the time of such issuance.
On
or after six months from the Issuance Date, the Company may convert all or a portion of the principal balance and all accrued
and unpaid interest due into a number of units equal to the proportion of the outstanding amount being converted multiplied by
33% of the total number of units issued and outstanding at the time of conversion, constituting 33% of the total percentage interest
(the “Conversion Percentage”). If KCB defaults on payment of the Original Debenture, the Company may, at its option,
extend all conversion rights, through and including the date KCB tenders or attempts to tender payment in full of all amounts
due under the Original Debenture. Conversion rights terminate upon acceptance by the Company of payment in full of principal,
accrued interest and any other amounts due under the Original Debenture.
5
If
(i) KCB does not elect to exercise its rights of prepayment prior to the Maturity Date, (ii) the Company does not elect to exercise
its rights of conversion, and (iii) KCB pays to the Company all outstanding principal and interest accrued and due under the terms
of the Original Debenture on the Maturity Date, the Company will still be entitled to receive a number of units, in addition to
such payment amount, constituting 8% of the total outstanding units and 8% of the total percentage interest following such issuance
and at the time of such issuance.
For
purposes of the Original Debenture, an “Event of Default” will be deemed to have occurred upon the occurrence of any
of the following:
(a) KCB
fails to make any payment of the principal, interest, costs, indemnities, or expenses
pursuant to the Original Debenture when and as the same shall become due and payable;
(b) There
occurs any default, whether in whole or in part, in the due observance or performance
of any obligations or other covenants, terms or provisions to be performed by KCB under
the Original Debenture or any of the representations and warranties of KCB ceases to
be true and correct in all respects;
(c) KCB
makes a general assignment for the benefit of its creditors;
(d) KCB
applies for or consents to the appointment of a receiver, trustee, assignee, custodian,
sequestrator, conservator, liquidator or similar official for itself or any of its assets
and properties;
(e) KCB
voluntarily commences any proceeding or file any petition seeking liquidation, reorganization
or other relief as a debtor under the United States Bankruptcy Code or any other liquidation,
conservatorship, bankruptcy, general assignment for the benefit of creditors, moratorium,
rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws
of the United States or other applicable jurisdictions from time to time in effect and
affecting the rights of creditors generally (collectively, the “Debtor Relief Laws”);
(f) An
involuntary proceeding is commenced or an involuntary petition is filed against KCB seeking
(1) liquidation, reorganization or other relief in respect of KCB or its debts, or of
a substantial part of its assets, under any Debtor Relief Law, or (2) the appointment
of a receiver, trustee, assignee, custodian, sequestrator, conservator, liquidator or
similar official for itself or any of its assets and properties;
(g) KCB
consents to the institution of or fails to contest in a timely and appropriate manner,
any proceeding or petition described in clause (f) above.
Upon
the occurrence of an Event of Default, the entire principal balance and accrued and unpaid interest outstanding under the Original
Debenture, and all other obligations of KCB under the Original Debenture, will be immediately due and payable and the Company
may exercise any and all rights, power and remedies available to it at law or in equity or other appropriate proceeding, whether
for the specific performance of any covenant or agreement contained in the Original Debenture and proceed to enforce the payment
thereof or any other legal or equitable right of the Company.
Any
amount of principal or interest not paid when due will bear interest at the rate of 12% per annum from the due date thereof until
paid.
The
Original Debenture contains customary representations, warranties and covenants of KCB.
On
February 19, 2021, after the end of the 2020 fiscal year, the Company made an additional investment of $100,000 into KCB (the
“Additional Investment”). In exchange, the KCB issued to the Company an amended and restated convertible debenture
(the “A&R Debenture”) on the same date (the “Amendment Date”).
The
A&R Debenture amends and restates in its entirety the Original Debenture. Pursuant to the A&R Debenture, the Company and
KCB agreed to certain new terms that did not exist in the Original Debenture, which are described below.
Interest
Accrual Commencement. Pursuant to the A&R Debenture, interest on the Initial Investment begins accruing as of March 19,
2020, while interest on the Additional Investment begins accruing on February 19, 2021.
Franchise
Fees. In the A&R Debenture, the parties acknowledge that each time that KCB sells one of its franchise locations, KCB
earns a fee (an “Initial Fee”), and that KCB also earns a fee when one of its franchise locations renews its franchise
with KCB (a “Renewal Fee”). Pursuant to the A&R Debenture, the Company and KCB agreed that, as additional consideration
for the Additional Investment, KCB will pay to the Company, in perpetuity, 5% of any Initial Fee received by KCB after the Amendment
Date, as well as 5% of any Renewal Fee received by KCB related to any franchise locations sold after the Amendment Date, in each
case to be paid within five (5) days of receipt of KCB thereof.
In
addition, following the Amendment Date, KCB agreed not to decrease the amount it charges its franchise locations for an Initial
Fee or any Renewal Fee as in effect on the Amendment Date without the prior written consent of the Company, or to take any other
actions that would reduce the value of KCB’s obligation to the Company with respect to these franchise fee payments.
KCB’s
obligation to pay the Company the franchise fees listed above will survive any termination, repayment or conversion of the A&R
Debenture. Failure by KCB to pay the Company the franchise fees in the manner described above will result in an event of default,
and, among other things, any due and unpaid franchise fees will accrue interest at 12% per year from the date the obligation was
due.
Apart
from the terms described above, the terms of the A&R Debenture are substantially identical to the terms of the Original Debenture.
6
Gilbert
Commercial Lease
On
March 3, 2021, subsequent to the 2020 fiscal year end, Gilbert Property Management, LLC (“Gilbert”), a wholly owned
subsidiary of Zoned Properties, Inc. (the “Company”), entered into that certain Commercial Lease Agreement (the “Lease”),
dated as of February 26, 2021, between Gilbert and AZ2CAL Enterprises, LLC (the “Tenant”).
Pursuant
to the terms of the Lease, Gilbert agreed to rent the property located at 988 S. 182 nd Place, Gilbert, AZ (the
“Property”) to the Tenant for a term of 24 months, from April 1, 2021 to March 31, 2023, for monthly rent of $2,750;
provided, however, that no rent is due for the month of April 2021.
In
addition, pursuant to the terms of the Lease, the Tenant has an option to purchase the Property (the “Option”) that
can be exercised any time after the fourth month of the lease term, but no later than the end of the 12 th month
of the lease term. The purchase price of the Property would be $335,000. If the Tenant exercises its Option, $750 of each lease
payment made prior to close of escrow, along with the security deposit will be credited toward the purchase price of the Property.
If the Tenant exercises its Option, close of escrow will occur no later than 30 days after opening of escrow. The parties agreed
to make every reasonable attempt to fully execute a purchase contract within seven business days of the Tenant’s notice
of its desire to exercise the Option.
Clients
We
target clients who require assistance with the identification and development of regulated cannabis properties. Our ideal prospective
clients will have a commitment to sophisticated, safe, and sustainable project development. The most significant barrier to success
for many industry operators and prospective clients includes distractions from primary business operations. These distractions
often include services related to the identification, zoning, permitting, and development of real estate.
We
complete significant due diligence on prospective tenants and prospective clients regardless of industry focus. Credit-worthiness,
character, and cash flows are all important traits that contribute to a sophisticated client for the Company.
Marketing
Currently,
the Company does not actively market its services using any direct marketing campaigns. Industry reputation, word-of-mouth, and
networking are the primary tools used to complete the marketing of our services. We maintain an updated website, shareholder presentation,
and profile outlining the Company’s services. These tools are created for transparency of operations and activities. Our
executive management believes the reputation of having integrity is an essential tool for marketing and business development.
Competition
The
commercial real estate market is highly competitive. We believe finding properties that are zoned for the specific use of allowing
regulated cannabis operations may be limited as more competitors enter the market. Several competitors have recently entered the
marketplace. We face significant competition from a diverse mix of market participants, including but not limited to, other public
companies with similar business models, independent investors, hedge funds and other real estate investors, hard money lenders,
as well as would be clients, regulated cannabis operators themselves, all of whom, who may compete against us in our efforts to
acquire real estate zoned for cannabis grow and retail operations. In some instances, we will be competing to acquire real estate
with persons who have no interest in the regulated cannabis business, but have identified value in a piece of real estate that
we may be interested in acquiring.
Government
Regulation
Real
Estate & General Business Regulations
We
are subject to applicable provisions of federal and state securities laws and to regulations specifically governing the real estate
industry, including those governing fair housing and federally backed mortgage programs. Our operations will also be subject to
regulations normally incident to business operations, such as occupational safety and health acts, workmen’s compensation
statutes, unemployment insurance legislation and income tax and social security related regulations. Although we will use our
best efforts to comply with applicable regulations, we can provide no assurance of our ability to do so, nor can we fully predict
the effect of these regulations on our proposed activities.
In
addition, zoning commercial properties for specific purposes, such as regulated cannabis dispensaries or cultivation facilities,
is subject to specific regulations to the zoning requirements for the city, county and state related to any regulated cannabis
facility. We expect regulations to get tighter as time goes on.
Federal
and State Regulation of Cannabis
The
U.S. Supreme Court has ruled that it is the federal government that has the right to regulate and criminalize cannabis, even for
medical purposes. Therefore, federal law criminalizing the use of marijuana preempts state laws that legalize its use for medicinal
purposes.
7
The
U.S. federal government regulates drugs through the CSA, which places controlled substances, including cannabis, in a schedule.
Cannabis is classified as a Schedule I controlled substance. A Schedule I controlled substance is defined as a substance
that has no currently accepted medical use in the United States, a lack of safety for use under medical supervision and a high
potential for abuse. The U.S. Department of Justice (the “DOJ”) defines Schedule I drugs, substances or chemicals
as “drugs with no currently accepted medical use and a high potential for abuse.” However, the U.S. Food and Drug
Administration (the “FDA”) has approved Epidiolex, which contains a purified form of the drug CBD, a non-psychoactive ingredient
in the cannabis plant, for the treatment of seizures associated with two epilepsy conditions. The FDA has not approved cannabis
or cannabis compounds as a safe and effective drug for any other condition. Moreover, pursuant to the Agriculture Improvement
Act of 2018 (the “Farm Bill”), CBD remains a Schedule I controlled substance under the CSA, with a narrow exception
for CBD derived from hemp with a tetrahydrocannabinol (“THC”) concentration of less than 0.3%.
The
Company maintains its operations so as to remain in compliance with the CSA. Even in those jurisdictions in which the manufacture
and use of medical marijuana has been legalized at the state level, the possession, use and cultivation all remain violations
of federal law that are punishable by imprisonment and substantial fines, and the prescription of marijuana is a violation of
federal law. Moreover, individuals and entities may violate federal law if they intentionally aid and abet another in violating
these federal controlled substance laws, or conspire with another to violate them.
The
inconsistencies between federal and state regulation of cannabis were addressed in a memorandum (the “Cole Memo”)
which then-Deputy Attorney General James Cole sent to all U.S. District Attorneys in 2013 outlining certain priorities for the
DOJ relating to the prosecution of cannabis offenses. The Cole Memo acknowledged that, notwithstanding the designation of cannabis
as a Schedule I controlled substance at the federal level, several states had enacted laws authorizing the use of cannabis for
medical purposes. The Cole Memo noted that jurisdictions that have enacted laws legalizing cannabis in some form have also implemented
strong and effective regulatory and enforcement systems to control the cultivation, processing, distribution, sale and possession
of cannabis. As such, conduct in compliance with those laws and regulations is less likely to implicate the Cole Memo’s
enforcement priorities. The DOJ did not provide (and has not provided since) specific guidelines for what regulatory and enforcement
systems would be deemed sufficient under the Cole Memo. In light of limited investigative and prosecutorial resources, the Cole
Memo concluded that the DOJ should be focused on addressing only the most significant threats related to cannabis, such as distribution
of cannabis from states where cannabis is legal to those where cannabis is illegal, the diversion of cannabis revenues to illicit
drug cartels and sales of cannabis to minors.
On
January 4, 2018, former U.S. Attorney General Jeff Sessions issued a new memorandum which rescinded the Cole Memo (the “Sessions
Memo”). The Sessions Memo stated, in part, that current law reflects “Congress’ determination that cannabis
is a dangerous drug and cannabis activity is a serious crime,” and Mr. Sessions directed all U.S. Attorneys to enforce
the laws enacted by Congress by following well-established principles when pursuing prosecutions related to cannabis activities.
The Company is not aware of any prosecutions of investment companies doing routine business with licensed marijuana related businesses
in light of the DOJ position following issuance of the Sessions Memo. However, there can be no assurance that the federal government
will not enforce federal laws relating to cannabis in the future. As a result of the Sessions Memo, federal prosecutors are now
free to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities, despite the existence of state-level
laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memo as
to the priority they should ascribe to such cannabis activities, and thus it is uncertain how active U.S. federal prosecutors
will be in relation to such activities.
Federal
prosecutors appear to continue to use the Cole Memo’s priorities as an enforcement guide. Merrick Garland, who became Attorney
General on March 10, 2021 has indicated that he would deprioritize enforcement of low-level cannabis crimes such
as possession, and has shared his view that the government should focus on large-scale criminal enterprises that circumvent state
legalization laws instead of going after people who abide by local cannabis policies. The Company believes it is too soon to determine
what prosecutorial effects will be created by the rescission of the Cole Memo or any replacement thereof and when or if the Sessions
Memo will be rescinded. President Joseph R. Biden, who assumed office in January 2021, has not yet indicated whether and when
he will decriminalize or legalize cannabis and has previously stated that he is opposed to legalization. The sheer size of the
cannabis industry, in addition to participation by state and local governments and investors, suggests that a large-scale federal
enforcement operation would more than likely create unwanted political backlash for the DOJ and the current administration. It
is also possible that the change of Congressional leadership in January 2021 could change the priorities of Congress and encourage
reconciliation of federal and state laws. Regardless, at this time, cannabis remains a Schedule I controlled substance at
the federal level. The U.S. federal government has always reserved the right to enforce federal law in regard to the sale and
disbursement of medical or adult use cannabis, even if state law authorizes such sale and disbursement. It is unclear whether
the risk of enforcement has been altered.
One
legislative safeguard for the medical cannabis industry, appended to the federal budget bill, remains in place following the rescission
of the Cole Memo. For fiscal years 2015, 2016, 2017 and 2018, Congress adopted a so-called “rider” provision
to the Consolidated Appropriations Acts (formerly referred to as the Rohrabacher-Farr Amendment and currently referred to as the
Rohrabacher-Blumenauer Amendment) to prevent the federal government from using congressionally appropriated funds to enforce federal
cannabis laws against regulated medical cannabis actors operating in compliance with state and local law. The Rohrabacher-Blumenauer
Amendment was included in the fiscal year 2018 budget passed on March 23, 2018. The Rohrabacher-Blumenauer Amendment was
included in the consolidated appropriations bill signed into legislation by former President Trump in February 2019. In signing
the Rohrabacher-Blumenauer Amendment, former President Trump issued a signing statement noting that the Rohrabacher-Blumenauer
Amendment “provides that the Department of Justice may not use any funds to prevent implementation of medical marijuana
laws by various States and territories,” and further stating “I will treat this provision consistent with the President’s
constitutional responsibility to faithfully execute the laws of the United States.” On June 20, 2019, the House approved
a broader amendment that, in addition to protecting state medical cannabis programs, would also protect state adult use programs.
On September 26, 2019, the Senate Appropriations Committee declined to take up the broader amendment but did approve the
Rohrabacher-Blumenauer Amendment for the fiscal year 2020 spending bill. On September 27, 2019, the Rohrabacher-Blumenauer
Amendment was renewed as part of a stopgap spending bill, in effect through November 21, 2019, and was then renewed through
a series of stopgap spending bills passed in 2020. On December 27, 2020, the amendment was renewed through the signing of
the fiscal year 2021 omnibus spending bill, effective through September 30, 2021. Despite the rescission of the Cole Memo,
the DOJ appears to continue to adhere to the enforcement priorities set forth in the Cole Memo.
8
The
Cole Memo and the Rohrabacher-Blumenauer Amendment gave licensed cannabis operators (particularly medical cannabis operators)
and investors in states with legal regimes greater certainty regarding the DOJ’s enforcement priorities and the risk of
operating cannabis businesses. While the Sessions Memo has introduced some uncertainty regarding federal enforcement, the cannabis
industry continues to experience growth in legal medical and adult use markets across the United States. Vice President Kamala
Harris is the lead sponsor of the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act, which seeks to end the federal
prohibition of marijuana, among other things, but in March 2020, it was reported that Vice President Harris has adopted the same
position as President Biden, who opposes legalization. Currently, there is no guarantee that state laws legalizing and regulating
the sale and use of cannabis will remain in place or that local governmental authorities will not limit the applicability of state
laws within their respective jurisdictions. Unless and until the U.S. Congress amends the CSA with respect to cannabis (and as
to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may
enforce current U.S. federal law criminalizing cannabis.
Although
the U.S. Supreme Court has ruled that it is the federal government that has the right to regulate and criminalize cannabis, and
federal law criminalizing the use of marijuana preempts state laws that legalize its use, cannabis is largely regulated at the
state level.
State
laws that permit and regulate the production, distribution and use of cannabis for adult use or medical purposes are in direct
conflict with the CSA, which makes cannabis use and possession federally illegal. Although certain states and territories of the
U.S. authorize medical and/or adult use cannabis production and distribution by licensed or registered entities, under U.S. federal
law, the possession, use, cultivation and transfer of cannabis and any related drug paraphernalia is illegal and any such acts
are criminal acts under federal law under any and all circumstances under the CSA. Although the Company’s activities are
believed to be compliant with applicable state and local laws, strict compliance with state and local laws with respect to cannabis
may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which
may be brought against the Company.
As
of December 31, 2020, 35 states, plus the District of Columbia (and the territories of Guam, Puerto Rico, the U.S. Virgin
Islands and the Northern Mariana Islands), have legalized the cultivation and sale of cannabis for medical purposes. In 15 of
those states, the sale and possession of cannabis is legal for both medical and adult use, and the District of Columbia has legalized
adult use but not commercial sale. In November 2020, voters in Arizona, Montana, New Jersey and South Dakota voted by referendum
to legalize cannabis for adult use, and voters in Mississippi and South Dakota voted to legalized cannabis for medical use, and
in February 2021, the Virginia legislature approved a bill that would legalize cannabis for adult use beginning in 2024. The Virginia
bill is awaiting signature by the governor, and if signed, Virginia will be the first southern state to legalize cannabis for
adult use. Also in February 2021, New Jersey Governor Phil Murphy signed three bills into law that legalize cannabis for adult
use.
In
addition, in November 2010, Arizona voters passed the Arizona Medical Marijuana Act (“AMMA”). The AMMA designates
the Arizona Department of Health Services (“ADHS”) as the licensing authority for the program. ADHS is tasked with
issuing Registry Identification Cards (“RIC”) to qualifying patients, designated caregivers, and dispensary agents,
as well as selecting, registering, and providing oversight for nonprofit medical marijuana dispensaries. With permission from
ADHS, qualifying patients or their caregivers may cultivate marijuana if the patient lives more than 25 miles from a dispensary.
Qualifying
patients can legally possess and purchase medical marijuana under Arizona law as long as they hold a RIC. They acquire their medicine
from non-profit medical marijuana dispensaries. These dispensaries acquire, possess, cultivate, manufacture, deliver, transfer,
transport, supply, sell, and dispense medical marijuana. Arizona is divided into 126 Community Health Assessment Areas (each,
a “CHAA”) and each CHAA may only have one dispensary located within it. Dispensaries are the only place patients are
legally allowed to purchase medical marijuana in Arizona. Arizona law permits the number of CHAAs to change based on the number
of registered pharmacies in Arizona. In order to operate, a dispensary must have a Dispensary Registration Certificate and Approval
to Operate Certificate from ADHS. The first dispensaries began operation in 2012, and it is anticipated that at maturity, there
will be about 112 dispensaries statewide - one in each CHAA not part of one of Arizona’s Native American Indian Reservations.
We
will continue to monitor compliance on an ongoing basis in accordance with our compliance program and standard operating procedures.
While our operations are in full compliance with all applicable state laws, regulations and licensing requirements, such activities
remain illegal under federal law. For the reasons described above and the risks further described in the section entitled “Risk
Factors,” there are significant risks associated with our business.
Financial
transactions involving proceeds generated by marijuana-related conduct can form the basis for prosecution under the federal money
laundering statutes, unlicensed money transmitter statute and the Bank Secrecy Act. Previous guidance issued by the Financial
Crimes Enforcement Network, a division of the U.S. Department of the Treasury (“FinCEN”), clarifies how financial
institutions can provide services to marijuana-related businesses consistent with their obligations under the Bank Secrecy Act.
Prior to the DOJ’s announcement in 2018 of the rescission of the Cole Memo and related memoranda, supplemental guidance
from the DOJ directed federal prosecutors to consider the federal enforcement priorities enumerated in the Cole Memo when determining
whether to charge institutions or individuals with any of the financial crimes described above based upon marijuana-related activity.
9
Consequently,
those businesses involved in the marijuana industry continue to encounter difficulty establishing banking relationships, which
may increase over time. Our inability to maintain our current bank accounts would make it difficult for us to operate our business,
increase our operating costs, and pose additional operational, logistical and security challenges and could result in our inability
to implement our business plan.
The
inability of our current and potential tenants to open accounts and continue using the services of banks will limit their ability
to enter into triple-net lease arrangements with us or may result in their default under our lease agreements, either of which
could materially harm our business and the trading price of our securities.
Local,
state and federal marijuana laws and regulations are broad in scope and subject to evolving interpretations, which could require
us to incur substantial costs associated with compliance or alter our business plan. In addition, violations of these laws, or
allegations of such violations, could disrupt our business and result in a material adverse effect on its operations. In addition,
it is possible that regulations may be enacted in the future that will be directly applicable to our proposed business. We cannot
predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional
governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business.
Employees
As
of December 31, 2020, we had one full-time employee, our chief executive officer, and multiple part-time employees who operate
as independent contractors of the Company. We have established an extensive network of external partners, contractors, and consultants
to which we outsource various operational tasks in an effort to minimize administrative overhead and maximize efficiency.
ITEM
1A. RISK FACTORS
Investing
in our common stock involves a high degree of risk. You should not invest in our stock unless you are able to bear the complete
loss of your investment. You should carefully consider the risks described below, as well as other information provided to you
in this annual report on Form 10-K, including information in “Management’s Discussion and Analysis of Financial Condition
and Results of Operations—Cautionary Note Regarding Forward-Looking Information and Factors That May Affect Future Results”
before making an investment decision. The risks and uncertainties described below are not the only ones facing Zoned Properties.
Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair our business
operations. If any of the following risks actually occur, our business, financial condition or results of operations could be
materially adversely affected, the value of our common stock could decline, and you may lose all or part of your investment.
Risks
Related to Our Business and Our Industry
Because
we have limited operating history in the real estate industry, we may not succeed.
We
have limited operating history or experience in procuring, building out or leasing real estate for agricultural purposes, specifically
medical marijuana grow facilities, or with respect to any other activity in the cannabis industry. Moreover, we are subject to
all risks inherent in a developing a new business enterprise. Our likelihood of success must be considered in light of the problems,
expenses, difficulties, complications, and delays frequently encountered in connection with establishing a new business and the
competitive and regulatory environment in which we operate. For example, the regulated cannabis industry is new and may not succeed,
particularly should the federal government change course and decide to prosecute those dealing in medical marijuana. If that happens
there may not be an adequate market for our properties or other activities we propose to engage in.
You
should further consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by
companies that, like us, are in their early stages. For example, unanticipated expenses, delays and or complications with build
outs, zoning issues, legal disputes with neighbors, local governments, communities and or tenants. We may not successfully address
these risks and uncertainties or successfully implement our operating strategies. If we fail to do so, it could materially harm
our business to the point of having to cease operations and could impair the value of our common stock to the point investors
may lose their entire investment.
We
may be unable to continue as a going concern if we do not successfully raise additional capital.
We
may need to raise additional funds through public or private debt or equity financings, as well as obtain credit from vendors
to be able to fully execute our business plan. If we cannot raise additional capital, we may be otherwise unable to achieve our
goals or continue our property development. While we believe that we will be able to raise the capital we need to continue our
operations, there can be no assurances that we will be successful in these efforts or will be able to resolve any liquidity issues
or eliminate our operating losses. In addition, any additional capital raised through the sale of equity may dilute your ownership
interest. We may not be able to raise additional funds on favorable terms, or at all. If we are unable to obtain additional funds
or credit from our vendors, we may be unable to execute our business plan and you could lose your investment.
10
Because
we may be unable to identify and or successfully acquire properties which are suitable for our business, our financial condition
may be negatively affected.
Our
business plan involves the identification and the successful acquisition of properties, which are zoned for medical cannabis businesses,
including cultivation and retail. The properties we acquire will be leased to regulated cannabis operators. Local governments
must approve and adopt zoning ordinances for medical cannabis facilities and retail dispensaries. A lack of properly zoned real
estate may reduce our prospects and limit our opportunity for growth and or increase the cost at which suitable properties are
available to us. Conversely a surplus of real estate zoned for medical cannabis establishments may reduce demand and prices we
are able to charge for properties we may have previously acquired.
In
addition, some jurisdictions, such as Arizona, impose limits on the number of medical cannabis dispensaries that will be permitted
to operate within designated geographic areas. Such limitations inherently place constraints on the number of properties we acquire
for lease to operators in the cannabis industry.
If
we fail to diversify our property portfolio or advisory and real estate services offered, downturns relating to certain industries
or business sectors or the financial stability of our significant tenants may have a significant adverse impact on our assets
and our ability to pay our operating expenses or pay dividends than if we had a diversified property portfolio and service offerings.
While
we intend to diversify our portfolio of properties, we are not required to observe specific diversification criteria. Therefore,
our total assets are concentrated into a limited number of tenants who were considered related parties through December 31, 2018
and are considered Significant Tenets thereafter. To the extent that our total assets are concentrated in a limited number of
tenants that are in the regulated cannabis industry, downturns relating generally to such industry or business sector, or a decline
in the financial stability of our Significant Tenants may result in defaults on all of our leases within a short time period,
which may reduce our net income and the value of our common stock and accordingly, limit our ability to pay or operating expenses
or pay dividends to our stockholders. As of December 31, 2020 and 2019, we had an asset concentration related to our Significant
Tenant leases at our Tempe, Chino Valley, Green Valley and Kingman, Arizona properties. As of December 31, 2020 and 2019, these
Significant tenants represented approximately 83.2% and 87.1% of total assets, respectively. If our tenants are prohibited from
operating or cannot pay their rent, we may not have enough working capital to support our operations and we would have to seek
out new tenants at rental rates per square foot that may be less than our current rate per square foot.
Any
adverse economic or real estate developments in the medical cannabis industry could adversely affect our operating results and
our ability to collect rent from out tenants, pay our operating expenses or pay dividends to our stockholders.
As
included in exhibit 99.1 and 99.2 to this report, we have included audited financial statements of our Significant Tenants since
they represent material information and are necessary for the protection of investors.
Because
our business is dependent upon continued market acceptance by our tenants’ consumers, any negative trends will adversely
affect our business operations.
Out
tenants are substantially dependent on continued market acceptance and proliferation of consumers of regulated cannabis. We believe
that as cannabis becomes more accepted, the stigma associated with cannabis use will diminish and as a result, consumer demand
will continue to grow. And while we believe that the market and opportunity in the cannabis space continues to grow, we cannot
predict the future growth rate and size of the market. Any negative outlook on the cannabis industry will adversely affect our
tenants’ business operations and their ability to pay rent to us.
In
addition, it is believed by many that large well-funded businesses may have a strong economic opposition to the cannabis industry.
We believe that the pharmaceutical industry clearly does not want to cede control of any product that could generate significant
revenue. For example, medical cannabis will likely adversely impact the existing market for the current “marijuana pill”
sold by the mainstream pharmaceutical industry, should cannabis displace other drugs or encroach upon the pharmaceutical industry’s
products. The pharmaceutical industry is well funded with a strong and experienced lobby that eclipses the funding of the medical
cannabis movement. Any inroads the pharmaceutical could make in halting the impending cannabis industry could have a detrimental
impact on our proposed business.
Because
we buy and lease property, we will be subject to general real estate risks.
We
will be subject to risks generally incident to the ownership of real estate, including: (a) changes in general economic or local
conditions; (b) changes in supply of, or demand for, similar or competing properties in the area; (c) bankruptcies, financial
difficulties or defaults by tenants or other parties; (d) increases in operating costs, such as taxes and insurance; (e) the inability
to achieve full stabilized occupancy at rental rates adequate to produce targeted returns; (f) periods of high interest rates
and tight money supply; (g) excess supply of rental properties in the market area; (h) liability for uninsured losses resulting
from natural disasters or other perils; (i) liability for environmental hazards; and (j) changes in tax, real estate, environmental,
zoning or other laws or regulations. For these and other reasons, no assurance can be given that we will be profitable.
11
Our
growth depends on external sources of capital, which may not be available on favorable terms or at all. In addition, banks and
other financial institutions may be reluctant to enter into lending transactions with us, including secured lending, because our
properties are used in the cannabis industry. If this source of funding is unavailable to us, our growth may be limited and our
business may be materially adversely affected.
Our
ability to acquire, operate and sell properties, engage in the business activities that we have planned and achieve positive financial
performance depends, in large measure, on our ability to obtain financing in amounts and on terms that are favorable. The capital
markets in the United States in general, and in the cannabis sector in particular, have undergone a turbulent period in which
lending was severely restricted. Although there appear to be signs that financial institutions are resuming lending, the market
has not yet returned to its pre-2008 state. The cannabis sector experienced significant volatility in 2019 and 2020 and such volatility
is expected to continue in 2021. Obtaining favorable financing in the current environment remains challenging.
In
order to grow our business, we may seek financing through newly issued equity or debt. We may not be in a position to take advantage
of attractive investment opportunities for growth if we are unable, due to global or regional economic uncertainty, changes in
the state or federal regulatory environment relating to the medical-use cannabis industry, changes in market conditions for the
regulated cannabis industry, our own operating or financial performance or otherwise, to access capital markets on a timely basis
and on favorable terms, or at all.
Our
access to capital will depend upon a number of factors over which we have little or no control, including general market conditions
and the market’s perception of our current and potential future earnings. If general economic instability or downturn, or
volatility within the cannabis sector, leads to an inability to borrow at attractive rates or at all, our ability to obtain capital
could be negatively impacted. In addition, banks and other financial institutions may be reluctant to enter into lending transactions
with us, particularly secured lending, because our properties are used in the cultivation, production or dispensing of medical-use
cannabis. If this source of funding is unavailable to us, our growth may be limited and our business may be materially adversely
affected.
If
we are unable to obtain capital on terms and conditions that we find acceptable, we likely will have to curtail operations and
reduce the number of properties we purchase in the future. In addition, our ability to refinance all or any debt we may incur
in the future, on acceptable terms or at all, is subject to all of the above factors, and will also be affected by our future
financial position, results of operations and cash flows, which additional factors are also subject to significant uncertainties,
and therefore we may be unable to refinance any debt we may incur in the future, as it matures, on acceptable terms or at all.
All of these events would have a material adverse effect on our business, financial condition, liquidity and results of operations.
In
addition, securities clearing firms may refuse to accept deposits of our securities, which may negatively impact the trading of
our securities and have a material adverse impact on our ability to obtain capital.
Because
we will compete with others for suitable properties, competition will result in higher costs that could materially affect our
financial condition.
We
will experience competition for real estate investments from individuals, corporations and other entities engaged in real estate
investment activities, many of whom have greater financial resources than us. Competition for investments may have the effect
of increasing costs and reducing returns to our investors.
Because
we are liable for hazardous substances on our properties, environmental liabilities are possible and can be costly.
Federal,
state and local laws impose liability on a landowner for releases or the otherwise improper presence on the premises of hazardous
substances. This liability is without regard to fault for, or knowledge of, the presence of such substances. A landowner may be
held liable for hazardous materials brought onto a property before it acquired title and for hazardous materials that are not
discovered until after it sells the property. Similar liability may occur under applicable state law. Sellers of properties may
make only limited representations as to the absence of hazardous substances. If any hazardous materials are found within our properties
in violation of law at any time, we may be liable for all cleanup costs, fines, penalties and other costs. This potential liability
will continue after we sell the properties and may apply to hazardous materials present within the properties before we acquire
the properties. If losses arise from hazardous substance contamination, which cannot be recovered from a responsible party, the
financial viability of the properties may be adversely affected. It is possible that we will purchase properties with known or
unknown environmental problems, which may require material expenditures for remediation.
Because
we may not be adequately insured, we could experience significant liability for uninsured events.
While
our tenants currently carry comprehensive insurance on our properties, including fire, liability and extended coverage insurance,
there are certain risks that may be uninsurable or not insurable on terms that management believes to be economical. For example,
management may not obtain insurance against floods, terrorism, mold-related claims, or earthquake insurance. If such an event
occurs to, or causes the damage or destruction of, a property, we could suffer financial losses.
If
we are found non-compliance with the Americans with Disabilities Act, we will be subject to significant liabilities.
If
any of our properties are not in compliance with the Americans with Disabilities Act of 1990, as amended (the “ADA”),
we may be required to pay for any required improvements. Under the ADA, public accommodations must meet certain federal requirements
related to access and use by disabled persons. The ADA requirements could require significant expenditures and could result in
the imposition of fines or an award of damages to private litigants. We cannot assure that ADA violations do not or will not exist
at any of our properties.
12
Our
inability to effectively manage our growth could harm our business and materially and adversely affect our operating results and
financial condition .
Our
strategy envisions growing our business. Any growth in or expansion of our business is likely to continue to place a strain on
our management and administrative resources, infrastructure and systems. As with other growing businesses, we expect that we will
need to further refine and expand our business development capabilities, our systems and processes and our access to financing
sources. We also will need to hire, train, supervise and manage new employees. These processes are time consuming and expensive,
will increase management responsibilities and will divert management attention. We cannot assure you that we will be able to:
●
expand
our business effectively or efficiently or in a timely manner;
●
allocate
our human resources optimally;
●
meet
our capital needs;
●
identify
and hire qualified employees or retain valued employees; or
●
effectively
incorporate the components of any business or product line that we may acquire in our effort to achieve growth.
Our
inability or failure to manage our growth and expansion effectively could harm our business and materially and adversely affect
our operating results and financial condition.
Unfavorable
global economic, business or political conditions could adversely affect our business, financial condition or results of operations.
Our
results of operations could be adversely affected by general conditions in the global economy and in the global financial markets,
including conditions that are outside of our control, including the impact of health and safety concerns, such as those relating
to the current COVID-19 outbreak. The most recent global financial crisis caused extreme volatility and disruptions in the capital
and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened
demand for our properties and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining
economy could strain our tenants, possibly resulting in delays in tenant payments. Any of the foregoing could harm our business
and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact
our business.
We
will be required to attract and retain top quality talent to compete in the marketplace.
We
believe our future growth and success will depend in part on our ability to attract and retain highly skilled managerial, sales
and marketing, and finance personnel. There can be no assurance of success in attracting and retaining such personnel. Shortages
in qualified personnel could limit our ability to compete in the marketplace.
We
are dependent on Bryan McLaren, our Chief Executive Officer, President, Chief Financial Officer and Chairman of the Board, and
the loss of this officer could harm our business and prevent us from implementing our business plan in a timely manner.
In
view of his direct relationships with industry partners that directly contribute to our business development strategy, our success
depends substantially upon the continued services of Mr. McLaren. In January 2019, we purchased a one-year key person life insurance
policy on Mr. McLaren with a base coverage amount of $8,000,000 renewable annually at a 10-year fixed guaranteed premium. The
policy was renewed in January 2021. The loss of Mr. McLaren’s services could have a material adverse effect on our business
and operations.
Risks
Related to Government Regulation
Marijuana
remains illegal under federal law, and therefore, strict enforcement of federal laws regarding marijuana would likely result in
our inability and the inability of our tenants to execute our respective business plans.
Marijuana
is a Schedule I controlled substance under the CSA. Even in those jurisdictions in which the manufacture and use of medical marijuana
has been legalized at the state level, the possession, use and cultivation all remain violations of federal law that are punishable
by imprisonment and substantial fines, and the prescription of marijuana is a violation of federal law. Moreover, individuals
and entities may violate federal law if they intentionally aid and abet another in violating these federal controlled substance
laws or conspire with another to violate them. The U.S. Supreme Court has ruled in United States v. Oakland Cannabis Buyers’
Coop. and Gonzales v. Raich that it is the federal government that has the right to regulate and criminalize marijuana,
even for medical purposes. We would likely be unable to execute our business plan if the federal government were to strictly enforce
federal law regarding marijuana.
On
January 4, 2018, then-U.S. Attorney General Jeff Sessions issued the Sessions Memo, rescinding the Cole Memo and related internal
guidance issued by the DOJ regarding federal law enforcement priorities involving marijuana. The Sessions Memo instructs federal
prosecutors that when determining which marijuana-related activities to prosecute under federal law with the DOJ’s finite
resources, prosecutors should follow the well-established principles set forth in the U.S. Attorneys’ Manual governing all
federal prosecutions. The Sessions Memo states that “these principles require federal prosecutors deciding which cases to
prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the
seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the
community.” The Sessions Memo went on to state that given the DOJ’s well-established general principles, “previous
nationwide guidance specific to marijuana is unnecessary and is rescinded, effective immediately.”
13
Federal
prosecutors appear to continue to use the Cole Memo’s priorities as an enforcement guide. Attorney General Merrick Garland
has indicated that he would deprioritize enforcement of low-level cannabis crimes such as possession, and has shared his view
that the government should focus on large-scale criminal enterprises that circumvent state legalization laws instead of going
after people who abide by local cannabis policies. The Company believes, however, it is too soon to determine what prosecutorial
effects will be created by the rescission of the Cole Memo or any replacement thereof and when or if the Sessions Memo will be
rescinded. At this time, cannabis remains a Schedule I controlled substance at the federal level. The U.S. federal government
has always reserved the right to enforce federal law in regard to the sale and disbursement of medical or adult use cannabis,
even if state law authorizes such sale and disbursement. It is unclear whether the risk of enforcement has been altered.
It
is unclear at this time what impact the Sessions Memo will have on the medical-use marijuana industry. One legislative safeguard
for the medical cannabis industry, appended to the federal budget bill, remains in place following the rescission of the Cole
Memo. For fiscal years 2015, 2016, 2017 and 2018, Congress adopted a so-called “rider” provision to the Consolidated
Appropriations Acts (formerly referred to as the Rohrabacher-Farr Amendment and currently referred to as the Rohrabacher-Blumenauer
Amendment) to prevent the federal government from using congressionally appropriated funds to enforce federal cannabis laws against
regulated medical cannabis actors operating in compliance with state and local law. On September 27, 2019, the Rohrabacher-Blumenauer
Amendment was renewed as part of a stopgap spending bill, in effect through November 21, 2019, and was then renewed through a
series of stopgap spending bills passed in 2020. On December 27, 2020, the amendment was renewed through the signing of the fiscal
year 2021 omnibus spending bill, effective through September 30, 2021. Despite the rescission of the Cole Memo, the DOJ appears
to continue to adhere to the enforcement priorities set forth in the Cole Memo.
Federal
prosecutors have significant discretion, however, and no assurance can be given that the federal prosecutor in each judicial district
where we own a property will not choose to strictly enforce the federal laws governing marijuana production or distribution. Any
change in the federal government’s enforcement posture with respect to state-licensed cultivation of medical-use cannabis,
including the enforcement postures of individual federal prosecutors in judicial districts where we own or may purchase properties,
would result in our inability to execute our business plan, and we would likely suffer significant losses with respect to our
investment in marijuana facilities in the United States, which would adversely affect the trading price of our securities. Furthermore,
following any such change in the federal government’s enforcement position, we could be subject to criminal prosecution,
which could lead to imprisonment and/or the imposition of penalties, fines, or forfeiture.
Owners
of properties located in close proximity to our properties may assert claims against us regarding the use of the property as a
marijuana dispensary or marijuana cultivation and processing facility, which if successful, could materially and adversely affect
our business.
Owners
of properties located in close proximity to our properties may assert claims against us regarding the use of our properties as
cannabis dispensaries or for cannabis cultivation and processing, including assertions that the use of the property constitutes
a nuisance that diminishes the market value of such owner’s nearby property. Such property owners may also attempt to assert
such a claim in federal court as a civil matter under the Racketeer Influenced and Corrupt Organizations Act. If a property owner
were to assert such a claim against us, we may be required to devote significant resources and costs to defending ourselves against
such a claim, and if a property owner were to be successful on such a claim, our tenants may be unable to continue to operate
their business in its current form at the property, which could materially adversely impact the tenant’s business and the
value of our property, our business and financial results and the trading price of our securities.
We
and our tenants may have difficulty accessing the services of banks, which may make it difficult to contract for real estate needs.
Financial
transactions involving proceeds generated by cannabis and cannabis-related conduct can form the basis for prosecution under the
federal money laundering statutes, unlicensed money transmitter statute and the Bank Secrecy Act. Previous guidance issued by
FinCEN clarifies how financial institutions can provide services to marijuana-related businesses consistent with their obligations
under the Bank Secrecy Act. Prior to the DOJ’s announcement in 2018 of the rescission of the Cole Memo and related memoranda,
supplemental guidance from the DOJ directed federal prosecutors to consider the federal enforcement priorities enumerated in the
Cole Memo when determining whether to charge institutions or individuals with any of the financial crimes described above based
upon marijuana-related activity. It is unclear what impact the rescission of the Cole Memo will have, but federal prosecutors
may increase enforcement activities against institutions or individuals that are conducting financial transactions related to
marijuana activities. The increased uncertainty surrounding financial transactions related to marijuana activities may also result
in financial institutions discontinuing services to the marijuana industry.
Consequently,
those businesses involved in the marijuana industry continue to encounter difficulty establishing banking relationships, which
may increase over time. Our inability to maintain our current bank accounts would make it difficult for us to operate our business,
increase our operating costs, and pose additional operational, logistical and security challenges and could result in our inability
to implement our business plan.
The
inability of our current and potential tenants to open accounts and continue using the services of banks will limit their ability
to enter into triple-net lease arrangements with us or may result in their default under our lease agreements, either of which
could materially harm our business and the trading price of our securities.
14
Laws
and regulations affecting the regulated cannabis and marijuana industry are constantly changing, which could materially adversely
affect our operations, and we cannot predict the impact that future regulations may have on us.
Local,
state and federal marijuana laws and regulations are broad in scope and subject to evolving interpretations, which could require
us to incur substantial costs associated with compliance or alter our business plan. In addition, violations of these laws, or
allegations of such violations, could disrupt our business and result in a material adverse effect on its operations. In addition,
it is possible that regulations may be enacted in the future that will be directly applicable to our proposed business. We cannot
predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional
governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business.
FDA
regulation of marijuana and the possible registration of facilities where medical marijuana is grown could negatively affect the
marijuana industry, which would directly affect our financial condition.
Should
the federal government legalize marijuana for medical use, it is possible that the FDA would seek to regulate it under the Food,
Drug and Cosmetics Act of 1938. Additionally, the FDA may issue rules and regulations including cGMPs (certified good manufacturing
practices) related to the growth, cultivation, harvesting and processing of medical marijuana. Clinical trials may be needed to
verify efficacy and safety. It is also possible that the FDA would require that facilities where medical marijuana is grown be
registered with the FDA and comply with certain federally prescribed regulations. In the event that some or all of these regulations
are imposed, we do not know what the impact would be on the medical marijuana industry, what costs, requirements and possible
prohibitions may be enforced. If we or our tenants are unable to comply with the regulations and or registration as prescribed
by the FDA, we and or our tenants may be unable to continue to operate their and our business in its current form or at all.
Risks
Related to Our Common Stock
Our
common stock is quoted on the OTCQB, which may limit the liquidity and price of our common stock more than if our common stock
were listed on The NASDAQ Stock Market or another national exchange.
Our
securities are currently quoted on the OTCQB, an inter-dealer automated quotation system for equity securities. Quotation of our
securities on the OTCQB may limit the liquidity and price of our securities more than if our securities were listed on The NASDAQ
Stock Market (“NASDAQ”) or another national exchange. As an OTCQB company, we do not attract the extensive analyst
coverage that accompanies companies listed on national securities exchanges. Further, institutional and other investors may have
investment guidelines that restrict or prohibit investing in securities traded on the OTCQB. These factors may have an adverse
impact on the trading and price of our common stock.
The
trading price of our common stock may decrease due to factors beyond our control.
The
stock market from time to time has experienced extreme price and volume fluctuations, which have particularly affected the market
prices for smaller reporting companies and which often have been unrelated to the operating performance of the companies. These
broad market fluctuations may adversely affect the market price of our common stock. If our shareholders sell substantial amounts
of their common stock in the public market, the price of our common stock could fall. These sales also might make it more difficult
for us to sell equity, or equity-related securities, in the future at a price we deem appropriate.
The
market price of our common stock may also fluctuate significantly in response to the following factors, most of which are beyond
our control:
●
variations
in our quarterly operating results,
●
changes
in general economic conditions and in the real estate industry,
●
changes
in market valuations of similar companies,
●
announcements
by us or our competitors of significant new contracts, acquisitions, strategic partnerships or joint ventures, or capital
commitments,
●
loss
of a major customer, partner or joint venture participant and
●
the
addition or loss of key managerial and collaborative personnel.
Any
such fluctuations may adversely affect the market price of our common stock, regardless of our actual operating performance. As
a result, stockholders may be unable to sell their shares, or may be forced to sell them at a loss.
15
The
market price for our common shares is particularly volatile given our status as a relatively unknown company with a small and
thinly traded public float, limited operating history and lack of profits which could lead to wide fluctuations in our share price.
You may be unable to sell your common shares at or above your purchase price, which may result in substantial losses to you.
The
market for our common shares is characterized by significant price volatility when compared to seasoned issuers, and we expect
that our share price will continue to be more volatile than a seasoned issuer for the indefinite future. The volatility in our
share price is attributable to a number of factors. First, as noted above, our common shares are sporadically and thinly traded.
As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our shareholders may disproportionately
influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously in
the event that a large number of our common shares are sold on the market without commensurate demand, as compared to a seasoned
issuer which could better absorb those sales without adverse impact on its share price. Secondly, we are a speculative or “risky”
investment due to our limited operating history and lack of profits to date. As a consequence of this enhanced risk, more risk-adverse
investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be
more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of
a seasoned issuer. Many of these factors are beyond our control and may decrease the market price of our common shares, regardless
of our operating performance. We cannot make any predictions or projections as to what the prevailing market price for our common
shares will be at any time, including as to whether our common shares will sustain their current market prices, or as to what
effect that the sale of shares or the availability of common shares for sale at any time will have on the prevailing market price.
Our
preferred stockholders together have voting control, which will limit your ability to influence the outcome of important transactions,
including a change in control.
Each
of our preferred stockholders beneficially owns 1,000,000 shares of our preferred stock. Each share of preferred stock entitles
the holder to 50 votes per share. In contrast, each share of our common stock has one vote per share. Each of our two preferred
stockholders holds approximately 46.1% and 45.7% of the voting power of our outstanding capital stock, respectively. Because of
the 50-to-1 voting ratio between our preferred stock and our common stock, our preferred stockholders together control a majority
of the combined voting power of our capital stock and therefore are able to control all matters submitted to our stockholders
for approval. The preferred stockholders may also have interests that differ from yours and may vote in a way with which you disagree
and which may be adverse to your interests. This concentrated control may have the effect of delaying, preventing or deterring
a change in control of our company, could deprive our stockholders of an opportunity to receive a premium for their capital stock
as part of a sale of our company and might ultimately affect the market price of our common stock.
We
may face continuing challenges in complying with the Sarbanes-Oxley Act, and any failure to comply or any adverse result from
management’s evaluation of our internal control over financial reporting may have an adverse effect on our stock price.
As
a smaller reporting company as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), we are required to evaluate our internal control over financial reporting under Section 404 of the Sarbanes-Oxley
Act of 2002 (“Section 404”). Section 404 requires us to include an internal control report with our Annual Report
on Form 10-K. The report must include management’s assessment of the effectiveness of our internal control over financial
reporting as of the end of the fiscal year. This report must also include disclosure of any material weaknesses in internal control
over financial reporting that we have identified.
Failure
to comply, or any adverse results from such evaluation, could result in a loss of investor confidence in our financial reports
and have an adverse effect on the trading price of our equity securities. Management concluded that our internal controls and
procedures as of December 31, 2020 were not effective. Management realizes there are deficiencies in the design or operation of
our internal control that adversely affect our internal controls, and management considers such deficiencies to be material weaknesses.
As of the end of our fiscal year, management had identified the following material weaknesses:
●
we
had not implemented comprehensive entity-level internal controls;
●
we
had not implemented adequate system and manual controls; and
●
we
did not have sufficient segregation of duties.
Achieving
continued compliance with Section 404 may require us to incur significant costs and expend significant time and management resources.
We cannot assure you that we will be able to fully comply with Section 404 or that we will be able to conclude that our internal
control over financial reporting is effective at fiscal year-end. As a result, investors could lose confidence in our reported
financial information, which could have an adverse effect on the trading price of our securities.
We
have never paid dividends on our common stock, and cannot guarantee that we will pay dividends to our stockholders in the future.
We
have never paid dividends on our common stock. For the foreseeable future, we intend to retain our future earnings, if any, in
order to reinvest in the development and growth of our business and, therefore, do not intend to pay dividends on our common stock.
However, in the future, our board of directors may declare dividends on our common stock. Any future determination to pay dividends
will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital
requirements, and such other factors as our board of directors deems relevant. Accordingly, investors may need to sell their shares
of our common stock to realize a return on their investment, and they may not be able to sell such shares at or above the price
paid for them. We cannot guarantee that we will pay dividends to our stockholders in the future.
16
Our
common stock is a “penny stock” under SEC rules. It may be more difficult to resell securities classified as “penny
stock.”
Our
common stock is considered a “penny stock” under applicable SEC rules (generally defined as non-exchange traded stock
with a per-share price below $5.00). Unless we maintain a per-share price above $5.00, these rules impose additional sales practice
requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify as
“established customers” or “accredited investors.” For example, broker-dealers must determine the appropriateness
for non-qualifying persons of investments in penny stocks. Broker-dealers must also provide, prior to a transaction in a penny
stock not otherwise exempt from the rules, a standardized risk disclosure document that provides information about penny stocks
and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations
for the penny stock, disclose the compensation of the broker-dealer and its salesperson in the transaction, furnish monthly account
statements showing the market value of each penny stock held in the customer’s account, provide a special written determination
that the penny stock is a suitable investment for the purchaser, and receive the purchaser’s written agreement to the transaction.
Legal
remedies available to an investor in “penny stocks” may include the following:
●
If
a “penny stock” is sold to the investor in violation of the requirements listed above, or other federal or states
securities laws, the investor may be able to cancel the purchase and receive a refund of the investment.
●
If
a “penny stock” is sold to the investor in a fraudulent manner, the investor may be able to sue the persons and
firms that committed the fraud for damages.
However,
investors who have signed arbitration agreements may have to pursue their claims through arbitration.
These
requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that
is or becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage
broker-dealers from effecting transactions in our securities, which could severely limit the market price and liquidity of our
securities. These requirements may restrict the ability of broker-dealers to sell our common stock and may affect your ability
to resell our common stock.
Many
brokerage firms will discourage or refrain from recommending investments in penny stocks. Most institutional investors will not
invest in penny stocks. In addition, many individual investors will not invest in penny stocks due, among other reasons, to the
increased financial risk generally associated with these investments.
For
these reasons, penny stocks may have a limited market and, consequently, limited liquidity. We can give no assurance that our
common stock will not be classified as a “penny stock” in the future.
Rule
144 Related Risks
Pursuant
to Rule 144, a person who has beneficially owned restricted shares of our common stock for at least six months is entitled to
sell his or her securities provided that: (i) such person is not deemed to have been one of our affiliates at the time of, or
at any time during the three months preceding, a sale, (ii) we are subject to the Exchange Act periodic reporting requirements
for at least 90 days before the sale and (iii) if the sale occurs prior to satisfaction of a one-year holding period, we provide
current information at the time of sale.
Persons
who have beneficially owned restricted shares of our common stock for at least six months but who are our affiliates at the time
of, or at any time during the three months preceding a sale, would be subject to additional restrictions, by which such person
would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either
of the following:
●
1%
of the total number of securities of the same class then outstanding; or
●
the
average weekly trading volume of such securities during the four calendar weeks preceding the filing of a notice on Form 144
with respect to the sale;
provided ,
in each case that we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale.
Such sales by affiliates must also comply with the manner of sale, current public information and notice provisions of Rule 144.
17
In
addition, as a former shell company, we are subject to additional restrictions. Historically, the SEC staff has taken the position
that Rule 144 is not available for the resale of securities initially issued by companies that are, or previously were, shell
companies, such as Zoned Properties. Rule 144 is not available for resale of securities issued by any shell companies (other than
business combination related shell companies) or any issuer that has been at any time previously a shell company. The SEC has
provided an exception to this prohibition, however, if the following conditions are met:
●
The
issuer of the securities that was formerly a shell company has ceased to be a shell company,
●
The
issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act,
●
The
issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding
12 months (or such shorter period that the issuer was required to file such reports and materials), other than current reports
on Form 8-K, and
●
At
least one year has elapsed from the time that the issuer filed current comprehensive disclosure with the SEC reflecting its
status as an entity that is not a shell company.
ITEM
1B. UNRESOLVED STAFF COMMENTS
This Item
1B is not applicable to smaller reporting companies.
ITEM
2. PROPERTIES
Our
principal executive office is currently located at 14269 N. 87th Street, #205, Scottsdale, AZ 85260.
Effective
April 1, 2019, we extended our one-year operating lease for our office space in Scottsdale, Arizona to end on March 31, 2020.
The annual base rent increased from $7,800 to $9,107. On July 16, 2019, we added additional office space and our monthly base
rent increased to $1,325 per month. On March 6, 2020, we extended our lease for twelve months to end on March 31, 2021 at an annual
base rent of $16,695. On March 17, 2021, we extended our lease for twelve months to end on March 31, 2022 at an annual base rent
of $17,583.
We
are in the business of property acquisition, development, and commercial leasing and intend to primarily structure lease agreements
with prospective tenants using a triple-net lease model. The property portfolio currently includes (i) land and real property
constructed in Green Valley, Arizona, (ii) land and real property in Kingman, Arizona, (iii) vacant land in Gilbert, Arizona,
(iv) land and real property in Tempe Arizona, and (v) land and real property of approximately 47 acres in Chino Valley, Arizona.
The properties in Tempe, Green Valley, Kingman, and Chino Valley, Arizona are currently leasing space to tenants that operate
licensed medical cannabis facilities. We lease our vacant land in Gilbert, Arizona to a third party. Each of these leased properties
is generating revenue to date.
ITEM
3. LEGAL PROCEEDINGS
There
are no pending or threatened legal or administrative actions pending or threatened against us that we believe would have a material
effect on our business.
ITEM
4. MINE SAFETY DISCLOSURES
Not applicable.
18
PART
II
ITEM
5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Our
common stock is quoted on the OTCQB, operated by the OTC Markets Group, under the symbol “ZDPY.” Trading in OTCQB
stocks can be volatile, sporadic and risky, as thinly traded stocks tend to move more rapidly in price than more liquid securities.
Such trading may also depress the market price of our common stock and make it difficult for our stockholders to resell their
common stock.
The
following table reflects the high and low closing price for our common stock for the period indicated. The bid information was
obtained from the OTC Markets Group, Inc. and reflects inter-dealer prices, without retail mark-up, markdown or commission, and
may not necessarily represent actual transactions.
Quarter
Ended
High
Low
December 31, 2020
$ 0.53
$ 0.22
September 30, 2020
$ 0.48
$ 0.12
June 30, 2020
$ 0.19
$ 0.11
March 31, 2020
$ 0.27
$ 0.13
December 31, 2019
$ 0.33
$ 0.21
September 30, 2019
$ 0.46
$ 0.20
June 30, 2019
$ 0.42
$ 0.21
March 31, 2019
$ 0.53
$ 0.27
On
March 30, 2021 the closing price of our common stock on the OTCQB was $0.13 per share.
Holders
of Common Stock
As
of March 30, 2021, there were approximately 103 record holders of our common stock. The number of record holders does not include
beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries.
Recent
Sales of Unregistered Securities
None.
Purchases
of Equity Securities by the Issuer and Affiliated Purchasers
None.
Securities
Authorized for Issuance under Equity Compensation Plans
On
August 9, 2016, our Board of Directors authorized the 2016 Equity Incentive Plan (the “2016 Plan”) and reserved 10,000,000
shares of common stock for issuance thereunder. The 2016 Plan’s purpose is to encourage ownership in the Company by employees,
officers, directors and consultants whose long-term service the Company considers essential to its continued progress and, thereby,
encourage recipients to act in the stockholders’ interest and share in the Company’s success. The 2016 Plan authorizes
the grant of awards in the form of options intended to qualify as incentive stock options under Section 422 of the Internal Revenue
Code (the “Code”), options that do not qualify (non-statutory stock options) and grants of restricted shares of common
stock. Restricted shares granted pursuant to the 2016 Plan are amortized to expense over the three-year vesting period. Options
vest and expire over a period not to exceed seven years. If any share of common stock underlying a stock option that has been
granted ceases to be subject to a stock option, or if any shares of common stock that are subject to any other stock-based award
granted are forfeited or terminate, such shares shall again be available for distribution in connection with future grants and
awards under the 2016 Plan. As of December 31, 2020, 75,000 stock option awards have been granted under the 2016 Plan. At December
31, 2020, 9,925,000 shares are available for future issuance.
The
Company also continues to maintain its 2014 Equity Compensation Plan (the “2014 Plan”), pursuant to which 1,250,000
previously awarded stock options are outstanding. The 2014 Plan has been superseded by the 2016 Plan. Accordingly, no additional
shares subject to the existing 2014 Plan will be issued and the 1,250,000 shares issuable upon exercise of stock options will
be issued pursuant to the 2014 Plan, if exercised. As of December 31, 2020, options to purchase 1,250,000 shares of common stock
are outstanding pursuant to the 2014 Plan.
DESCRIPTION
OF SECURITIES
General
Outstanding
Shares and Holders
As
of March 30, 2021, our authorized capital stock consists of 100,000,000 shares of common stock, $0.001 par value per share, 12,141,548
of which were issued and outstanding, and 5,000,000 shares of preferred stock, $0.001 par value per share, 2,000,000 of which
were issued and outstanding.
19
Common
Stock
Holders
of the Company’s common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders
of common stock do not have cumulative voting rights. Holders of the Company’s common stock are entitled to share in all
dividends that our board of directors, in its discretion, declares from legally available funds. In the event of a liquidation,
dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after
payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The Company’s
common stock has no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to the Company’s
common stock.
Preferred
Stock
Our
articles of incorporation, as amended, authorizes our board of directors, subject to any limitations prescribed by law, without
further stockholder approval, to establish and to issue from time to time one or more classes or series of preferred stock. Each
class or series of preferred stock will cover the number of shares and will have the powers, preferences, rights, qualifications,
limitations and restrictions determined by the board of directors, which may include, among others, dividend rights, liquidation
preferences, voting rights, conversion rights, preemptive rights and redemption rights. Except as provided by law or in a preferred
stock designation, the holders of preferred stock will not be entitled to vote at or receive notice of any meeting of stockholders.
The
certificate of designation for the preferred stock provides that the shares are not convertible into any other class or series
of stock. Holders of preferred shares are entitled to 50 votes for each share held. Voting rights are not subject to adjustment
for splits that increase or decrease the common shares outstanding. Upon liquidation, holders of preferred stock will be entitled
to receive $1.00 per share plus redemption provision before assets are distributed to other stockholders. Holders of preferred
shares are entitled to dividends equal to common share dividends. Once any shares of preferred stock are outstanding, at least
51% of the total number of shares of preferred stock outstanding must approve the following transactions:
●
alteration
of the rights, preferences of privileges of the preferred stock,
●
creation
of any new class of stock having preferences over the preferred stock,
●
repurchase
of any of our common stock,
●
merger
of consolidation with any other company, other than one of our wholly owned subsidiaries,
●
sale,
conveyance or other disposal of, or creation or incurrence of any mortgage, lien, or charge or encumbrance or security interest
in or pledge of, or sale and leaseback of, all or substantially all of our property or business, or
●
incurrence,
assumption or guarantee of any indebtedness maturing more than 18 months after the date on which it is incurred, assumed or
guaranteed by us, except for operating leases and obligations assumed as part of the purchase price of property.
Holders
of a majority of the voting power of our capital stock issued, outstanding and entitled to vote, represented in person or by proxy,
are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders of a majority of our outstanding voting
shares is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to our articles
of incorporation.
Holders
of preferred shares vote along with common stockholders on each matter submitted to a vote of security holders. As a result of
the multiple votes accorded to holders of the preferred stock, Greg Johnston and Alex McLaren have the ability to control the
outcome of all matters submitted to a vote of stockholders, including the election of directors. On those matters that require
the approval of at least 51% of the preferred stock, both Mr. Johnston and Mr. McLaren must provide their approval inasmuch as
each of them owns 50% of the outstanding preferred stock.
Dividends
Historically,
we have not paid any cash dividends on our common stock. It is our present intention not to pay any cash dividends in the foreseeable
future, but rather to reinvest earnings, if any, in our business operations. However, in the future, our board of directors may
declare dividends on our common stock. Payment of future dividends on our common stock, if any, will be at the discretion of our
board of directors and will depend on, among other things, our results of operations, cash requirements and surplus, financial
condition, contractual restrictions and other factors that our board of directors may deem relevant. In addition, the agreements
into which we may enter in the future, including indebtedness, may impose limitations on our ability to pay dividends or make
other distributions on our capital stock. We cannot guarantee that we will pay dividends to our stockholders in the future. Holders
of preferred shares are entitled to dividends equal to common share dividends.
Anti-Takeover
Effects of Certain Provisions of Our Articles of Incorporation, as Amended, and Our Bylaws
These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions
are also designed to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits
of increased protection and our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to
acquire or restructure us outweigh the disadvantages of discouraging these proposals because, among other things, negotiation
of these proposals could result in an improvement of their terms.
Preferred
Stock. Our articles of incorporation, as amended, authorize our board of directors to issue from time to time any series of
preferred stock and fix the voting powers, designation, powers, preferences and rights of the shares of such series of preferred
stock.
20
Calling
of Special Meetings of Stockholders. Our bylaws provide that special meetings of the stockholders may be called only by the
chairman of the board or the chief executive officer, and shall be called by the chairman of the board or the secretary (i) when
so directed by the board, or (ii) at the written request of stockholders owning shares representing at least 25% of voting power
in the election of directors.
Advance
Notice Requirements for Stockholder Proposals and Director Nominations. Our bylaws establish an advance notice procedure for
stockholder proposals to be brought before a meeting of our stockholders, including proposed nominations of persons for election
to the board of directors.
Removal
of Directors; Vacancies. Our bylaws provide that a director may be removed from office by stockholders for cause, or without
cause by a majority vote of the stockholders. A vacancy on the board of directors may be filled only by a majority of the directors
then in office.
ITEM
6. RESERVED
ITEM
7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary
Note Regarding Forward-Looking Information and Factors That May Affect Future Results
This
annual report on Form 10-K contains forward-looking statements regarding our business, financial condition, results of operations
and prospects. The Securities and Exchange Commission (the “SEC”) encourages companies to disclose forward-looking
information so that investors can better understand a company’s future prospects and make informed investment decisions.
This annual report on Form 10-K and other written and oral statements that we make from time to time contain such forward-looking
statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance.
We have tried, wherever possible, to identify such statements by using words such as “anticipate,” “estimate,”
“expect,” “project,” “intend,” “plan,” “believe,” “will”
and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include
statements relating to future actions, future performance or results of current and anticipated sales efforts, expenses, the outcome
of contingencies, such as legal proceedings, and financial results. Factors that could cause our actual results of operations
and financial condition to differ materially are set forth in the “Risk Factors” section of this annual report on
Form 10-K.
We
caution that these factors could cause our actual results of operations and financial condition to differ materially from those
expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking
statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake
no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement
is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to
time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on
our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially
from those contained in any forward-looking statements.
The
following discussion should be read in conjunction with our audited financial statements and the related notes that appear elsewhere
in this annual report on Form 10-K.
Overview
Zoned
Properties is a strategic real estate development firm whose primary mission is to provide specialized real estate and sustainability
services for clients in the regulated cannabis industry, positioning the company for real estate investments and revenue growth .
We intend to pioneer sustainable development for emerging industries, including the regulated cannabis industry. We are an
accredited member of the Better Business Bureau, the U.S. Green Building Council, and the Forbes Real Estate Council. We focus
on investing capital to acquire and develop commercial properties to be leased on a triple-net basis, and engaging clients that
face zoning, permitting, development, and operational challenges. We provide development strategies and advisory services that
could potentially have a major impact on cash flow and property value. We do not grow, harvest, sell or distribute cannabis or
any substances regulated under United States law such as the CSA.
We are in the process of developing and
expanding multiple business divisions; including an advisory services division, a licensed commercial real estate brokerage division,
a real estate division focused on franchise services, a real estate division focused on real estate data, and a nonprofit charitable
organization to focus on community prosperity. Each of these operating divisions are important elements of the overall business
development strategy for long-term growth. We believe in the value of building relationships with clients and local communities
in order to position the Company for long-term portfolio and revenue growth backed by sophisticated, safe, and sustainable assets
and clients.
The core of our business involves identifying
and developing commercial properties that intend to operate within highly regulated industries, including the regulated cannabis
industry. Within highly regulated industries, local municipalities typically develop strict regulations, including zoning and permitting
requirements related to commercial real estate, that dictate the specific locations and parameters under which regulated properties
can operate. These regulations often include complex permitting processes and can include non-standard codes governing each location;
for example, restricting a regulated property or facility from operating within a certain distance of any parks, schools, churches,
or residential districts, or restricting a regulated property from operating outside a defined set of hours of operation. When
an organization can collaborate with local representatives, a proactive set of rules and regulations can be established and followed
to meet the needs of both the regulated operators and the local community.
21
For
the year ended December 31, 2020 and 2019, substantially all of our revenues were generated from triple-net leases to tenants
that are controlled by one entity (each, a “Significant Tenant” and collectively, the “Significant Tenants”),
which is located in the State of Arizona.
The Company currently maintains a portfolio of properties that
we own, develop, and lease. We currently lease land and/or building space at all five of the properties in our portfolio. Four
of the properties are leased to licensed and regulated cannabis tenants and are located in areas with established zoning and permitting
procedures. Two of the leased properties are zoned and permitted as licensed and regulated cannabis dispensaries, and two of the
leased properties are zoned and permitted as licensed and regulated cannabis cultivation facilities. Each regulated property may
undergo a non-standard development process. Various development requirements in this process may include initial property identification,
zoning authorization, and permitting guidance in order to qualify a commercial property for subsequent architectural design, utility
installation, construction and development, property management, facilities management systems, and security system installation.
During the year ended December 31, 2020,
we made improvements to rental properties of $9,565. No improvements were made during the year ended December 31, 2019.
As
of December 31, 2020, a summary of rental properties owned by us consisted of the following:
Location
Tempe,
AZ
Chino Valley,
AZ
Gilbert,
AZ
Green Valley,
AZ
Kingman,
AZ
Description
Industrial
/Office
Greenhouse/
Nursery
Vacant
Land
Retail
(special use)
Retail
(special use)
Current
Use
Cannabis
Facility
Cannabis
Facility
Vacant
Land
Cannabis
Dispensary
Cannabis
Dispensary
Date
Acquired
March 2014
August 2015
January 2014
October 2014
May 2014
Lease
Start Date
May 2018
May 2018
April 2021
May 2018
May 2018
Lease
End Date
April 2040
April 2040
March 2023
April 2040
April 2040
Total
No. of Tenants
1
1
1
1
1
Total
Properties
Land
Area (Acres)
3.65
47.60
0.80
1.33
0.32
53.70
Land
Area (Sq. Feet)
158,772
2,072,149
34,717
57,769
13,939
2,337,346
Undeveloped
Land Area (Sq. Feet)
-
1,812,563
34,717
-
6,878
1,854,158
Developed
Land Area (Sq. Feet)
158,772
259,586
-
57,769
7,061
483,188
Total
Rentable Building Sq. Ft.
60,000
40,000
-
1,440
1,497
102,937
Vacant
Rentable Sq. Ft.
-
-
-
-
-
-
Sq.
Ft. rented as of December 31, 2020
60,000
40,000
-
1,440
1,497
102,937
Annual
Base Rent:*
2021
$ 590,400
$ 393,600
$ 22,000
$ 42,000
$ 48,000
$
1,096,000
2022
590,400
393,600
33,000
42,000
48,000
1,107,000
2023
590,400
393,600
8,250
42,000
48,000
1,082,250
2024
590,400
393,600
-
42,000
48,000
1,074,000
2025
590,400
393,600
-
42,000
48,000
1,074,000
Thereafter
8,462,400
5,641,600
-
602,000
688,000
15,394,000
Total
$ 11,414,400
$ 7,609,600
$ 63,250
$ 812,000
$ 928,000
$
20,827,250
*
Annual
base rent represents amount of cash payments due from tenants.
22
Annualized
$ per Rented Building Sq. Ft. (Base Rent)
Year
Tempe,
AZ
Chino
Valley,
AZ
Gilbert,
AZ
**
Green
Valley,
AZ
Kingman,
AZ
2021
$
9.8
$
9.8
$
29.2
$
32.1
2022
$
9.8
$
9.8
$
29.2
$
32.1
2023
$
9.8
$
9.8
$
29.2
$
32.1
2024
$
9.8
$
9.8
-
$
29.2
$
32.1
2025
$
9.8
$
9.8
-
$
29.2
$
32.1
**
- rented vacant land only.
The
U.S. Supreme Court has ruled that it is the federal government that has the right to regulate and criminalize cannabis, even for
medical purposes. Therefore, federal law criminalizing the use of marijuana preempts state laws that legalize its use for medicinal
purposes.
The
U.S. federal government regulates drugs through the CSA, which places controlled substances, including cannabis, in a schedule.
Cannabis is classified as a Schedule I controlled substance. A Schedule I controlled substance is defined as a substance
that has no currently accepted medical use in the United States, a lack of safety for use under medical supervision and a high
potential for abuse. The DOJ defines Schedule I drugs, substances or chemicals as “drugs with no currently accepted medical
use and a high potential for abuse.” However, the FDA has approved Epidiolex, which contains a purified form of the drug
CBD, a non-psychoactive ingredient in the cannabis plant, for the treatment of seizures associated with two epilepsy
conditions. The FDA has not approved cannabis or cannabis compounds as a safe and effective drug for any other condition. Moreover,
pursuant to the Farm Bill, CBD remains a Schedule I controlled substance under the CSA, with a narrow exception for CBD derived
from hemp with a THC concentration of less than 0.3%.
The
Company maintains its operations so as to remain in compliance with the CSA. Even in those jurisdictions in which the manufacture
and use of medical marijuana has been legalized at the state level, the possession, use and cultivation all remain violations
of federal law that are punishable by imprisonment and substantial fines, and the prescription of marijuana is a violation of
federal law. Moreover, individuals and entities may violate federal law if they intentionally aid and abet another in violating
these federal controlled substance laws, or conspire with another to violate them.
The
inconsistencies between federal and state regulation of cannabis were addressed in the Cole Memo, which then-Deputy Attorney General
James Cole sent to all U.S. District Attorneys in 2013 outlining certain priorities for the DOJ relating to the prosecution of
cannabis offenses. The Cole Memo acknowledged that, notwithstanding the designation of cannabis as a Schedule I controlled substance
at the federal level, several states had enacted laws authorizing the use of cannabis for medical purposes. The Cole Memo noted
that jurisdictions that have enacted laws legalizing cannabis in some form have also implemented strong and effective regulatory
and enforcement systems to control the cultivation, processing, distribution, sale and possession of cannabis. As such, conduct
in compliance with those laws and regulations is less likely to implicate the Cole Memo’s enforcement priorities. The DOJ
did not provide (and has not provided since) specific guidelines for what regulatory and enforcement systems would be deemed sufficient
under the Cole Memo. In light of limited investigative and prosecutorial resources, the Cole Memo concluded that the DOJ should
be focused on addressing only the most significant threats related to cannabis, such as distribution of cannabis from states where
cannabis is legal to those where cannabis is illegal, the diversion of cannabis revenues to illicit drug cartels and sales of
cannabis to minors.
On
January 4, 2018, former U.S. Attorney General Jeff Sessions issued the Sessions Memo, which rescinded the Cole Memo. The
Sessions Memo stated, in part, that current law reflects “Congress’ determination that cannabis is a dangerous drug
and cannabis activity is a serious crime,” and Mr. Sessions directed all U.S. Attorneys to enforce the laws enacted
by Congress by following well-established principles when pursuing prosecutions related to cannabis activities. The Company is
not aware of any prosecutions of investment companies doing routine business with licensed marijuana related businesses in light
of the DOJ position following issuance of the Sessions Memo. However, there can be no assurance that the federal government will
not enforce federal laws relating to cannabis in the future. As a result of the Sessions Memo, federal prosecutors are now free
to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities, despite the existence of state-level
laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memo as
to the priority they should ascribe to such cannabis activities, and thus it is uncertain how active U.S. federal prosecutors
will be in relation to such activities.
Federal
prosecutors appear to continue to use the Cole Memo’s priorities as an enforcement guide. Merrick Garland, who became Attorney
General on March 10, 2021 has indicated that he would deprioritize enforcement of low-level cannabis crimes such
as possession, and has shared his view that the government should focus on large-scale criminal enterprises that circumvent state
legalization laws instead of going after people who abide by local cannabis policies. The Company believes it is too soon to determine
what prosecutorial effects will be created by the rescission of the Cole Memo or any replacement thereof and when or if the Sessions
Memo will be rescinded. President Joseph R. Biden, who assumed office in January 2021, has not yet indicated whether and when
he will decriminalize or legalize cannabis and has previously stated that he is opposed to legalization. The sheer size of the
cannabis industry, in addition to participation by state and local governments and investors, suggests that a large-scale federal
enforcement operation would more than likely create unwanted political backlash for the DOJ and the current administration. It
is also possible that the change of Congressional leadership in January 2021 could change the priorities of Congress and encourage
reconciliation of federal and state laws. Regardless, at this time, cannabis remains a Schedule I controlled substance at
the federal level. The U.S. federal government has always reserved the right to enforce federal law in regard to the sale and
disbursement of medical or adult use cannabis, even if state law authorizes such sale and disbursement. It is unclear whether
the risk of enforcement has been altered.
23
One
legislative safeguard for the medical cannabis industry, appended to the federal budget bill, remains in place following the rescission
of the Cole Memo. For fiscal years 2015, 2016, 2017 and 2018, Congress adopted the Rohrabacher-Blumenauer Amendment to prevent
the federal government from using congressionally appropriated funds to enforce federal cannabis laws against regulated medical
cannabis actors operating in compliance with state and local law. The Rohrabacher-Blumenauer Amendment was included in the fiscal
year 2018 budget passed on March 23, 2018. The Rohrabacher-Blumenauer Amendment was included in the consolidated appropriations
bill signed into legislation by former President Trump in February 2019. In signing the Rohrabacher-Blumenauer Amendment, former
President Trump issued a signing statement noting that the Rohrabacher-Blumenauer Amendment “provides that the Department
of Justice may not use any funds to prevent implementation of medical marijuana laws by various States and territories,”
and further stating “I will treat this provision consistent with the President’s constitutional responsibility to
faithfully execute the laws of the United States.” On June 20, 2019, the House approved a broader amendment that, in
addition to protecting state medical cannabis programs, would also protect state adult use programs. On September 26, 2019,
the Senate Appropriations Committee declined to take up the broader amendment but did approve the Rohrabacher-Blumenauer Amendment
for the fiscal year 2020 spending bill. On September 27, 2019, the Rohrabacher-Blumenauer Amendment was renewed as part of
a stopgap spending bill, in effect through November 21, 2019, and was then renewed through a series of stopgap spending bills
passed in 2020. On December 27, 2020, the amendment was renewed through the signing of the fiscal year 2021 omnibus spending
bill, effective through September 30, 2021. Despite the rescission of the Cole Memo, the DOJ appears to continue to adhere
to the enforcement priorities set forth in the Cole Memo.
The
Cole Memo and the Rohrabacher-Blumenauer Amendment gave licensed cannabis operators (particularly medical cannabis operators)
and investors in states with legal regimes greater certainty regarding the DOJ’s enforcement priorities and the risk of
operating cannabis businesses. While the Sessions Memo has introduced some uncertainty regarding federal enforcement, the cannabis
industry continues to experience growth in legal medical and adult use markets across the United States. Vice President Kamala
Harris is the lead sponsor of the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act, which seeks to end the federal
prohibition of marijuana, among other things, but in March 2020, it was reported that Vice President Harris has adopted the same
position as President Biden, who opposes legalization. Currently, there is no guarantee that state laws legalizing and regulating
the sale and use of cannabis will remain in place or that local governmental authorities will not limit the applicability of state
laws within their respective jurisdictions. Unless and until the U.S. Congress amends the CSA with respect to cannabis (and as
to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may
enforce current U.S. federal law criminalizing cannabis.
Although
the U.S. Supreme Court has ruled that it is the federal government that has the right to regulate and criminalize cannabis, and
federal law criminalizing the use of marijuana preempts state laws that legalize its use, cannabis is largely regulated at the
state level.
State
laws that permit and regulate the production, distribution and use of cannabis for adult use or medical purposes are in direct
conflict with the CSA, which makes cannabis use and possession federally illegal. Although certain states and territories of the
U.S. authorize medical and/or adult use cannabis production and distribution by licensed or registered entities, under U.S. federal
law, the possession, use, cultivation and transfer of cannabis and any related drug paraphernalia is illegal and any such acts
are criminal acts under federal law under any and all circumstances under the CSA. Although the Company’s activities are
believed to be compliant with applicable state and local laws, strict compliance with state and local laws with respect to cannabis
may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which
may be brought against the Company.
As
of December 31, 2020, 35 states, plus the District of Columbia (and the territories of Guam, Puerto Rico, the U.S. Virgin
Islands and the Northern Mariana Islands), have legalized the cultivation and sale of cannabis for medical purposes. In 15 of
those states, the sale and possession of cannabis is legal for both medical and adult use, and the District of Columbia has legalized
adult use but not commercial sale. In November 2020, voters in Arizona, Montana, New Jersey and South Dakota voted by referendum
to legalize cannabis for adult use, and voters in Mississippi and South Dakota voted to legalized cannabis for medical use, and
in February 2021, the Virginia legislature approved a bill that would legalize cannabis for adult use beginning in 2024. The Virginia
bill is awaiting signature by the governor, and if signed, Virginia will be the first southern state to legalize cannabis for
adult use. Also in February 2021, New Jersey Governor Phil Murphy signed three bills into law that legalize cannabis for adult
use.
The
Company will focus heavily on the growth of a diversified revenue stream in 2021. We intend to accomplish this by prospecting
new advisory services across the country for private, public, and municipal clients. We believe that strategic real estate and
sustainability services are likely to emerge as the growth engine for Zoned Properties. We are moving to take advantage of new
opportunities.
Pursuant
to the terms of the several lease amendments our Significant Tenants, among other things, base rent base rent was abated from
June 1, 2020 to July 31, 2020 on all of our Significant Tenant leases which decreased our cash flow from operation during the
year ended December 31, 2020 by $179,000. In addition, the parties agreed that from the period from May 31, 2020 to June 30, 2022,
our Significant Tenants will invest a combined total of at least $8,000,000 improvements in and to the properties in Chino Valley
and Tempe prior to June 30, 2022. Any increase in the rentable area of the leased premises will result in an increase in all amounts
calculated based on the same, including, without limitation, base rent.
COVID-19
In
March 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures
worldwide. We are monitoring this closely, and although operations have not been materially affected by the COVID-19 outbreak
to date, the ultimate duration and severity of the outbreak and its impact on the economic environment and our business is uncertain.
Currently, all of the properties in our portfolio are open to our Significant Tenants and their customers and will remain open
pursuant to state and local government requirements. We did not experience in 2020, and we do not foresee in 2021, any material
changes to our operations from COVID-19. Our tenants are continuing to generate revenue at these properties and they have continued
to make rental payments in full and on time and we believe the tenants’ liquidity position is sufficient to cover its expected
rental obligations. Accordingly, while we do not anticipate an impact on our operations, we cannot estimate the duration of the
pandemic and potential impact on our business if the properties must close or if the tenants are otherwise unable or unwilling
to make rental payments. In addition, a severe or prolonged economic downturn could result in a variety of risks to our business,
including weakened demand for our properties and a decreased ability to raise additional capital when needed on acceptable terms,
if at all.
24
Results
of Operations
The
following comparative analysis of results of operations was based primarily on comparative consolidated financial statements,
footnotes and related information for the periods identified below and should be read in conjunction with the audited consolidated
financial statements and the notes to those statements for the years ended December 31, 2020 and 2019, which are included elsewhere
in this annual report on Form 10-K. The results discussed below are for the years ended December 31, 2020 and 2019.
Comparison
of Results of Operations for the Years ended December 31, 2020 and 2019
Revenues
For
the years ended December 31, 2020 and 2019, revenues consisted of the following:
Years
Ended
December 31,
2020
2019
Rent revenues
$ 1,125,346
$ 1,115,861
Advisory revenues
90,096
144,560
Total revenues
$ 1,215,442
$ 1,260,421
For
the year ended December 31, 2020, total revenues amounted to $1,215,442, including Significant Tenants revenues of $1,176,666,
as compared to $1,260,421, including Significant Tenant revenues of $1,115,861, for the year ended December 31, 2019, a decrease
of $44,979, or 3.6%.
For
the year ended December 31, 2020, the decrease in revenues was attributable to a decrease in advisory revenues of $54,464, or
37.7%, and an increase in rent revenues of $9,485, or 0.9%. Substantially all of the Company’s real estate properties are
leased under triple-net leases to the Significant Tenants.
Operating
expenses
For
the year ended December 31, 2020, operating expenses amounted to $1,177,709 as compared to $1,259,706 for the year ended December
31, 2019, a decrease of $81,997, or 6.5%. For the years ended December 31, 2020 and 2019, operating expenses consisted of the
following:
Years
Ended
December 31,
2020
2019
Compensation and benefits
$ 342,692
$ 383,648
Professional fees
195,684
233,940
General and administrative expenses
190,806
196,299
Depreciation and amortization
362,833
361,940
Real estate taxes
85,694
83,879
Total
$ 1,177,709
$ 1,259,706
●
For
the year ended December 31, 2020, compensation and benefit expense decreased by $40,956, or 10.7%, as compared to the year
ended December 31, 2019 and was primarily attributable to a decrease in stock-based compensation related to the accretion
of stock option expense and the value of shares issued for services, and a decrease in salary paid due to the reduction of
one employee.
●
For
the year ended December 31, 2020, professional fees decreased by $38,256, or 16.3%, as compared to the year ended December
31, 2019. This decrease in professional fees was primarily attributable to a decrease in public relations fees of $13,908,
a decrease in legal fees of $7,853, a decrease in accounting fees of $5,515, and a decrease in other professional fees
of $10,980 related to the decrease in advisory fees.
●
General
and administrative expenses consist of expenses such as rent expense, directors’ and officers’ liability insurance,
travel expenses, office expenses, telephone and internet expenses and other general operating expenses. For the year ended
December 31, 2020, general and administrative expenses decreased by $5,493, or 2.8%, as compared to the year ended December
31, 2019. This decrease was primarily attributable to a decrease in travel expense of $4,736, a decrease in due and subscription
fees of $7,030, a decrease in filing fees of $8,262 and a decrease in other general and administrative expenses of $10,888,
offset by an increase in advertising and promotion expense of $3,084 related to attending conferences, an increase in technology
fees of $7,076, an increase in rent expense of $4,520. and an increase in insurance expense of $2,039. Additionally, in the
2019 period, we received a tax refund of $8,704 which we did not receive in the 2020 period.
●
For
the year ended December 31, 2020, depreciation and amortization expense increased by $893, or 0.3%, as compared to the year
ended December 31, 2019.
●
For
the year ended December 31, 2020, real estate taxes increased by $1,815, or 2.2%, as compared to the year ended December 31,
2019.
25
Income
from operations
As
a result of the factors described above, for the year ended December 31, 2020, income from operations amounted to $37,733 as compared
to income from operations amounted to $715 for the year ended December 31, 2019, an increase of $37,018, or 5,177.3%.
Other
(expenses) income
Other
(expenses) income primarily includes interest expense incurred on debt with third parties and a related party and also includes
other income (expenses). For the year ended December 31, 2020, total other expenses, net amounted to $116,071 as compared to total
other expenses, net of $12,996, respectively, representing an increase of $103,075, or 793.1%. During the year ended December
31, 2019, we recognized other income of $108,204 related to a cash rebate received from the utility company as compared to nil
during the year ended December 31, 2020.
Net
loss
As
a result of the foregoing, for the years ended December 31, 2020 and 2019, net loss amounted to $78,338, or $(0.01) per common
share (basic and diluted), and $12,281, or $(0.00) per common share (basic and diluted), respectively.
Liquidity
and Capital Resources
Liquidity
is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. We had cash of $699,335
and $639,781 of cash as of December 31, 2020 and 2019, respectively.
Our
primary uses of cash have been for compensation and benefits, fees paid to third parties for professional services, real estate
taxes, general and administrative expenses, and the development of rental properties. All funds received have been expended in
the furtherance of growing the business. We receive funds from the collection of rental income and advisory fees. The following
trends are reasonably likely to result in changes in our liquidity over the near to long term:
●
An
increase in working capital requirements to finance our current business,
●
Addition
of administrative and sales personnel as the business grows, and
●
The
cost of being a public company.
We
may need to raise additional funds, particularly if we are unable to generate positive cash flow as a result of our operations.
We estimate that based on current plans and assumptions, that our available cash will be sufficient to satisfy our cash requirements
under our present operating expectations for the next 12 months from the date of this annual report on Form 10-K. Other than revenue
received from the lease of our rental properties and from advisory fees, we presently have no other significant alternative source
of working capital.
We
have used these funds to fund our operating expenses, pay our obligations, develop rental properties, and grow our company. We
need to raise significant additional capital or debt financing to acquire new properties, to develop existing properties, and
to assure we have sufficient working capital for our ongoing operations and debt obligations.
On
March 19, 2020, we made an initial investment of $100,000 into KCB Jade Holdings, LLC (“KCB”). In exchange for the
investment, KCB issued to us a convertible debenture (the “Debenture”) dated March 19, 2020 (the “Issuance Date”)
in the original principal amount of $100,000. The Debenture bears interest at the rate of 6.5% per annum and matures on March
19, 2025 (the “Maturity Date”). Interest on the outstanding principal sum of the Debenture commences accruing on the
Issuance Date and is computed on the basis of a 365-day year and the actual number of days elapsed and shall be payable annually
due by the first day of each calendar anniversary following the Issuance Date. KCB may prepay the Debenture at any point after
18 months following the Issuance Date, in whole or in part. However, if KCB elects to prepay the Debenture prior to the Maturity
Date or prior to any conversion as provided in the Debenture in whole or in part, we will be entitled to receive a number of KCB
units, in addition to such prepayment amount, constituting 10% of the total outstanding units and 10% of the total percentage
interest following such issuance and at the time of such issuance. On or after six months from the Issuance Date, we may convert
all or a portion of the principal balance and all accrued and unpaid interest due into a number of units equal to the proportion
of the outstanding amount being converted multiplied by 33% of the total number of units issued and outstanding at the time of
conversion, constituting 33% of the total percentage interest (the “Conversion Percentage”). If KCB defaults on payment
of the Debenture, we may, at its option, extend all conversion rights, through and including the date KCB tenders or attempts
to tender payment in full of all amounts due under the Debenture. Conversion rights terminate upon acceptance by the Company of
payment in full of principal, accrued interest and any other amounts due under the Debenture. If (i) KCB does not elect to exercise
its rights of prepayment prior to the Maturity Date, (ii) we do not elect to exercise its rights of conversion, and (iii) KCB
pays to the Company all outstanding principal and interest accrued and due under the terms of the Debenture on the Maturity Date,
we will still be entitled to receive a number of units, in addition to such payment amount, constituting 8% of the total outstanding
units and 8% of the total percentage interest following such issuance and at the time of such issuance.
On
February 19, 2021, we made an additional investment of $100,000 into KCB (the “Additional Investment”). In exchange,
the KCB issued to the Company an amended and restated convertible debenture (the “A&R Debenture”) on the Amendment
Date. The A&R Debenture amends and restates in its entirety the Original Debenture. Pursuant to the A&R Debenture, the
Company and KCB agreed to certain new terms that did not exist in the Original Debenture, which are described below.
● Interest
Accrual Commencement : Pursuant to the A&R Debenture, interest on the Initial
Investment begins accruing as of March 19, 2020, while interest on the Additional Investment
begins accruing on February 19, 2021.
26
● Franchise
Fees . In the A&R Debenture, the parties acknowledge that each time that KCB sells
one of its franchise locations, KCB earns a fee (an “Initial Fee”), and that
KCB also earns a fee when one of its franchise locations renews its franchise with KCB
(a “Renewal Fee”). Pursuant to the A&R Debenture, the Company and KCB
agreed that, as additional consideration for the Additional Investment, KCB will pay
to the Company, in perpetuity, 5% of any Initial Fee received by KCB after the Amendment
Date, as well as 5% of any Renewal Fee received by KCB related to any franchise locations
sold after the Amendment Date, in each case to be paid within five (5) days of receipt
of KCB thereof.
In
addition, following the Amendment Date, KCB agreed not to decrease the amount it charges its franchise locations for an Initial
Fee or any Renewal Fee as in effect on the Amendment Date without the prior written consent of the Company, or to take any other
actions that would reduce the value of KCB’s obligation to the Company with respect to these franchise fee payments. KCB’s
obligation to pay the Company the franchise fees listed above will survive any termination, repayment or conversion of the A&R
Debenture. Failure by KCB to pay the Company the franchise fees in the manner described above will result in an event of default,
and, among other things, any due and unpaid franchise fees will accrue interest at 12% per year from the date the obligation was
due.
Apart
from the terms described above, the terms of the A&R Debenture are substantially identical to the terms of the Original Debenture.
Our
future operations are dependent on our ability to manage our current cash balance, on the collection of rental and advisory revenues
and the attainment of new advisory clients. Our real estate properties are leased to Significant Tenants under triple-net leases
for which terms vary. We monitor the credit of these tenants to stay abreast of any material changes in credit quality. We monitor
tenant credit by (1) reviewing financial statements and related metrics and information that are publicly available or that are
provided to us upon request, and (2) monitoring the timeliness of rent collections. As of December 31, 2020 and 2019, we
had an asset concentration related to our Significant Tenant leases. As of December 31, 2020 and 2019, these Significant Tenants
represented approximately 83.2% and 90.7% of total assets, respectively. If our Significant Tenants are prohibited from operating
due to federal or state regulations or due to COVID-19, or cannot pay their rent, we may not have enough working capital to support
our operations and we would have to seek out new tenants at rental rates per square less than our current rate per square foot.
We
included audited financial statements of our Significant Tenants as Exhibits 99.1 and 99.2 to this Annual Report on Form 10-K
since such audited financial statements represent material information and are necessary for the protection of investors.
We
may secure additional financing to acquire and develop additional and existing properties. Financing transactions may include
the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to
raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements
that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, stockholders
may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of
existing holders of our common stock. The inability to obtain additional capital may restrict our ability to grow our business
operations.
Cash
Flow
For
the Years Ended December 31, 2020 and 2019
Net
cash flow provided by operating activities was $170,040 for the year ended December 31, 2020 as compared net cash flow provided
by operating activities of $284,914 for the year ended December 31, 2019, representing a decrease of $114,874.
●
Net
cash flow provided by operating activities for the year ended December 31, 2020 primarily reflected net loss of $78,338 adjusted
for the add-back of non-cash items consisting of depreciation and amortization of $362,833, stock-based compensation expense
of $24,200 and accretion of stock-based stock option expense of $24,231, offset by changes in operating assets and liabilities
primarily consisting of an increase in deferred rent receivable of $173,757 attributable to the abatement of May and June
2020 rent as part of lease amendments effective on May 31, 2020.
●
Net
cash flow provided by operating activities for the year ended December 31, 2019 primarily reflected net loss of $12,281 adjusted
for the add-back of non-cash items consisting of depreciation and amortization of $361,940, stock-based compensation expense
of $31,100 and accretion of stock-based stock option expense of $23,612, offset by changes in operating assets and liabilities
primarily consisting of a decrease in accounts payable of $(117,984), and net changes in other operating assets and liabilities
of $(1,473).
For
the year ended December 31, 2020, net cash flow used in investing activities amounted to $110,486. This use of cash was attributable
to cash used for an investment in a convertible note receivable of $100,000 as discussed above and cash used in the improvement
of rental properties of $9,563 and for the purchase of property and equipment of $923.We did not have any investing activities
for the year ended December 31, 2019.
Contractual
Obligations and Off-Balance Sheet Arrangements
Contractual
Obligations
We
have certain fixed contractual obligations and commitments that include future estimated payments. Changes in our business needs,
cancellation provisions, changing interest rates, and other factors may result in actual payments differing from the estimates.
We cannot provide certainty regarding the timing and amounts of payments. We have presented below a summary of the most significant
assumptions used in our determination of amounts presented in the tables, in order to assist in the review of this information
within the context of our consolidated financial position, results of operations, and cash flows.
27
The
following tables summarize our contractual obligations as of December 31, 2020 (dollars in thousands), and the effect these obligations
are expected to have on our liquidity and cash flows in future periods.
Payments
Due by Period
Contractual obligations:
Total
Less
than
1 year
1-3
years
3-5
years
5
+ years
Convertible notes
$
2,020
$
-
$
20
$
-
$
2,000
Interest on convertible notes
1,126
155
241
240
490
Total
$
3,146
$
155
$
261
$
240
$
2,490
Off-balance
Sheet Arrangements
We
have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties.
We have not entered into any derivative contracts that are indexed to our shares and classified as shareholders’ equity
or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest
in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do
not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support
to us or engages in leasing, hedging or research and development services with us.
Critical
Accounting Policies
Our
discussion and analysis of our financial condition and results of operations are based upon our audited and unaudited consolidated
financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.
The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually
evaluate our estimates, including those related to income taxes, and the valuation of equity transactions. We base our estimates
on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts
of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation
of the unaudited consolidated financial statements.
Rental
Properties
Rental
properties are carried at cost less accumulated depreciation and amortization. Betterments, major renovations and certain costs
directly related to the improvement of rental properties are capitalized. Maintenance and repair expenses are charged to expense
as incurred. Depreciation is recognized on a straight-line basis over estimated useful lives of the assets, which range from 5
to 39 years. Tenant improvements are amortized on a straight-line basis over the lives of the related leases, which approximate
the useful lives of the assets.
Upon
the acquisition of real estate, we assess the fair value of acquired assets (including land, buildings and improvements, identified
intangibles, such as acquired above-market leases and acquired in-place leases) and acquired liabilities (such as acquired below-market
leases) and allocate the purchase price based on these assessments. The Company assesses fair value based on estimated cash flow
projections that utilize appropriate discount and capitalization rates and available market information. Estimates of future cash
flows are based on a number of factors including historical operating results, known trends, and market/economic conditions.
Our
properties are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds the aggregate projected
future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is measured based on the excess
of the property’s carrying amount over its estimated fair value. Impairment analyses are based on our current plans, intended
holding periods and available market information at the time the analyses are prepared. If our estimates of the projected future
cash flows, anticipated holding periods, or market conditions change, our evaluation of impairment losses may be different and
such differences could be material to our consolidated financial statements. The evaluation of anticipated cash flows is subjective
and is based, in part, on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially
from actual results.
We
have capitalized land, which is not subject to depreciation.
Revenue
recognition
Effective
on January 1, 2018, we adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Update
(“ASU”) 2014-09 and Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with
Customers (“ASC 606”). ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing
revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or
services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for
those goods or services and also requires certain additional disclosures. We adopted this standard using the modified retrospective
approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording
a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The adoption of ASU 2014-09
did not have any impact on the process for, timing of, and presentation and disclosure of revenue recognition from contracts with
tenants.
28
Rental
income includes base rents that each tenant pays in accordance with the terms of its respective lease and is reported on a straight-line
basis over the non-cancellable term of the lease, which includes the effects of rent abatements under the leases. We commence
rental revenue recognition when the tenant takes possession of the leased space or controls the physical use of the leased space
and the leased space is substantially ready for its intended use.
Revenues
from advisory services is recognized when the Company performs services pursuant to its agreements with customers and collectability
is reasonably assured.
Stock-based
compensation
Stock-based
compensation is accounted for based on the requirements of ASC 718 – “Compensation – Stock Compensation ”,
which requires recognition in the financial statements of the cost of employee, director, and non-employee services received in
exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the
services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee,
director, and non-employee services received in exchange for an award based on the grant-date fair value of the award. The Company
has elected to recognize forfeitures as they occur as permitted under ASU 2016-09 Improvements to Employee Share-Based Payment .
Recent
Accounting Pronouncements
Effective
January 1, 2019, we adopted ASU 2016-02, “ Leases (Topic 842)” using a modified retrospective method. On adoption
we also applied the package of practical expedients to leases, where we are the lessee or lessor, that commenced before the effective
date whereby we elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the
lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.
ASU
2016-02, “ Leases (Topic 842)” sets out the principles for the recognition, measurement, presentation and disclosure
of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach,
classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed
purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest
method or on a straight-line basis over the term of the lease. A lessee is also required to recognize a right-of-use asset and
a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term
of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires
lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct
financing leases and operating leases.
For
contracts entered into on or after the effective date, where we are the lessee, at the inception of a contract the Company assess
whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct
identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout
the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to
each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January
1, 2019, are accounted for under ASC 840 and were not reassessed.
For
leases entered into on or after the effective date, where we are the lessor, at the inception of the contract we assess whether
the contract is a sales-type, direct financing or operating lease by reviewing the terms of the lease and determining if the lessee
obtains control of the underlying asset implicitly or explicitly.
If
a change to a pre-existing lease occurs, we evaluate if the modification results in a separate new lease or a modified lease.
A new lease results when a modification provides additional right of use. The new lease or modified lease is then reassessed to
determine its classification based on the modified terms.
The
adoption of ASU 2016-02 did not have a material impact on the operating leases where we are the lessor. We will continue to record
revenues from rental properties for our operating leases on a straight-line basis. For leases where we are a lessee, primarily
for our administrative office lease, we analyzed if it would be required to record a lease liability and a right of use asset
on our consolidated balance sheets at fair value upon adoption of ASU 2016-02. Since the terms of the Company’s operating
lease for its office space is 12 months or less, pursuant to ASC 842, we determined that the lease meets the definition of a short-term
lease and we did not recognize the right-of use asset and lease liability arising from this lease.
Recent
Accounting Pronouncements
Management
does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material
effect on the accompanying consolidated financial statements.
ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not
applicable.
29
ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
See
Index to Consolidated Financial Statements and Consolidated Financial Statement Schedules appearing on pages F-1 to F-24 of this
annual report on Form 10-K.
ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM
9A. CONTROLS AND PROCEDURES
Disclosure
controls and procedures
We
maintain “disclosure controls and procedures,” as that term is defined in Rule 13a-15(e), promulgated by the SEC pursuant
to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Disclosure controls and procedures include
controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and
forms, and that such information is accumulated and communicated to our management, including our principal executive officer
and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation
of our principal executive officer and principal financial officer, evaluated our company’s disclosure controls and procedures
as of the end of the period covered by this annual report on Form 10-K. Based on this evaluation, our principal executive officer
and principal financial officer concluded that as of December 31, 2020, our disclosure controls and procedures were not effective.
The ineffectiveness of our disclosure controls and procedures was due to material weaknesses, which we identified in our report
on internal control over financial reporting.
Internal
control over financial reporting
Management’s
annual report on internal control over financial reporting
Our
management, including our principal executive officer and principal financial officer, is responsible for establishing and maintaining
adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management, with
the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our internal
control over financial reporting as of December 31, 2020. Our management’s evaluation of our internal control over financial
reporting was based on the 2013 framework in Internal Control-Integrated Framework, issued by the Committee of Sponsoring Organizations
of the Treadway Commission. Based on this evaluation, our management concluded that as of December 31, 2020, our internal control
over financial reporting was not effective.
The
ineffectiveness of our disclosure controls and procedures was due to the following material weaknesses which we identified in
our internal control over financial reporting: (1) the lack of multiples levels of management review on complex accounting and
financial reporting issues, (2) we had not implemented adequate system and manual controls, and (3) a lack of adequate segregation
of duties and necessary corporate accounting resources in our financial reporting process and accounting function as a result
of our limited financial resources to support hiring of personnel and implementation of accounting systems. Until such time as
we expand our staff to include additional accounting personnel and hire a full time chief financial officer, it is likely we will
continue to report material weaknesses in our internal control over financial reporting.
A
material weakness is a deficiency or a combination of control deficiencies in internal control over financial reporting such that
there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented
or detected on a timely basis.
Limitations
on Effectiveness of Controls
Our
principal executive officer and principal financial officer does not expect that our disclosure controls or our internal control
over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can
provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to
their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include
the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake.
Additional controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management
override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with
the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements
due to error or fraud may occur and not be detected.
Changes
in internal control over financial reporting
There
were no changes in our internal control over financial reporting during the fourth quarter of our fiscal year ended December 31,
2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
ITEM
9B. OTHER INFORMATION
None.
30
PART
III
ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The
following table sets forth the names, positions and ages of our directors and executive officers as of the date of this annual
report on Form 10-K. Our Board of Directors currently has five members. All of the current directors’ terms expire as of
the Annual Meeting and will serve until their successors are duly elected and qualified.
Set
forth below is certain information regarding our executive officers and directors.
Name
Age
Position
Bryan
McLaren
33
Chief
Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and Chairman
Art
Friedman
61
Director
Alex
McLaren, MD
68
Director
David
G. Honaman
69
Director
Derek
Overstreet, PhD.
34
Director
Bryan
McLaren is the son of Dr. Alex McLaren.
Background
Information about our Officers and Directors
Biographical
information concerning the directors and executive officers listed above is set forth below. The information presented includes
information each individual has given us about all positions they hold and their principal occupation and business experience
for the past five years. In addition to the information presented below regarding each director’s specific experience, qualifications,
attributes and skills that led our board to conclude that he should serve as a director, we also believe that each of our directors
has a reputation for integrity, honesty and adherence to high ethical standards. Each has demonstrated business acumen and an
ability to exercise sound judgment, as well as a commitment of service to our company and our board of directors.
Bryan
McLaren. Mr. McLaren has a dedicated history of work in the sustainability industry and in business development. Prior to
his appointment as President, CEO and a director of our company in 2014, Mr. McLaren was recruited as our Chief Sustainability
Officer and VP of Operations. Before joining the Company, from 2013 to 2014, Mr. McLaren worked as a sustainability consultant
for Waste Management, Inc., where he served as a Project Manager for the Arizona State University account. Prior to 2013, Mr.
McLaren worked as a Sustainability Manager for Northern Arizona University and as a Sustainability Commissioner for the City of
Flagstaff, Arizona. Mr. McLaren has a Master’s Degree in Sustainable Community Development, and Executive Master’s
Degree in Sustainability Leadership, and a Masters of Business Administration Degree with an emphasis on Sustainable Development.
Mr. McLaren has served as the Chairman of our board of directors since 2014. As Chief Executive Officer and President, Mr. McLaren
is able to provide our Board with valuable insight regarding the Company’s operations, its management team and associates
as a result of his day-to-day involvement with the Company. Mr. McLaren’s business development experience, academic achievements,
and knowledge of our business, has led our board of directors to conclude that he should continue to serve as a director and in
his current roles.
Art
Friedman. Mr. Friedman, who was appointed as a director in 2014, has served as Owner/Principal of Triple J Management Services,
which specializes in consulting and professional services for the alcoholic beverage industry. Art was most recently President
and CEO of Gold Coast Beverage Distributors, a position he held for the last 10 years of his 23 years with the company. During
his tenure as President/CEO, Gold Coast more than tripled sales revenue and increased EBITDA by more than five-fold. Over the
same period, Mr. Friedman led significant market share gains through organic growth as well as consolidating wholesaler acquisitions.
Mr. Friedman began his career with General Foods Corporation, now part of Kraft Foods. He has served on the distributor advisory
councils of Diageo-Guinness, Heineken USA, InBev and Miller-Coors. Mr. Friedman graduation Cum Laude with a Bachelor of Science
in Business Management from the University of Florida, Warrington School of Business. We believe that Mr. Friedman’s background
as an advisor in the area of business management and his experience in operating, growing and advising companies provides us with
the requisite skills and qualifications to serve on our board. Mr. Friedman’s service as a director at the Company since
2014 together with his business background, provides business, governance, organizational and strategic planning expertise to
our Board and makes him a valued member of the Audit Committee, the Compensation Committee, which he chairs, and the Strategic
Committee.
Alex
McLaren, MD. Dr. McLaren, who has served as a director since 2014, is an accomplished and well-known orthopedic surgeon, professor
and researcher. He joined SharedClarity, LLC as Vice President of Clinical Outcomes in 2016. From 2006 until 2016, Dr. McLaren
served as program director of the Banner University Medical Center-Phoenix (Ariz.) Residency Program in Orthopaedic Surgery. He
is the former director of Orthopaedic Education for Banner Good Samaritan Medical Center in Phoenix. He was also the program director
of the Phoenix Orthopedic Residency Program at Maricopa County Medical Center between 1998 and 2000. He has been in private orthopedic
surgery practice twice during his career in Phoenix. After graduating from Queen’s University School of Medicine, Kingston,
Ontario, Canada in 1977, Dr. McLaren completed an orthopedic residency at the University of Western Ontario in 1982 and a fellowship
at the University of Southern California in 1983. Dr. McLaren is first and foremost an orthopedic educator and researcher
whose career has included teaching, research and administration of educational programs. His clinical interest includes orthopedic
infections, revision arthroplasty and complex musculoskeletal trauma. With hundreds of publications, numerous grand-funded projects,
and medical association postings, Dr. McLaren has established a prized reputation in his field. We believe that Dr. McLaren’s
services provided to numerous organizations provides us with the requisite skills and qualifications to serve on our board and
as a member of the Compensation Committee and the Strategic Committee, which he chairs.
31
David
G. Honaman. Mr. Honaman, who has served as a director since 2016, has served as Principal and CFO of Advanced Benefit Solutions,
Inc. (d/b/a 44 North), an insurance agent and consultant, since 2010. From 2008 to 2009, Mr. Honaman served as an independent
financial consultant. Prior to that time, Mr. Honaman spent seven years at Wilcox Associates, Inc., a civil engineering firm,
most recently as CFO and Treasurer. Mr. Honaman also served in several capacities at Wolohan Lumber Co. for over 20 years, including
as Vice President of Merchandising, Senior Vice President of Finance and CFO. Mr. Honaman began his career as a CPA on the audit
staff at Ernst & Young LLP. Mr. Honaman brings to the Board extensive experience dealing with and overseeing the implementation
of accounting principles and financial reporting rules and regulations. With his substantial business and management experience
for five years as a certified public accountant and an auditor at Ernst & Young LLP serving numerous public companies
in various business sectors, including insurance agencies, Mr. Honaman provides relevant expertise on accounting, investment and
financial matters. His service as a chief financial officer at Advanced Benefit Solutions, Inc. (d/b/a 44 North), Wilcox Associates,
Inc. and Wolohan Lumber Co., together with his accounting and management experience, make him a valued member of our Board, Compensation
Committee and Strategic Committee, and an effective Non-Executive Chair of the Audit Committee. Mr. Honaman meets the definition
of an “audit committee financial expert” as established by the SEC.
Derek
Overstreet, PhD. Dr. Overstreet has served as a director since April 2017. In 2012, Dr. Overstreet co-founded Sonoran Biosciences,
Inc. and has served as its CEO since that time. Sonoran Biosciences, Inc. develops new sustained-release pharmaceutical formulations
for applications including orthopedic infection and postoperative pain management. Dr. Overstreet holds a Bachelor’s degree
in Biomedical Engineering from Case Western Reserve University and a Doctoral degree in Biomedical Engineering from Arizona State
University. His expertise is in the development of novel polymer-based materials for medical applications including drug delivery.
He has authored 11 peer-reviewed scientific publications and two patent applications. We believe that Dr. Overstreet’s experience
navigating the scientific field of pharmaceuticals and drug delivery can be instrumental in assisting the strategic development
and implementation of the Zoned Properties’ business model. Prior to 2012, Dr. Overstreet was a post-doctoral fellow at
the Laboratory for Nanomedicine at the Barrow Neurological Institute.
Involvement
in Certain Legal Proceedings
Our
directors and executive officers have not been involved in any of the following events during the past 10 years:
1.
any
bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either
at the time of the bankruptcy or within two years prior to that time;
2.
any
conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other
minor offenses);
3.
being
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities
or banking activities;
4.
being
found by a court of competent jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have
violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
5.
being
the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated, relating to an alleged violation of: (i) any federal or state securities or commodities law
or regulation; or (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited
to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
cease- and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting mail or wire fraud or
fraud in connection with any business entity; or
6.
being
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of
the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority
over its members or persons associated with a member.
Code
of Ethics
We
have adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those
employees responsible for financial reporting. The code of business conduct and ethics is available on our corporate website,
www.zonedproperties.com. We intend to disclose any amendments to our code of business conduct and ethics, or waivers of its requirements,
on our website or in filings under the Exchange Act to the extent required by applicable rules and exchange requirements.
32
Director
Independence
Three
of our five board members are independent. The Board has determined that each of Messrs. Friedman and Honaman and Dr. Overstreet
is an independent director pursuant to the NASDAQ listing standards. Under the NASDAQ rules, no director qualifies as independent
unless the Board affirmatively determines that the director has no material relationship with us (directly, or as a partner, stockholder
or officer of an organization that has a relationship with us).
In
assessing the independence of our directors, the Board considers all of the business relationships between the Company and our
directors and their respective affiliated companies. This review is based primarily on the Company’s review of its own records
and on responses of the directors to questions in a questionnaire regarding employment, business, familial, compensation and other
relationships with the Company and our management. Where relationships exist, the Board determines whether the relationship between
the Company and the directors or the directors’ affiliated companies impairs the directors’ independence. After consideration
of the directors’ relationships with the Company, the Board has affirmatively determined that none of the individuals serving
as non-employee directors during the fiscal year ended December 31, 2020 had a material relationship with us and that each of
such non-employee directors is independent.
Bryan
McLaren was not considered an independent director during his service on the Board during the fiscal year ended December 31, 2020
because of his employment as our CEO, President, Treasurer, Secretary and Chairman of the Board. Alex McLaren, MD was not considered
an independent director during his service on the Board during the fiscal year ended December 31, 2020 because Bryan McLaren is
the son of Dr. McLaren.
Board
of Directors and Board Committees
All
of our directors and director nominees are encouraged to attend the annual meetings of our stockholders.
The
Board of Directors held one meeting during the fiscal year ended December 31, 2020. Each of our current directors attended 100%
of the aggregate number of the meetings of the Board and meetings of the committees on which he or she served.
Our
Board currently has three committees: the Audit Committee, the Strategic Committee, and the Compensation Committee. As of March
30, 2021, the members and Chairs of our standing Board committees were:
Audit
Compensation
Strategic
Independent
Directors
Art Friedman
X
Chair
X
David G. Honaman
Chair
X
X
Derek Overstreet
X
X
X
Non-Independent
Director
Alex McLaren, MD
X
Chair
Audit
Committee
All
Audit Committee members are “independent” under the NASDAQ listing standards and SEC rules and regulations. Our Board
of Directors has determined that one of the members of the Audit Committee, Mr. Honaman, meets the definition of an “audit
committee financial expert” as established by the SEC, and that Mr. Friedman and Dr. Overstreet, the two other members of
the Audit Committee, meet the definition of “financially literate” as established by the SEC. The Audit Committee
provides assistance to the Board in fulfilling its oversight responsibilities relating to the quality and integrity of the financial
reports of the Company. The Audit Committee has the sole authority to appoint, review and discharge our independent accountants,
and has established procedures for the receipt, retention, response to and treatment of complaints regarding accounting, internal
controls and audit matters. In addition, the Audit Committee is responsible for:
●
reviewing
the scope, results, timing and costs of the audit with our independent accountants and reviewing the results of the annual
audit examination and any accompanying management letters;
●
assessing
the independence of the outside accountants on an annual basis, including receipt and review of a written report from the
independent accountants regarding their independence consistent with the independence standards of the board;
●
reviewing
and approving the services provided by the independent accountants;
●
overseeing
the internal audit function; and
●
reviewing
our significant accounting policies, financial results and earnings releases, and the adequacy of our internal controls and
procedures.
The
responsibilities of the Audit Committee are more fully described in the Audit Committee’s charter.
The
Audit Committee held four meetings during the fiscal year ended December 31, 2020.
33
Compensation
Committee
All
Compensation Committee members (except for Dr. McLaren) are “independent” under applicable NASDAQ listing standards.
The Compensation Committee assists the Board in fulfilling its oversight responsibilities relating to executive compensation,
employee compensation and benefit programs and plans, and leadership development and succession planning. In addition, the Compensation
Committee is responsible for:
●
reviewing
the performance of our Chief Executive Officer;
●
determining
the compensation and benefits for our Chief Executive Officer and other executive officers;
●
establishing
our compensation policies and practices;
●
administering
our incentive compensation and stock plans (except for the issuance of securities to non-employee directors for services which
is administered by the Board); and
●
approving
the adoption of material changes to or the termination of our benefit plans.
The
Compensation Committee reviews and discusses with management the disclosures regarding executive compensation to be included in
our annual proxy statement. The responsibilities of the Compensation Committee are more fully described in the Compensation Committee’s
charter.
The
Compensation Committee held one meeting during the fiscal year ended December 31, 2020.
Strategic
Committee
All
Strategic Committee members (except for Dr. McLaren) are “independent” under the applicable NASDAQ listing standards.
The Strategic Committee assists the Board in developing and maintaining the Company’s business strategies and any related
matters required by federal securities laws. In addition, the Strategic Committee is responsible for:
●
Review
the Company’s current business strategies.
●
Explore
new business strategies for the Company.
●
Report
business strategy analyses to the Board.
The Strategic Committee held one meeting during the fiscal year ended December 31, 2020.
During
the fourth quarter of the fiscal year ended December 31, 2020, there were no material changes to the procedures by which stockholders
may recommend nominees to the Board.
ITEM
11. EXECUTIVE COMPENSATION
Summary
Compensation
The
following table summarizes all compensation recorded by us for the years ended December 31, 2020 and 2019 for our “named
executive officers” as such term is defined in Item 402(m)(2) of Regulation S-K.
2020
Summary Compensation Table
Name
and principal position
Year
Salary
$
Bonus
$
Stock
Awards
$
Option
Awards
$
Non-Equity
Incentive Plan
Compensation $
Nonqualified
Deferred
Compensation
Earnings
$
All
Other
Compensation $
Total
$
Bryan
McLaren,
Chief Executive Officer,
2020
214,500
-
-
-
-
-
-
214,500
President and Chief Financial Officer (1)
2019
214,500
-
-
-
-
-
-
214,500
34
Narrative
Disclosure to Summary Compensation Table
Except
as otherwise described below, there are no compensatory plans or arrangements, including payments to be received from the Company
with respect to any executive officer, that would result in payments to such person because of his or her resignation, retirement
or other termination of employment with the Company, or our subsidiaries, any change in control, or a change in the person’s
responsibilities following a change in control of the Company.
On
May 23, 2018, we entered into an employment agreement with Mr. McLaren (the “2018 Employment Agreement”). Pursuant
to the terms of the 2018 Employment Agreement, the Company agreed to continue to pay Mr. McLaren a base annual salary of $214,500,
and to award Mr. McLaren with an annual and/or quarterly bonus payable in either cash and/or equity of no less than 2% of the
Company’s net income for the associated period.
The
2018 Employment Agreement has a term of 10 years. The term and Mr. McLaren’s employment will terminate (a “Termination”)
in any of the following circumstances:
(i)
immediately,
if Mr. McLaren dies;
(ii)
immediately,
if Mr. McLaren receives benefits under the long-term disability insurance coverage then
(iii)
provided
by the Company or, if no such insurance is in effect, upon Mr. McLaren’s disability;
(iv)
on
the expiration date, as the same may be extended by the parties by written amendment to the 2018 Employment Agreement prior
to the occasion thereof;
(v)
at
the option of the Company for Cause (as hereinafter defined) upon the Company’s provision of written notice to Mr. McLaren
of the basis for such Termination;
(vi)
at
the option of the Company, without Cause;
(vii)
by
Mr. McLaren at any time with Good Reason (as hereinafter defined), upon 30 days’ prior written notice to the Company
delivered not later than within 90 days of the existence of the condition therefor; or
(viii)
by
Mr. McLaren at any time without Good Reason, upon not less than three months’ prior written notice to the Company.
In
the event of a Termination for any reason or for no reason whatsoever, or upon the expiration date of the 2018 Employment Agreement,
whichever comes first, all rights and obligations under the 2018 Employment Agreement shall cease (i) as to the Company, except
for the Company’s obligations for the payment of applicable severance benefits thereunder, and for indemnification thereunder,
and (ii) as to Mr. McLaren, except for his obligation under the restrictive covenants in the 2018 Employment Agreement.
The
Company and Mr. McLaren also entered into a Golden Parachute Agreement (the “Golden Parachute Agreement”) on May 23,
2018. No benefits shall be payable under the Golden Parachute Agreement unless there shall have been a change in control of the
Company, as set forth below. For purposes of the Golden Parachute Agreement, a “change in control of the Company”
shall mean a change of control of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation
14A promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), whether or not the Company
is in fact required to comply with that regulation, provided that, without limitation, such a change in control shall be deemed
to have occurred if (A) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), other
than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or a corporation owned, directly
or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company,
is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of
securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities;
or (B) during any period of two consecutive years (not including any period prior to the execution of the Golden Parachute Agreement),
individuals who at the beginning of such period constitute the Board and any new director (other than a director designated by
a person who has entered into an agreement with the Company to effect a transaction described in clauses (A) or (D) of this paragraph)
whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least
two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or
nomination for election was previously so approved, cease for any reason to constitute a majority; (C) the Company enters into
an agreement, the consummation of which would result in the occurrence of a change in control of the Company; or (D) the shareholders
of the Company approve a merger or consolidation of the Company with any other corporation, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior to it continuing to represent (either
by remaining outstanding or by being converted into voting securities of the surviving entity) of more than 50% of the combined
voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation,
or the shareholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition
by the Company of all or substantially all the Company’s assets.
For
purposes of the Golden Parachute Agreement, “Cause” means termination upon (a) the willful and continued failure to
substantially perform duties with the Company after a written demand for substantial performance is delivered by the Board, which
demand specifically identifies the manner in which the Board believes that duties have not substantially been performed, or (b)
the willful engaging in conduct which is demonstrably and materially injurious to the Company, monetarily or otherwise.
For
purposes of the Golden Parachute Agreement, “Good Reason” means, without express written consent, the occurrence after
a change in control of the Company of any of the following circumstances unless, such circumstances are fully corrected prior
to the date of Termination specified in the notice of Termination:
(a)
a
material diminution in Mr. McLaren’s authority, duties or responsibility from those in effect immediately prior to the
change in control of the Company;
35
(b)
a
material diminution in Mr. McLaren’s base compensation;
(c)
a
material change in the geographic location at which Mr. McLaren performs his duties;
(d)
a
material diminution in the authority, duties, or responsibilities of the supervisor to whom Mr. McLaren is required to report,
including a requirement that McLaren report to a corporate officer or employee instead of reporting directly to the Board;
(e)
a
material diminution in the budget over which Mr. McLaren retains authority;
(f)
a
material breach under any agreement with the Company to continue in effect any bonus to which Mr. McLaren was entitled, or
any compensation plan in which Mr. McLaren participates immediately prior to the change in control of the Company which is
material to Mr. McLaren’s total compensation;
(g)
a
material breach under any agreement with the Company to provide Mr. McLaren benefits substantially similar to those enjoyed
by Mr. McLaren under any of the Company’s life insurance, medical, health and accident, or disability plans in which
he was participating at the time of the change in control of the Company, the failure to continue to provide Mr. McLaren with
a Company automobile or allowance in lieu of it, if Mr. McLaren was provided with such an automobile or allowance in lieu
of it at the time of the change of control of the Company, the taking of any action by the Company which would directly or
indirectly materially reduce any of such benefits or deprive Mr. McLaren of any material fringe benefit enjoyed by Mr. McLaren
at the time of the change in control of the Company, or the failure by the Company to provide him with the number of paid
vacation days to which he is entitled on the basis of years of service with the Company in accordance with the Company’s
normal vacation policy in effect at the time of the change in control of the Company;
Following
a change in control of the Company, upon termination of Mr. McLaren’s employment or during a period of disability, Mr. McLaren
will be entitled to the following benefits:
(i)
During
any period that Mr. McLaren fails to perform his full-time duties with the Company as a result of incapacity due to physical
or mental illness, Mr. McLaren will continue to receive his base salary at the rate in effect at the commencement of any such
period, together with all amounts payable to Mr. McLaren under any compensation plan of the Company during such period, until
the Golden Parachute Agreement is terminated.
(ii)
If
Mr. McLaren’s employment is terminated by the Company for Cause or by Mr. McLaren other than for Good Reason, disability,
death or retirement, the Company will pay Mr. McLaren his full base salary through the date of Termination at the rate in
effect at the time notice of Termination is given, plus all other amounts and benefits to which Mr. McLaren is entitled under
any compensation plan of the Company at the time such payments are due.
(iii)
If
employment by the Company shall be terminated (a) by the Company other than for Cause, death or disability or (b) by Mr. McLaren
for Good Reason, Mr. McLaren will be entitled to benefits provided below:
a.
The
Company will pay Mr. McLaren his full base salary through the date of Termination at the rate in effect at the time notice
of Termination is given, plus all other amounts and benefits to which Mr. McLaren is entitled under any compensation plan
of the Company.
b.
In
lieu of any further salary payments to Mr. McLaren for periods subsequent to the date of Termination, the Company will pay
as severance pay to Mr. McLaren a lump sum severance payment (together with the payments provided in clauses (c) and (d) below)
equal to five times the sum of Mr. McLaren’s annual base salary in effect immediately prior to the occurrence of the
circumstance giving rise to the notice of Termination given in respect of them.
c.
The
Company will pay to Mr. McLaren any deferred compensation allocated or credited to Mr. McLaren or his account as of the date
of Termination.
d.
In
lieu of shares of common stock of the Company issuable upon exercise of outstanding options, if any, granted to Mr. McLaren
under the Company’s stock option plans (which options shall be cancelled upon the making of the payment referred to
below), Mr. McLaren will receive an amount in cash equal to the product of (i) the excess of the closing price of the Company’s
common stock as reported on or nearest the date of Termination (or, if not so reported, on the basis of the average of the
lowest asked and highest bid prices on or nearest the date of Termination), over the per share exercise price of each option
held by Mr. McLaren (whether or not then fully exercisable) plus the amount of any applicable cash appreciation rights, times
(ii) the number of the Company’s common stock covered by each such option.
e.
The
Company will also pay to Mr. McLaren all legal fees and expenses incurred by Mr. McLaren as a result of such Termination.
(iv)
In
the event that Mr. McLaren is a “disqualified individual” within the meaning of Section 280G of the Code, the
parties expressly agree that the payments described herein and all other payments to Mr. McLaren under any other agreements
or arrangements with any persons which constitute “parachute payments” within the meaning of Section 280G of the
Code are collectively subject to an overall maximum limit. Such maximum limit shall be $1 less than the aggregate amount which
would otherwise cause any such payments to be considered a “parachute payment” within the meaning of Section 280G
of the Code, as determined by the Company.
36
Outstanding
Equity Awards at 2020 Fiscal Year-End
The
following table sets forth information as options outstanding on December 31, 2020.
OUTSTANDING
EQUITY AWARDS AT 2020 FISCAL YEAR-END
OPTION
AWARDS
STOCK
AWARDS
Name
Number
of
Securities
Underlying
Unexercised
options (#)
Exercisable
Equity
Incentive Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
Unexercisable
Equity
Incentive Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
Option
Exercise
Price
($)
Option
Expiration
Date
Number
of Shares
or Units
of Stock
that have
not
Vested
(#)
Market
Value of
Shares or
Units of
Stock
that
Have not
Vested
($)
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other Rights
that have
not
Vested
(#)
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
other Rights
that have not
Vested
($)
Bryan McLaren
150,000
100,000
(a)
—
1.00
12/26/2026
—
—
—
—
(a)
Vest
annually at 25,000 options per year through December 2024.
Securities
Authorized for Issuance under Equity Compensation Plans
On
August 9, 2016, our Board of Directors authorized the 2016 Plan and reserved 10,000,000 shares of common stock for issuance thereunder.
The 2016 Plan was approved by shareholders on November 21, 2016. The 2016 Plan’s purpose is to encourage ownership in the
Company by employees, officers, directors and consultants whose long-term service the Company considers essential to its continued
progress and, thereby, encourage recipients to act in the stockholders’ interest and share in the Company’s success.
The 2016 Plan authorizes the grant of awards in the form of options intended to qualify as incentive stock options under Section
422 of the Code, options that do not qualify (non-statutory stock options) and grants of restricted shares of common stock. Restricted
shares granted pursuant to the 2016 Plan are amortized to expense over the three-year vesting period. Options vest and expire
over a period not to exceed seven years. If any share of common stock underlying a stock option that has been granted ceases to
be subject to a stock option, or if any shares of common stock that are subject to any other stock-based award granted are forfeited
or terminate, such shares shall again be available for distribution in connection with future grants and awards under the 2016
Plan. As of December 31, 2020, 75,000 stock option awards have been granted under the 2016 Plan. At December 31, 2020, 9,925,000
shares are available for future issuance.
The
Company also continues to maintain its 2014 Plan, pursuant to which 1,250,000 previously awarded stock options are outstanding.
The 2014 Plan has been superseded by the 2016 Plan. Accordingly, no additional shares subject to the existing 2014 Plan will be
issued and the 1,250,000 shares issuable upon exercise of stock options will be issued pursuant to the 2014 Plan, if exercised.
As of December 31, 2020, options to purchase 1,325,000 shares of common stock are outstanding pursuant to the 2014 Plan.
The
table below sets forth information as of December 31, 2020.
Plan
Category
Number
of
securities to
be issued upon
exercise of
outstanding
options,
warrants and
rights
Weighted-average
exercise price of
outstanding options,
warrants and rights
Number
of
securities
remaining
available for
future issuance
under equity
compensation
plans
(excluding
securities
reflected in
column (a))
(a)
(b)
(c)
Equity
compensation plans approved by security holders
75,000
$ 0.86
9,925,000
Equity
compensation plans not approved by security holders
1,250,000
$ 1.00
0
Total
1,325,000
$ 0.99
9,925,000
37
Director
Compensation
The
following table sets forth compensation paid, earned or awarded during 2020 to each of our directors, other than Bryan McLaren,
whose compensation is described above in the “2020 Summary Compensation Table”.
2020
Director Compensation
Name
Fees Earned
or Paid in
Cash ($)
Stock
Awards
($) (1)
All
Other
Compensation ($)
Total
($)
Art Friedman
1,050
6,600
-
7,650
David G. Honaman
-
5,500
-
5,500
Alex McLaren, MD
-
7,700
-
7,700
Derek Overstreet
-
4,400
-
4,400
(1)
As
required by SEC rules, the amounts in this column reflect the grant date or modification date fair value as required by FASB
ASC Topic 718. A discussion of the assumptions and methodologies used to calculate these amounts is contained in the notes
to our financial statements under “Shareholders’ Deficit”. In January 2020, Mr. Freidman received 30,000
shares of restricted stock, Dr. Overstreet received 20,000 shares of restricted stock, Dr. McLaren received 35,000 shares
of restricted stock and Mr. Honaman received 25,000 shares of restricted stock.
ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The
following table sets forth certain information regarding beneficial ownership of our common stock and preferred stock as of March
30, 2021, by:
●
Each
director and each of our Named Executive Officers,
●
All
executive officers and directors as a group, and
●
Each
person known by us to be the beneficial owner of more than 5% of our outstanding common stock.
As
of March 30, 2021, there were 12,141,548 shares of our common stock outstanding and 2,000,000 shares of Preferred Stock outstanding.
The
number of shares of common stock beneficially owned by each person is determined under the rules of the SEC and the information
is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any
shares as to which such person has sole or shared voting power or investment power and also any shares which the individual has
the right to acquire within 60 days after the date hereof, through the exercise of any stock option, warrant or other right. Unless
otherwise indicated, each person has sole investment and voting power (or shares such power with his or her spouse) with respect
to the shares set forth in the following table. The inclusion herein of any shares deemed beneficially owned does not constitute
an admission of beneficial ownership of those shares.
Common
Stock
Name
and Address of Beneficial Owner
Amount and
Nature of
Beneficial Ownership
Percent
of Class
Named Executive Officers and
Directors:
Bryan
McLaren
150,000
(1)
1.2
%
Art Friedman
140,000
1.2
%
Alex McLaren,
MD
1,676,667
(2)
13.8
%
David G. Honaman
115,000
(3)
*
Derek Overstreet,
PhD
90,000
(4)
*
All executive
officers and directors as a group (five persons)
2,171,667
(5)
17.6
%
Other 5%
Stockholders:
Greg Johnston
16912 61 st Dr. NW
Stanwood, WA 98292
1,262,500
10.4
%
Melinda Jay Johnston
915 Stitch Rd.
Lake Stevens, WA 98258
1,250,000
10.3
%
Joseph Bartonek
949 Durham Rd.
Edison, NJ 08817
756,250
6.2
%
*
Less
than 1%.
(1)
Consists
of 150,000 vested stock options.
(2)
Includes
1,501,667 shares held by McLaren Family LLLP. Dr. McLaren is the general partner of McLaren Family LLLP and has voting and
dispositive power over such shares and includes 15,000 vested stock options.
(3)
Includes
15,000 vested stock options.
(4)
Includes
10,000 vested stock options.
(5)
Includes
190,000 vested stock options.
38
Preferred
Stock
Name
and Address of Beneficial Owner
Shares
of
Preferred Stock
Beneficially
Owned
Percent of Class
Beneficially
Owned
Percent of
Voting
Power (1)
Greg Johnston
c/o Zoned Properties, Inc.
14269 N. 87 th
Street, #205
Scottsdale, AZ 85260
1,000,000
50.0 %
44.6 % (2)
Alex McLaren
c/o Zoned Properties, Inc.
14269 N. 87 th
Street, #205
Scottsdale, AZ 85260
1,000,000 (3)
50.0 %
44.6 % (4)
(1)
As
a result of the multiple votes accorded to holders of the preferred stock (50 votes per share), Mr. Johnston and Dr. McLaren
have the ability to control the outcome of all matters submitted to a vote of stockholders, including the election of directors.
The percent of voting power in the table gives effect to the holder’s beneficial ownership of common stock and preferred
stock.
(2)
Combined
with Mr. Johnston’s common stockholdings, Mr. Johnston holds 45.7% of the voting power of the Company.
(3)
Shares
are held by McLaren Family LLLP. Dr. McLaren is the general partner of McLaren Family LLLP and has voting and dispositive
power over such shares.
(4)
Combined
with Dr. McLaren’s common stockholdings, Dr. McLaren holds 46.1% of the voting power of the Company.
ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
We
do not have a written policy for the review, approval or ratification of transactions with related parties or conflicted transactions.
When such transactions arise, they are referred to the audit committee for consideration for referral to our board of directors
for its consideration.
Convertible
Notes Payable
On
January 9, 2017, the Company issued a convertible debenture (the “Abrams Debenture”) in the aggregate principal amount
of $2,000,000 in favor of Alan Abrams, a significant stockholder of the Company, in exchange for cash from Mr. Abrams of $2,000,000.
Also on January 9, 2017, the Company issued a convertible debenture (the “McLaren Debenture” and together with the
Abrams Debenture, the “Debentures”) in the aggregate principal amount of $20,000 in favor of Bryan McLaren, the Company’s
then Chief Executive Officer and President and a member of the Company’s Board of Directors (effective May 23, 2018, Mr.
McLaren also assumed the title of Chief Financial Officer), in exchange for cash from Mr. McLaren of $20,000. Each of Mr. Abrams
and Mr. McLaren is referred to herein as a “Holder.” Each of the Debentures accrues interest at the rate of 6% per
annum payable quarterly by the first of each quarter and matures on January 9, 2022. The Company may prepay the Debentures at
any point after nine months, in whole or in part. Pursuant to the terms of each of the Debentures, the Holder is entitled to convert
all or a portion of the principal balance and all accrued and unpaid interest due under the respective Debenture into shares of
the Company’s common stock at a conversion price of $5.00 per share. If the Company defaults on payment, the Holder may
at his option, extend all conversion rights, through and including the date the Company tenders or attempts to tender payment
in full of all amounts due under the Debenture. Any amount of principal or interest, which is not paid when due shall bear interest
at the rate of 12% per annum. Upon an Event of Default (as defined in each Debenture), the Holder may (i) declare the entire principal
amount and all accrued and unpaid interest under the Debenture immediately due and payable, and (ii) exercise any and all rights,
powers and remedies available to the Holder at law or in equity or other appropriate proceeding, whether for the specific performance
of any covenant or agreement contained in the Debenture and proceed to enforce the payment thereof or any other legal or equitable
right of the Holder.
Pursuant
to a Stock Redemption Agreement, effective January 1, 2019, the Company and Mr. Abrams amended the Abrams Debenture to extend
the maturity date of the Abrams Debenture from January 9, 2022 until January 9, 2030.
Director
Independence
Three
of our five board members are independent. The Board has determined that each of Messrs. Friedman and Honaman and Dr. Overstreet
is an independent director pursuant to the NASDAQ listing standards. Under the NASDAQ rules, no director qualifies as independent
unless the Board affirmatively determines that the director has no material relationship with us (directly, or as a partner, stockholder
or officer of an organization that has a relationship with us).
In
assessing the independence of our directors, the Board considers all of the business relationships between the Company and our
directors and their respective affiliated companies. This review is based primarily on the Company’s review of its own records
and on responses of the directors to questions in a questionnaire regarding employment, business, familial, compensation and other
relationships with the Company and our management. Where relationships exist, the Board determines whether the relationship between
the Company and the directors or the directors’ affiliated companies impairs the directors’ independence. After consideration
of the directors’ relationships with the Company, the Board has affirmatively determined that none of the individuals serving
as non-employee directors during the fiscal year ended December 31, 2020 had a material relationship with us and that each of
such non-employee directors is independent.
Bryan
McLaren was not considered an independent director during his service on the Board during the fiscal year ended December 31, 2020
because of his employment as our CEO, President, Treasurer, Secretary and Chairman of the Board. Alex McLaren, MD was not considered
an independent director during his service on the Board during the fiscal year ended December 31, 2020 because Bryan McLaren is
the son of Dr. McLaren.
39
ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The
following table sets forth the fees that were billed or that will be billed to our company for the years ended December 31, 2020
and 2019 for professional services rendered by D. Brooks and Associates CPAs, P.A.:
Fees
2020
2019
Audit Fees
$ 45,000
$ 45,000
Audit-Related Fees
0
0
Tax Fees
0
0
Other Fees
0
0
Total
Fees
$ 45,000
$ 45,000
Audit
Fees
Audit
fees were for professional services rendered for the audits of our financial statements and for review of our quarterly financial
statements.
Audit-Related
Fees
During
2020 and 2019, our independent registered public accountants did not provide any assurance and related services that are reasonably
related to the performance of the audit or review or our financial statements that are not reported under the caption “Audit
Fees” above.
Tax
Fees
As
our independent registered public accountants did not provide any services to us for tax compliance, tax advice and tax planning
during 2020 and 2019, no tax fees were billed or paid during those fiscal years.
All
Other Fees
Our
independent registered public accountants did not provide any products and services not disclosed in the table above during 2020
and 2019. As a result, there were no other fees billed or paid during 2020 and 2019.
Pre-Approval
Policies and Procedures
Our
Audit Committee pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed
and approved by our Audit Committee before the respective services were rendered.
Our
board of directors has considered the nature and amount of fees billed by our independent registered public accounting firm and
believe that the provision of services for activities unrelated to the audit is compatible with maintaining their respective independence.
40
PART
IV
ITEM
15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
Exhibits
required by Item 601 of Regulation S-K:
EXHIBIT
INDEX
Exhibit
Number
Description
of Exhibit
3.1
Articles
of Incorporation, as amended, of Zoned Properties, Inc. (1)
3.2
Bylaws
of Zoned Properties, Inc. (1)
10.1+
Board
Member Agreement dated as of October 1, 2014 by and between the registrant and Alex McLaren. (1)
10.2+
Board
Member Agreement dated as of October 1, 2014 by and between the registrant and Art Friedman. (1)
10.3+
Board
Member Agreement dated as of September 26, 2016 by and between the registrant and David G, Honaman. (8)
10.4+
Board
Member Agreement effective April 1, 2017 by and between Zoned Properties, Inc. and Derek Overstreet. (9)
10.5
Lease
dated as of August 6, 2015 by and between Chino Valley Properties, LLC and CCC Holdings, LLC. (1)
10.6
First
Amendment to Commercial Lease Agreement dated September 25, 2015 by and among Chino Valley Properties, LLC, CCC Holdings,
LLC and Alan Abrams. (1)
10.7
Lease
dated as of August 15, 2015 by and between the registrant and CCC Holdings, LLC. (1)
10.8
First
Amendment to Commercial Lease Agreement dated September 25, 2015 by and among the registrant, CCC Holdings, LLC and Alan Abrams.
(1)
10.9
Lease
Agreement dated as of October 1, 2014 by and between Green Valley Group, LLC and Broken Arrow Herbal Center, Inc. (1)
10.10
Lease
dated as of October 1, 2014 by and between Kingman Property Group, LLC and CJK, Inc. (1)
10.11+
Agreement
dated as of October 1, 2015 by and between the registrant and CFO Oncall, Inc. (1)
10.12
Stock
Option Grant Notice and Agreement between registrant and Newbridge Financial, Inc. (1)
10.13
Deed
of Trust dated March 7, 2015 in favor of Investment Property Exchange Services, Inc. covering Tempe, AZ property. (1)
10.14+
Stock
Option Grant Notice and Agreement dated December 20, 2015 between Zoned Properties, Inc. and Bryan McLaren. (2)
10.15
Contract
to Buy and Sell Real Estate (Commercial) entered into on April 21, 2016 between Zoned Colorado Properties, LLC and Parachute
Development Corporation. (3)
10.16
Second
Amendment to Commercial Lease by and between Zoned Properties, Inc., C3C3 Group, LLC and Alan Abrams. (4)
10.17
Third
Amendment to Commercial Lease by and between Chino Valley Properties, LLC, C3C3 Group, LLC and Alan Abrams. (5)
10.18
Commercial
Real Estate Purchase Contract dated December 22, 2016 by and between Zoned Properties, Inc. and Big Lake Estates, LLC. (6)
41
Exhibit
Number
Description
of Exhibit
10.19
Convertible
Debenture dated January 9, 2017 Issued by Zoned Properties, Inc. in Favor of Alan Abrams. (7)
10.20
Convertible
Debenture dated January 9, 2017 Issued by Zoned Properties, Inc. in Favor of Bryan McLaren . (7)
10.21
Fourth
Amendment to Commercial Lease by and between Chino Valley Properties, LLC, C3C3 Group, LLC and Alan Abrams. (9)
10.22
Third
Amendment to Commercial Lease by and between Zoned Properties, Inc., C3C3 Group, LLC and Alan Abrams, and Zoned Arizona Properties,
LLC, dated as of October 1, 2017. (10)
10.23
Licensed
Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 by and between Chino Valley Properties, LLC
and Broken Arrow Herbal Center, Inc. (11)
10.24
Licensed
Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 by and between Green Valley Group, LLC and Broken
Arrow Herbal Center, Inc. (11)
10.25
Licensed
Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 by and between Zoned Arizona Properties, LLC
and CJK, Inc. (11)
10.26
Licensed
Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 by and between Kingman Property Group, LLC and
CJK, Inc. (11)
10.27
Confidential
Advisory Services Agreement dated May 1, 2018 by and between Zoned Properties, Inc. and Broken Arrow Herbal Center, Inc. (11)
10.28
Confidential
Advisory Services Agreement dated May 1, 2018 by and between Zoned Properties, Inc. and CJK, Inc. (11)
10.29+
Employment
Agreement by and between the registrant and Bryan McLaren dated May 23, 2018. (12)
10.30+
Golden
Parachute Agreement by and between the registrant and Bryan McLaren dated May 23, 2018. (12)
10.31
Stock
Redemption Agreement effective January 1, 2019 by and among Zoned Properties, Inc., Christopher Carra, Alan B. Abrams, Clayton
Abrams Revocable Trust and Kyle Abrams Revocable Trust. (13)
10.32
First
Amendment to Confidential Advisory Services Agreement dated January 1, 2019 by and between Zoned Properties, Inc., on behalf
of Chino Valley Properties, LLC and Broken Arrow Herbal Center, Inc. (13)
10.33
First
Amendment to Confidential Advisory Services Agreement dated January 1, 2019 by and between Zoned Properties, Inc., on behalf
of Zoned Arizona Properties, LLC and CJK, Inc. (13)
10.34
Amendment
to Convertible Debenture entered into as of January 2, 2019 by and between Zoned Properties, Inc. and Alan Abrams. (13)
10.35
First
Amendment to Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated January 1, 2019 by and between Chino
Valley Properties, LLC and Broken Arrow Herbal Center, Inc. (13)
10.36
Convertible
Debenture issued March 19, 2020 from KCB Jade Holdings, LLC. (14)
10.37
First
Amendment to Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated as of May 31, 2020, by and between
Zoned Arizona Properties, LLC and CJK, Inc. (15)
10.38
Second
Amendment to Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated as of May 31, 2020, by and between
Chino Valley Properties, LLC and Broken Arrow Herbal Center, Inc. (15)
10.39
First
Amendment to Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated as of May 31, 2020, by and between
Green Valley Properties, LLC and Broken Arrow Herbal Center, Inc. (15)
10.40
First
Amendment to Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated as of May 31, 2020, by and between
Kingman Property Group, LLC and CJK, Inc. (15)
10.41
Amended
and Restated Convertible Debenture issued February 19, 2021 from KCB Jade Holdings, LLC. (16)
10.42
Commercial
Lease Agreement entered into on March 3, 2021, and dated as of February 26, 2021, between Gilbert Property Management, LLC
and AZ2CAL Enterprises, LLC. (17)
21.1*
List of Subsidiaries.
23.1*
Consent of Independent Registered Public Accounting Firm – D, Brooks and Associates CPA’s P.A. *
42
Exhibit
Number
Description
of Exhibit
31.1*
Certification
of Chief Executive Officer pursuant to Rule 13(a)-14(a) under the Securities Exchange Act of 1934, as amended.
31.2*
Certification
of Chief Financial Officer pursuant to Rule 13(a)-14(a) under the Securities Exchange Act of 1934, as amended.
32.1*
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
99.1
Audited financial statements of AC Management Group, LLC for the year ended December 31, 2020.
101.INS*
XBRL INSTANCE
DOCUMENT
101.SCH*
XBRL TAXONOMY
EXTENSION SCHEMA
101.CAL*
XBRL TAXONOMY
EXTENSION CALCULATION LINKBASE
101.DEF*
XBRL TAXONOMY
EXTENSION DEFINITION LINKBASE
101.LAB*
XBRL TAXONOMY
EXTENSION LABEL LINKBASE
101.PRE*
XBRL TAXONOMY
EXTENSION PRESENTATION LINKBASE
+
Management contract
or compensatory plan or arrangement.
*
Filed herewith
(1)
Incorporated
by reference to exhibit to Registration Statement on Form S-1 filed by the Company on November 25, 2015.
(2)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on January 7, 2016.
(3)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on April 22, 2016.
(4)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on August 25, 2016.
(5)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on October 13, 2016.
(6)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on December 29, 2016.
(7)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on January 12, 2017.
(8)
Incorporated
by reference to exhibit to Annual Report on Form 10-K filed with the SEC by the Company on March 27, 2017.
(9)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on April 4, 2017.
(10)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on October 3, 2017.
(11)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on May 3, 2018.
(12)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on May 24, 2018.
(13)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on January 3, 2019.
(14)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on March 23, 2020.
(15)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on June 4, 2020.
(16)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on February 19, 2021.
(17)
Incorporated
by reference to exhibit to Current Report on Form 8-K filed with the SEC by the Company on March 8, 2021.
ITEM
16. 10-K SUMMARY
As
permitted, the registrant has elected not to supply a summary of information required by Form 10-K.
43
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
Zoned Properties,
Inc.
Date: March 31, 2021
By:
/s/
Bryan McLaren
Bryan McLaren
Chief Executive Officer, President
and
Chief Financial Officer
POWER
OF ATTORNEY
Each
person whose signature appears below hereby appoints Bryan McLaren as attorney-in-fact with full power of substitution to execute
in the name and on behalf of the registrant and each such person, individually and in each capacity stated below, one or more
amendments to the annual report on Form 10-K, which amendments may make such changes in the report as the attorney-in-fact acting
deems appropriate and to file any such amendment to the annual report on Form 10-K with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons
on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/
Bryan McLaren
Chief
Executive Officer, Chief Financial Officer,
President, Treasurer, Secretary and
Director
March
31, 2021
Bryan McLaren
(principal
executive officer, principal financial officer and
principal
accounting officer)
/s/
Derek Overstreet
Director
March
31, 2021
Derek Overstreet
/s/
Art Friedman
Director
March
31, 2021
Art Friedman
/s/
Alex McLaren
Director
March
31, 2021
Alex McLaren
/s/
David G. Honaman
Director
March
31, 2021
David G.
Honaman
44
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2020 AND 2019
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Page
Report
of Independent Registered Public Accounting Firm
F-2
Consolidated
Financial Statements:
Consolidated
Balance Sheets as of December 31, 2020 and 2019
F-3
Consolidated
Statements of Operations – For the Years Ended December 31, 2020 and 2019
F-4
Consolidated
Statements of Changes in Stockholders’ Equity - For the Years Ended December 31, 2020 and 2019
F-5
Consolidated
Statements of Cash Flows – For the Years Ended December 31, 2020 and 2019
F-6
Notes
to Consolidated Financial Statements
F-7
to F-24
F- 1
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and
Stockholders of Zoned Properties, Inc.
Opinion
on the Consolidated Financial Statements
We
have audited the accompanying consolidated balance sheets of Zoned Properties, Inc. (the Company) as of December 31, 2020 and
2019, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the years ended December
31, 2020 and 2019, and related notes (collectively referred to as the consolidated financial statements)
In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2020 and 2019 the results of its operations and its cash flows for the years ended December 31, 2020 and 2019
in conformity with accounting principles generally accepted in the United States of America.
Basis
for Opinion
These
consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on
the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but
not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.
Critical
Audit Matters
Critical
audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial statements
and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit
matters.
D.
Brooks and Associates CPAs, P.A.
We
have served as the Company’s auditor since 2018.
Palm
Beach Gardens, Florida
March
30, 2021
F- 2
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31,
December 31,
2020
2019
ASSETS
Cash
$ 699,335
$ 639,781
Accounts
receivable
4,988
8,188
Deferred
rent receivable
173,757
-
Rental
properties, net
7,027,436
7,374,807
Prepaid
expenses and other assets
104,062
113,592
Convertible
note receivable
100,000
-
Property
and equipment, net
17,059
22,035
Security
deposits
1,100
1,100
Total
Assets
$ 8,127,737
$ 8,159,503
LIABILITIES
AND STOCKHOLDERS’ EQUITY
LIABILITIES:
Convertible
note payable
$ 2,000,000
$ 2,000,000
Convertible
note payable - related party
20,000
20,000
Accrued
expenses
92,750
94,641
Accrued
expenses - related party
4,200
3,000
Deferred
revenues
3,250
1,750
Security
deposits payable
71,800
74,468
Total
Liabilities
2,192,000
2,193,859
Commitments
and Contingencies (Note 11)
STOCKHOLDERS’
EQUITY:
Preferred stock,
$0.001 par value, 5,000,000 shares authorized; 2,000,000 shares issued and outstanding at December 31, 2020 and 2019 ($1.00
per share liquidation preference)
2,000
2,000
Common
stock: $0.001 par value, 100,000,000 shares authorized; 12,011,548 and 11,901,548 issued and outstanding at December 31, 2020
and 2019, respectively
12,012
11,902
Additional
paid-in capital
20,854,773
20,806,452
Accumulated
deficit
(14,933,048 )
(14,854,710 )
Total
Stockholders’ Equity
5,935,737
5,965,644
Total
Liabilities and Stockholders’ Equity
$ 8,127,737
$ 8,159,503
See
accompanying notes to consolidated financial statements.
F- 3
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS
For the
Year Ended
December
31,
2020
2019
REVENUES:
Rental
revenues
$ 1,125,346
$ 1,115,861
Advisory
revenues
90,096
144,560
Total
revenues
1,215,442
1,260,421
OPERATING EXPENSES:
Compensation
and benefits
342,692
383,648
Professional
fees
195,684
233,940
General
and administrative expenses
190,806
196,299
Depreciation
and amortization
362,833
361,940
Real
estate taxes
85,694
83,879
Total
operating expenses
1,177,709
1,259,706
INCOME
FROM OPERATIONS
37,733
715
OTHER (EXPENSES) INCOME:
Interest
expenses
(120,000 )
(120,000 )
Interest
expenses - related party
(1,200 )
(1,200 )
Other
income
-
108,204
Interest
income
5,129
-
Total
other expenses, net
(116,071 )
(12,996 )
LOSS BEFORE INCOME TAXES
(78,338 )
(12,281 )
PROVISION
FOR INCOME TAXES
-
-
NET LOSS
$ (78,338 )
$ (12,281 )
NET LOSS PER COMMON SHARE:
Basic
$ (0.01 )
$ 0.00
Diluted
$ (0.01 )
$ 0.00
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic
12,009,745
11,913,164
Diluted
12,009,745
11,913,164
See
accompanying notes to consolidated financial statements.
F- 4
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019
Total
Preferred
Stock
Common
Stock
Additional
Accumulated
Stockholders’
#
of Shares
Amount
#
of Shares
Amount
Paid-in
Capital
Deficit
Equity
Balance,
December 31, 2018
2,000,000
$ 2,000
17,441,552
$ 17,442
$ 20,746,200
$ (14,842,429 )
$ 5,923,213
Stock
redemption and cencellation
-
-
(5,640,004 )
(5,640 )
5,640
-
-
Common
stock issued for services
-
-
100,000
100
31,000
-
31,100
Accretion
of stock based compensation related to stock options issued
-
-
-
-
23,612
-
23,612
Net
loss
-
-
-
-
-
(12,281 )
(12,281 )
Balance,
December 31, 2019
2,000,000
2,000
11,901,548
11,902
20,806,452
(14,854,710 )
5,965,644
Common
stock issued for services
-
-
110,000
110
24,090
-
24,200
Accretion
of stock based compensation related to stock options issued
-
-
-
-
24,231
-
24,231
Net
loss
-
-
-
-
-
(78,338 )
(78,338 )
Balance,
December 31, 2020
2,000,000
$ 2,000
12,011,548
$ 12,012
$ 20,854,773
$ (14,933,048 )
$ 5,935,737
See
accompanying notes to consolidated financial statements.
F- 5
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
For the
Year Ended
December
31,
2020
2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net
loss
$ (78,338 )
$ (12,281 )
Adjustments to
reconcile net loss to net cash provided by operating activities:
Depreciation expense
362,833
361,940
Stock-based compensation
24,200
31,100
Stock option expense
24,231
23,612
Change in operating
assets and liabilities:
Accounts receivable
3,200
(8,188 )
Deferred rent
receivable
(173,757 )
-
Prepaid expenses
and other assets
9,530
3,375
Security deposits
-
(500 )
Accounts payable
-
(117,984 )
Accrued expenses
(1,891 )
7,005
Accrued expenses -
related parties
1,200
1,200
Deferred revenues
1,500
(1,000 )
Security
deposits payable
(2,668 )
(3,365 )
NET CASH PROVIDED
BY OPERATING ACTIVITIES
170,040
284,914
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of convertible
note receivable
(100,000 )
-
Purrchase of
rental property improvements
(9,563 )
-
Purrchase
of property and equipment
(923 )
-
NET CASH USED
IN INVESTING ACTIVITIES
(110,486 )
-
NET INCREASE IN CASH
59,554
284,914
CASH, beginning
of year
639,781
354,867
CASH, end of year
$ 699,335
$ 639,781
SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION
Interest
paid
$ 120,000
$ 120,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH
INVESTING AND FINANCING ACTIVITIES:
Reclassification
of convertible note payable - related party to convertible note payable
$ -
$ 2,000,000
Reclassification
of security deposits - related party to security deposits
$ -
$ 71,800
Reclassification
of accrued expenses - related party to accrued expenses
$ -
$ 33,000
See
accompanying notes to consolidated financial statements.
F- 6
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
NOTE
1 – ORGANIZATION AND NATURE OF OPERATIONS
Organization
Zoned
Properties, Inc. (“Zoned Properties” or the “Company”), was incorporated in the State of Nevada on August
25, 2003. The Company is a strategic real estate development firm whose primary mission is to provide real estate and sustainability
services for clients in the regulated cannabis industry, positioning the company for real estate acquisitions and revenue growth.
The Company intends to pioneer sustainable development for emerging industries, including the regulated cannabis industry. The
Company is an accredited member of the Better Business Bureau, the U.S. Green Building Council, and the Forbes Real Estate Council.
The Company focuses on investing capital to acquire and develop commercial properties to be leased on a triple-net basis, and
engaging clients that face zoning, permitting, development, and operational challenges. The Company provides development strategies
and advisory services that could potentially have a major impact on cash flow and property value. The Company does not grow, harvest,
sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substance Act of 1970,
as amended (the “CSA”).
The
Company has the following wholly owned subsidiaries:
●
Gilbert
Property Management, LLC (“Gilbert”) was organized in the State of Arizona on February 10, 2014.
●
Chino
Valley Properties, LLC (“Chino Valley”) was organized in the State of Arizona on April 15, 2014.
●
Kingman
Property Group, LLC (“Kingman”) was organized in the State of Arizona on April 15, 2014.
●
Green
Valley Group, LLC (“Green Valley”) organized in the State of Arizona on April 15, 2014.
●
Zoned
Oregon Properties, LLC was organized in the State of Oregon on June 16, 2015.
●
Zoned
Colorado Properties, LLC (“Zoned Colorado”) was organized in the State of Colorado on September 17, 2015.
●
Zoned
Illinois Properties, LLC was organized in the State of Illinois on July 15, 2015.
●
Zoned
Arizona Properties, LLC (“Zoned Arizona”) was organized in the State of Arizona on June 2, 2017.
●
Zoned
Advisory Services, LLC (“Zoned Advisory”) was organized in the State of Arizona on July 27, 2018.
In
March 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures
worldwide. The Company is monitoring this closely, and although operations have not been materially affected by the COVID-19 outbreak
to date, the ultimate duration and severity of the outbreak and its impact on the economic environment and our business is uncertain.
Currently, all of the properties in the Company’s portfolio are open to its Significant Tenants and their customers and
will remain open pursuant to state and local government requirements. At this time, the Company does not foresee any material
changes to its operations from COVID-19. The Company’s tenants are continuing to generate revenue at these properties, and
they have continued to make rental payments in full and on time and we believe the tenants’ liquidity position is sufficient
to cover its expected rental obligations. Accordingly, while the Company does not anticipate an impact on its operations, it cannot
estimate the duration of the pandemic and potential impact on its business if the properties must close or if the tenants are
otherwise unable or unwilling to make rental payments. In addition, a severe or prolonged economic downturn could result in a
variety of risks to the Company’s business, including weakened demand for its properties and a decreased ability to raise
additional capital when needed on acceptable terms, if at all. At this time, the Company is unable to estimate the impact of this
event on its operations.
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of presentation and principles of consolidation
The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries.
All intercompany balances and transactions have been eliminated upon consolidation.
F- 7
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Effective
January 1, 2019, the Company and certain beneficial shareholders entered into a Stock Redemption Agreement (See Note 8). Pursuant
to Securities and Exchange Commission (“SEC”) rules, each of these beneficial shareholders was deemed to be a “related
person” due solely to their status as significant stockholders of the Company. Pursuant to the terms of the Stock Redemption
Agreement, these beneficial shareholders would no longer be significant stockholders of the Company and would no longer be deemed
to be “related persons” under SEC rules. Accordingly, as of January 1, 2019, the Company will no longer reflect transactions
and balances related to these beneficial shareholders as related party transactions.
Use
of estimates
The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results
could differ from those estimates. Significant estimates for the years ended December 31, 2020 and 2019 include the collectability
of accounts and note receivable, the useful life of rental properties and property and equipment, assumptions used in assessing
impairment of long-term assets, valuation allowances for deferred tax assets, and the fair value of non-cash equity transactions,
including options and stock-based compensation.
Risks
and uncertainties
The
Company’s operations are subject to risk and uncertainties including financial, operational, regulatory and other risks
including the potential risk of business failure. The Company conducts a significant portion of its business in Arizona. Additionally,
the Company’s tenants operate in the medical marijuana industry. Consequently, any significant economic downturn in the
Arizona market or any changes in the federal government’s enforcement of current federal laws or changes in state laws could
potentially have a negative effect on the Company’s business, results of operations and financial condition. Additionally,
substantially all of the Company’s real estate properties are leased under triple-net leases to tenants that are controlled
by one entity (each, a “Significant Tenant” and collectively, the “Significant Tenants”). For the years
ended December 31, 2020 and 2019, rental and advisory revenue associated with the Significant Tenants amounted to $1,176,666 and
$1,146,654, which represents 96.8% and 91.0% of the Company’s total revenues, respectively (see Note 3).
Fair
value of financial instruments
The
carrying amounts reported in the consolidated balance sheets for cash, accounts receivable, prepaid expenses and other assets,
accounts payable, accrued expenses, and other payables approximate their fair market value based on the short-term maturity of
these instruments.
The
Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard
Board’s (the “FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities
are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company
did not identify any assets or liabilities that are required to be presented on the balance sheet at fair value in accordance
with Accounting Standards Codification (“ASC”) Topic 820.
Cash
Cash
is carried at cost and represents cash on hand, demand deposits placed with banks or other financial institutions and all highly
liquid investments with an original maturity of three months or less as of the purchase date of such investments. The Company
had no cash equivalents on December 31, 2020 and 2019. The majority of the Company’s cash is held at major commercial banks,
which may at times exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. To date, the Company has not experienced
any losses on its invested cash. On December 31, 2020 and 2019, the Company had approximately $449,000 and $390,000, respectively,
of cash in excess of FDIC limits of $250,000.
Accounts
receivable
The
Company recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries.
The allowance is based on an analysis of historical bad debt experience, current receivables aging and expected future write-offs,
as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The expense associated
with the allowance for doubtful accounts is recognized in general and administrative expense. For the years ended December 31,
2020 and 2019, the Company did not record any allowances for doubtful accounts.
F- 8
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Rental
properties
Rental
properties are carried at cost, less accumulated depreciation and amortization. Betterments, major renovations and certain costs
directly related to the improvement of rental properties are capitalized. Maintenance and repair expenses are charged to expense
as incurred. Depreciation is recognized on a straight-line basis over estimated useful lives of the assets, which range from 5
to 39 years. Tenant improvements are amortized on a straight-line basis over the lives of the related leases, which approximate
the useful lives of the assets.
Upon
the acquisition of real estate, the Company assesses the fair value of acquired assets (including land, buildings and improvements,
identified intangibles, such as acquired above-market leases and acquired in-place leases) and acquired liabilities (such as acquired
below-market leases) and allocate the purchase price based on these assessments. The Company assesses fair value based on estimated
cash flow projections that utilize appropriate discount and capitalization rates and available market information. Estimates of
future cash flows are based on a number of factors including historical operating results, known trends, and market/economic conditions.
The
Company’s rental properties are individually reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds
the aggregate projected future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is
measured based on the excess of the property’s carrying amount over its estimated fair value. Impairment analyses are based
on our current plans, intended holding periods and available market information at the time the analyses are prepared.
If
the Company’s estimates of the projected future cash flows, anticipated holding periods, or market conditions change, the
Company’s evaluation of impairment losses may be different and such differences could be material to its consolidated financial
statements. The evaluation of anticipated cash flows is subjective and is based, in part, on assumptions regarding future occupancy,
rental rates and capital requirements that could differ materially from actual results. For the years ended December 31, 2020
and 2019, the Company did not record any impairment losses.
The
Company has capitalized land, which is not subject to depreciation.
Property
and equipment
Property
and equipment is stated at cost, less accumulated depreciation. Depreciation of property and equipment is provided utilizing the
straight-line method over the estimated useful lives. The Company uses a five-year life for office equipment, seven years for
furniture and fixtures, and five to ten years for vehicles. Expenditures for maintenance and repairs are charged to expense as
incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the
accounts and any gain or loss is reflected in statements of operations.
The
Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the
fact that their recorded value may not be recoverable.
Revenue
recognition
The
Company follows Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers
(“ASC 606”). This standard establishes a single comprehensive model for entities to use in accounting for revenue
arising from contracts with customers and supersedes most of the existing revenue recognition guidance. ASC 606 requires an entity
to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.
Rental
income includes base rents that each tenant pays in accordance with the terms of its respective lease and is reported on a straight-line
basis over the non-cancellable term of the lease, which includes the effects of rent abatements under the leases. The Company
commences rental revenue recognition when the tenant takes possession of the leased space or controls the physical use of the
leased space and the leased space is substantially ready for its intended use.
Currently,
the Company’s leases provide for payments with fixed monthly base rents over the term of the leases. The leases also require
the tenant to remit estimated monthly payments to the Company for property taxes. These payments are recorded as rental income
and the related property tax expense reflected separately on the statements of operations.
F- 9
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
See
below for the adoption of ASU 2016-02, “Leases (Topic 842)” and its impact on our consolidated financial statements
upon adoption.
Revenues
from advisory services is recognized when the Company performs services pursuant to its agreements with clients and collectability
is reasonably assured.
Basic
and diluted income (loss) per share
Basic
(loss) income per share is computed by dividing net (loss) income available to common shareholders by the weighted average number
of shares of common stock outstanding during each period. Diluted (loss) income per share is computed by dividing net (loss) income
available to common shareholders by the weighted average number of shares of common stock, common stock equivalents and potentially
dilutive securities outstanding during the period using the treasury stock method and as-if converted method. Potentially dilutive
common shares and participating securities are excluded from the computation of diluted shares outstanding if they would have
an anti-dilutive impact on the Company’s net losses. The Company’s preferred stock is considered a participating security
since the preferred shares are entitled to dividends equal to common share dividends and accordingly, are included in the computation
of earnings per share pursuant to the two-class method. The two-class method of computing (loss) income per share is an earnings
allocation formula that determines (loss) income per share for common stock and any participating securities according to dividends
declared (whether paid or unpaid) and participation rights in undistributed earnings.
The
following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect would
be anti-dilutive for the years ended December 31, 2020 and 2019.
December 31,
2020
2019
Convertible
debt
404,000
404,000
Stock
options
1,325,000
1,290,000
1,729,000
1,694,000
Segment
reporting
The
Company’s business is comprised of one reportable segment. The Company has determined that its properties have similar economic
characteristics to be aggregated into one reportable segment (operating, leasing and managing commercial properties, and advisory
services related to commercial properties). The Company’s determination was based primarily on its method of internal reporting.
Income
tax
Deferred
income tax assets and liabilities arise from temporary differences between the financial statements and tax basis of assets and
liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred
tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities
to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current
depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when
necessary to reduce deferred tax assets to the amount expected to be realized.
The
Company follows the provisions of FASB ASC 740-10, “Uncertainty in Income Taxes”. Certain recognition thresholds must
be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize
tax positions that meet a “more-likely-than-not” threshold. The Company does not believe it has any uncertain tax
positions as of December 31, 2020 and 2019 that would require either recognition or disclosure in the accompanying consolidated
financial statements.
Stock-based
compensation
Stock-based
compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation ”,
which requires recognition in the financial statements of the cost of employee, director, and non-employee services received in
exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the
services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee,
director, and non-employee services received in exchange for an award based on the grant-date fair value of the award. The Company
has elected to recognize forfeitures as they occur as permitted under ASU 2016-09 Improvements to Employee Share-Based Payment .
F- 10
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Recently
adopted accounting pronouncements
Effective
January 1, 2019, the Company adopted ASU 2016-02, “ Leases (Topic 842)” using a modified retrospective method.
On adoption the Company also applied the package of practical expedients to leases, where the Company is the lessee or lessor,
that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or
existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct
costs for any existing leases.
ASU
2016-02, “ Leases (Topic 842)” sets out the principles for the recognition, measurement, presentation and disclosure
of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach,
classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed
purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest
method or on a straight-line basis over the term of the lease. A lessee is also required to recognize a right-of-use asset and
a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term
of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires
lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct
financing leases and operating leases.
For
contracts entered into on or after the effective date, where we are the lessee, at the inception of a contract the Company assess
whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct
identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout
the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to
each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January
1, 2019, are accounted for under ASC 840 and were not reassessed.
For
leases entered into on or after the effective date, where we are the lessor, at the inception of the contract the Company assess
whether the contract is a sales-type, direct financing or operating lease by reviewing the terms of the lease and determining
if the lessee obtains control of the underlying asset implicitly or explicitly.
If
a change to a pre-existing lease occurs, we evaluate if the modification results in a separate new lease or a modified lease.
A new lease results when a modification provides additional right of use. The new lease or modified lease is then reassessed to
determine its classification based on the modified terms. As disclosed in Note 3, on January 1, 2019, the Chino Valley lease was
modified to increase the monthly base rent from $35,000 to $40,000. Additionally, on May 31, 2020, the Chino Valley lease was
modified to decrease the monthly base rent from $40,000 to $32,800 and the Tempe lease was modified to increase the monthly base
rent from $33,500 to $49,200. At the commencement of the modified terms, the Company reassessed its lease classification and concluded
it remained properly classified as an operating lease.
The
adoption of ASU 2016-02 did not have a material impact on the operating leases where the Company is a lessor. The Company will
continue to record revenues from rental properties for its operating leases on a straight-line basis. Any revenue on the straight-line
basis exceeding the monthly payment amount required on the operating lease is reflected as a deferred rent receivable. Effective
May 31, 2020, the Company amended its leases for which it is the lessor on its Chino Valley, Tempe, Kingman and Green Valley properties.
The amendments resulted in an abatement of rent for the months of June and July 2020. This rent abatement resulted in a deferred
rent receivable as of December 31, 2020 of $173,757 (see Note 3).
For
leases where the Company is a lessee, primarily for the Company’s administrative office lease, the Company analyzed if it
would be required to record a lease liability and a right of use asset on its consolidated balance sheets at fair value upon adoption
of ASU 2016-02. Since the terms of the Company’s operating lease for its office space is 12 months or less, pursuant to
ASC 842, the Company determined that the lease meets the definition of a short-term lease and the Company did not recognize a
right-of use asset and lease liability arising from this lease.
Recently
issued accounting pronouncements
Management
does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material
effect on the accompanying consolidated financial statements.
F- 11
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
NOTE
3 – CONCENTRATIONS AND RISKS
Lease
Agreements with Significant Tenants
Chino
Valley
On
May 1, 2018, Chino Valley and Broken Arrow Herbal Center, Inc. (“Broken Arrow”) agreed to terminate the prior Chino
Valley Lease dated April 6, 2015, as amended, in consideration of (i) entry into that certain Licensed Medical Marijuana Facility
Triple Net (NNN) Lease Agreement dated May 1, 2018 between Chino Valley and Broken Arrow (the “2018 Chino Valley Lease”),
with a term of 22 years, expiring April 30, 2040, and (ii) abatement of rent that would otherwise have been due for the month
of April 2018 under the prior Chino Valley Lease. The 2018 Chino Valley Lease provided for payment by Broken Arrow of a fixed
monthly base rent of $35,000, as well as real property taxes, personal property taxes, privilege, sales, rental, excise, use and/or
other taxes (excluding income or estate taxes) levied upon or assessed against Chino Valley. In addition, pursuant to the terms
of the 2018 Chino Valley Lease, Broken Arrow agreed to maintain insurance in full force during the term of the 2018 Chino Valley
Lease and any other period of occupancy of the premises by Broken Arrow. On January 1, 2019, Chino Valley and Broken Arrow entered
into that the First Amendment to the 2018 Chino Valley Lease (the “2019 Chino Valley Lease Amendment”), pursuant to
which the monthly base rent was increased from $35,000 to $40,000. Except for the increase in base rent, the terms of the 2018
Chino Valley Lease remain in full force and effect.
On
May 29, 2020, Chino Valley and Broken Arrow entered into a second amendment to the 2018 Chino Valley Lease, as amended (the “2020
Chino Valley Amendment”), effective May 31, 2020 (“Effective Date”). Pursuant to the terms of the 2020 Chino
Valley Amendment, among other things, the base rent was adjusted to $32,800 per month, and the base rent was abated from June
1, 2020 to July 31, 2020. Any increase in the rentable area of the leased premises will result in an increase in all amounts calculated
based on the same, including, without limitation, base rent. Pursuant to the terms of the 2020 Chino Valley Amendment, the parties
agreed that if there is any change in laws such that the dispensing, sale or cultivation of marijuana upon the premises is prohibited
or materially and adversely affected as mutually and reasonably determined by Chino Valley and Broken Arrow, Broken Arrow may
terminate the 2018 Chino Valley Lease, as amended, by delivering written notice to Chino Valley, together with a termination payment
which shall be the sum of (i) any unpaid rent and interest, plus (ii) 5% of the base rent which would have been earned after termination
for the balance of the term.
In
addition, the parties agreed that from the period from the Effective Date to June 30, 2022 (the “Improvement Period”),
Broken Arrow will and/or Broken Arrow will cause its affiliate, CJK, to invest a combined total of at least $8,000,000 of improvements
(“Investment by Tenants”) in and to the property that is the subject of the Chino Valley Lease and the property that
is the subject of the Tempe Lease (discussed below, and collectively referred to as the “Facilities”). If Broken Arrow
and/or CJK fails to deliver to the Company receipted bills for hard and soft costs of improvements to the Facilities totaling
at least $8,000,000 on or before June 30, 2022, Broken Arrow will be in default under the Chino Valley Lease and Tempe Lease,
as amended.
Green
Valley
On
May 1, 2018, Green Valley and Broken Arrow agreed to terminate the prior Green Valley Lease dated October 1, 2014, in consideration
of (i) entry into that certain Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between
Green Valley and Broken Arrow (the “Green Valley Lease”), with a term of 22 years, expiring April 30, 2040, and (ii)
abatement of rent that would otherwise have been due for the month of April 2018 under the prior Green Valley Lease. The Green
Valley Lease provided for payment by Broken Arrow of a fixed monthly base rent of $3,500, as well as real property taxes, personal
property taxes, privilege, sales, rental, excise, use and/or other taxes (excluding income or estate taxes) levied upon or assessed
against Chino Valley. In addition, pursuant to the terms of the Green Valley Lease, Broken Arrow agreed to maintain insurance
in full force during the term of the Green Valley Lease and any other period of occupancy of the premises by Broken Arrow.
On
May 29, 2020, Green Valley and Broken Arrow entered into the First Amendment (the “Green Valley Amendment”) to the
Green Valley Lease, effective May 31, 2020. Pursuant to the terms of the Green Valley Amendment, among other things, the parties
agreed to abate the fixed base rent of $3,500 from June 1, 2020 to July 31, 2020. In addition, the Green Valley Amendment provides
that any increase in the rentable area of the leases premises will result in an increase in all amounts calculated based on the
same, including, without limitation, base rent. The parties also agreed that if there is any change in laws such that the dispensing,
sale or cultivation of marijuana upon the premises is prohibited or materially and adversely affected as mutually and reasonably
determined by Green Valley and Broken Arrow, Broken Arrow may terminate the Green Valley Lease by delivering written notice to
Green Valley, together with a termination payment which shall be the sum of (i) any unpaid rent and interest, plus (ii) 5% of
the base rent which would have been earned after termination for the balance of the term.
F- 12
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Tempe
On
May 1, 2018, Zoned Arizona and CJK, Inc. (“CJK”) agreed to terminate the prior Tempe Leases dated August 15, 2015,
as amended, and June 15, 2017, in consideration of (i) entry into that certain Licensed Medical Marijuana Facility Triple Net
(NNN) Lease Agreement dated May 1, 2018 between Zoned Arizona and CJK (the “Tempe Lease”), with a term of 22 years,
expiring April 30, 2040, and (ii) abatement of rent that would otherwise have been due for the month of April 2018 under the prior
Tempe Leases. The Tempe Lease provided for payment by CJK of a fixed monthly base rent of $33,500, as well as real property taxes,
personal property taxes, privilege, sales, rental, excise, use and/or other taxes (excluding income or estate taxes) levied upon
or assessed against Zoned Arizona. In addition, pursuant to the terms of the Tempe Lease, CJK agreed to maintain insurance in
full force during the term of the Tempe Lease and any other period of occupancy of the premises by CJK.
On
May 29, 2020, Zoned Arizona and CJK entered into the First Amendment (the “Tempe Amendment”) to the Tempe Lease, effective
May 31, 2020. Pursuant to the terms of the Tempe Amendment, among other things, the base rent was increased to $49,200 per month,
and the base rent was abated from June 1, 2020 to July 31, 2020. Any increase in the rentable area of the leased premises will
result in an increase in all amounts calculated based on the same, including, without limitation, base rent. Pursuant to the terms
of the Tempe Amendment, the parties agreed that if there is any change in laws such that the dispensing, sale or cultivation of
marijuana upon the premises is prohibited or materially and adversely affected as mutually and reasonably determined by Zoned
Arizona and CJK, CJK may terminate the Tempe Lease by delivering written notice to Zoned Arizona, together with a termination
payment which shall be the sum of (i) any unpaid rent and interest, plus (ii) 5% of the base rent which would have been earned
after termination for the balance of the term.
In
addition, under the Tempe Amendment the parties agreed to an Investment by Tenant (as defined above in the subheading Chino
Valley ) to the property that is the subject of the Chino Valley Lease and the property that is the subject of the Tempe Lease.
If Broken Arrow and/or CJK fails to deliver to the Company receipted bills for hard and soft costs of improvements to the Facilities
totaling at least $8,000,000 on or before June 30, 2022, Broken Arrow and CJK will be in default under the Chino Valley Lease
and Tempe Lease, as amended.
Kingman
On
May 1, 2018, Kingman and CJK agreed to terminate the prior Kingman Lease dated October 1, 2014, in consideration of (i) entry
into that certain Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between Kingman and CJK
(the “Kingman Lease”), with a term of 22 years, expiring April 30, 2040, and (ii) abatement of rent that would otherwise
have been due for the month of April 2018 under the Prior Kingman Lease. The Kingman Lease provides for payment by CJK of a fixed
monthly base rent of $4,000, as well as real property taxes, personal property taxes, privilege, sales, rental, excise, use and/or
other taxes (excluding income or estate taxes) levied upon or assessed against Kingman. In addition, pursuant to the terms of
the Kingman Lease, CJK agreed to maintain insurance in full force during the term of the Kingman Lease and any other period of
occupancy of the premises by CJK.
On
May 29, 2020, Kingman and CJK entered into the First Amendment (the “Kingman Amendment”) to the Kingman Lease, effective
May 31, 2020. Pursuant to the terms of the Kingman Amendment, among other things, the parties agreed to abate the $4,000 base
rent from June 1, 2020 to July 31, 2020. In addition, the Kingman Amendment provides that any increase in the rentable area of
the leases premises will result in an increase in all amounts calculated based on the same, including, without limitation, base
rent. The parties also agreed that if there is any change in laws such that the dispensing, sale or cultivation of marijuana upon
the premises is prohibited or materially and adversely affected as mutually and reasonably determined by Kingman and CJK, CJK
may terminate the Kingman Lease by delivering written notice to Kingman, together with a termination payment which shall be the
sum of (i) any unpaid rent and interest, plus (ii) 5% of the base rent which would have been earned after termination for the
balance of the term.
CJK
and Broken Arrow, together, operate under the company brand, “Hana Meds”, and are referred to as the Company’s
Significant Tenants.
The
Tempe Lease, Kingman Lease, Chino Valley Lease and Green Valley Lease (together referred to as the “New Leases”) includes
a Guarantee of Payment and Performance by Mr. Abrams and the Company’s Significant Tenants. Mr. Abrams guarantee is collateralized
by the convertible debt of $2,000,000 owed to him (see Note 7).
F- 13
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
As
of December 31, 2020 and 2019, security deposits payable to the Significant Tenants amounted to $71,800 in both periods.
Future
minimum lease payments primarily consist of minimum base rent payments from Significant Tenants and the Commercial Lease Agreement
executed by Gilbert subsequent to December 31, 2020 (see Note 12). Future minimum lease payments to be received, on all leased
properties, for each of the five succeeding calendar years and thereafter as of December 31, 2020 consists of the following:
Future
annual base rent:
2021
$ 1,096,000
2022
1,107,000
2023
1,082,250
2024
1,074,000
2025
1,074,000
Thereafter
15,394,000
Total
$ 20,827,250
Rental
and advisory revenue and receivable –Significant Tenants
For
the years ended December 31, 2020 and 2019, rental and advisory revenue associated with the Significant Tenant leases described
above amounted to $1,176,666 and $1,146,654, which represents 96.8% and 91.0% of the Company’s total revenues, respectively.
On
December 31, 2020 and 2019, accounts receivable from advisory services provided to the Significant Tenant amounted to $2,375 and
$8,188, respectively. Further, as of December 31, 2020 a deferred rent receivable of $173,757 is due from Significant Tenants
due to the abatement of rent in the months of June and July 2020 under the amendments executed effective May 31, 2020 discussed
above.
Asset
concentration
The
majority of the Company’s real estate properties are leased to the Significant Tenant under triple-net leases that terminate
in April 2040. The Company monitors the credit of all tenants to stay abreast of any material changes in credit quality. The Company
monitors tenant credit by (1) reviewing financial statements and related metrics and information that are publicly available or
that are provided to us upon request, and (2) monitoring the timeliness of rent collections.
As
of December 31, 2020 and 2019, the Company had an asset concentration related to the Significant Tenants. As of December 31, 2020
and 2019, the Significant Tenants represented approximately 83.2% and 87.1% of the Company’s total assets, respectively.
Through December 31, 2020, all rental payments have been made on a timely basis. As of December 31, 2020, the lease agreements
with the Significant Tenants were personally guaranteed by Alan Abrams and are collateralized by convertibles notes of $2,000,000
owed to Mr. Abrams (see Note 7). On March 1, 2018, the Company and Alan Abrams entered into a Reaffirmation Agreement (See Note
7).
Confidential
advisory services agreements
On
May 1, 2018, the Company entered into that certain Confidential Advisory Services Agreement by and between the Company and Broken
Arrow (the “Broken Arrow CASA”), with a term expiring on April 30, 2040, unless earlier terminated as provided in
the Broken Arrow CASA. Additionally, on May 1, 2018, the Company entered into that certain Confidential Advisory Services Agreement
by and between the Company and CJK (the “CJK CASA”), with a term expiring on April 30, 2040, unless earlier terminated
as provided in the CJK CASA. These Agreements may be terminated prior to the expiration of the Term upon the occurrence of any
of the following: (a) by the Company for any reason at any time upon thirty calendar days’ written notice to the other party;
(b) by either party immediately upon the mutual agreement of the parties, evidenced by a writing signed by the parties; or (c)
immediately by either party in the event of an actual finding, by a court of competent jurisdiction, of fraud, gross negligence
or willful misconduct of the other party in connection with these Agreements. Pursuant to the terms of the Broken Arrow CASA and
CJK CASA, Broken Arrow and CJK engaged the Company to perform certain advisory services in exchange for a fee equal to 10% of
Broken Arrow’s and CJK’s gross revenues (the (“Revenue Fee”), commencing January 2019.
F- 14
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
On
January 1, 2019, as part of a Stock Redemption Agreement, the Company, on behalf of Chino Valley, and Broken Arrow entered into
the First Amendment to Confidential Advisory Services Agreement (the “Broken Arrow CASA Amendment”). The Broken Arrow
CASA Amendment amended the Broken Arrow CASA to (i) reduce the gross revenue fee payable by Broken Arrow from 10% to 0%, and (ii)
add a $250 hourly advisory fee payable by Broken Arrow. Except as set forth herein, the terms of the Broken Arrow CASA remain
in full force and effect.
On
January 1, 2019, as part of the Stock Redemption Agreement, the Company, on behalf of Zoned Arizona, and CJK entered into the
First Amendment to Confidential Advisory Services Agreement (the “CJK CASA Amendment”). The CJK CASA Amendment amended
the CJK CASA to (i) reduce the gross revenue fee payable by CJK from 10% to 0%, and (ii) add a $250 hourly advisory fee payable
by CJK. Except as set forth herein, the terms of the CJK CASA remain in full force and effect.
NOTE
4 – RENTAL PROPERTIES
On
December 31, 2020 and 2019, rental properties, net consisted of the following:
Description
Useful
Life
(Years)
December 31,
2020
December 31,
2019
Building
and building improvements
5-39
$ 6,260,524
$ 6,250,959
Land
-
2,283,214
2,283,214
Rental
properties, at cost
8,543,738
8,534,173
Less:
accumulated depreciation
(1,516,302 )
(1,159,366 )
Rental
properties, net
$ 7,027,436
$ 7,374,807
For
the years ended December 31, 2020 and 2019, depreciation of rental properties amounted to $356,934 and $355,280, respectively.
NOTE
5 – PROPERTY AND EQUIPMENT
On
December 31, 2020 and 2019, property and equipment consisted of the following:
Description
Useful
Life
(Years)
December 31,
2020
December 31,
2019
Vehicle
and site trailers
5
- 10
$
38,855
$
38,855
Office
furniture and equipment
5
- 7
18,268
17,345
57,123
56,200
Less:
accumulated depreciation
(40,064
)
(34,165
)
Property
and equipment, net
$
17,059
$
22,035
For
the years ended December 31, 2020 and 2019, depreciation expense amounted to $5,899 and $6,660, respectively.
NOTE
6 – CONVERTIBLE NOTE RECEIVABLE
On
March 19, 2020, the Company made an initial investment of $100,000 into KCB Jade Holdings, LLC (“KCB”). In exchange
for the investment, KCB issued to the Company a convertible debenture (the “KCB Debenture”) dated March 19, 2020 (the
“Issuance Date”) in the original principal amount of $100,000. The KCB Debenture bears interest at the rate of 6.5%
per annum and matures on March 19, 2025 (the “Maturity Date”). Interest on the outstanding principal sum of the KCB
Debenture commences accruing on the Issuance Date and is computed on the basis of a 365-day year and the actual number of days
elapsed and shall be payable annually due by the first day of each calendar anniversary following the Issuance Date. KCB may prepay
the KCB Debenture at any point after 18 months following the Issuance Date, in whole or in part. However, if KCB elects to prepay
the KCB Debenture prior to the Maturity Date or prior to any conversion as provided in the KCB Debenture in whole or in part,
the Company will be entitled to receive a number of KCB units, in addition to such prepayment amount, constituting 10% of the
total outstanding units and 10% of the total percentage interest following such issuance and at the time of such issuance.
On
or after six months from the Issuance Date, the Company may convert all or a portion of the principal balance and all accrued
and unpaid interest due into a number of units equal to the proportion of the outstanding amount being converted multiplied by
33% of the total number of units issued and outstanding at the time of conversion, constituting 33% of the total percentage interest
(the “Conversion Percentage”). If KCB defaults on payment of the KCB Debenture, the Company may, at its option, extend
all conversion rights, through and including the date KCB tenders or attempts to tender payment in full of all amounts due under
the KCB Debenture. Conversion rights terminate upon acceptance by the Company of payment in full of principal, accrued interest
and any other amounts due under the KCB Debenture.
F- 15
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
If
(i) KCB does not elect to exercise its rights of prepayment prior to the Maturity Date, (ii) the Company does not elect to exercise
its rights of conversion, and (iii) KCB pays to the Company all outstanding principal and interest accrued and due under the terms
of the KCB Debenture on the Maturity Date, the Company will still be entitled to receive a number of units, in addition to such
payment amount, constituting 8% of the total outstanding units and 8% of the total percentage interest following such issuance
and at the time of such issuance.
Upon
the occurrence of an Event of Default, as defined in the KCB Debenture, the entire principal balance and accrued and unpaid interest
outstanding under the KCB Debenture, and all other obligations of KCB under the KCB Debenture, will be immediately due and payable
and the Company may exercise any and all rights, power and remedies available to it at law or in equity or other appropriate proceeding,
whether for the specific performance of any covenant or agreement contained in the KCB Debenture and proceed to enforce the payment
thereof or any other legal or equitable right of the Company.
Any
amount of principal or interest not paid when due will bear interest at the rate of 12% per annum from the due date thereof until
paid.
On
December 31, 2020, convertible note receivable and interest receivable amounted to $100,000 and $5,129, respectively.
On
February 19, 2021, the Company made an additional investment of $100,000 into KCB. In exchange, the KCB issued to the Company
an amended and restated convertible debenture (the “A&R Debenture”) on February 19, 2021 (the “Amendment
Date”). (See Note - 12 – Subsequent Events).
NOTE
7 – CONVERTIBLE NOTE PAYABLE
On
January 9, 2017, the Company issued a convertible debenture (the “Abrams Debenture”) in the aggregate principal amount
of $2,000,000 in favor of Alan Abrams, who was a significant stockholder of the Company through December 31, 2018, in exchange
for cash from Mr. Abrams of $2,000,000. The Abrams Debenture accrues interest at the rate of 6% per annum payable quarterly by
the 1 st of each quarter and was originally due on January 9, 2022. On January 2, 2019, as part of a Stock Redemption
Agreement, the Company and Mr. Abrams entered into an amendment of the Abrams Debenture (the “Debenture Amendment”),
pursuant to which the parties agreed to extend the maturity date of the Abrams Debenture from January 9, 2022 to January 9, 2030.
Except as set forth herein, the terms of the Abrams Debenture remain in full force and effect.
The
Company may prepay the Abrams Debenture at any point after nine months, in whole or in part. Pursuant to the terms of the Abrams
Debenture, Mr. Abrams is entitled to convert all or a portion of the principal balance and all accrued and unpaid interest due
under the Abrams Debenture into shares of the Company’s common stock at a conversion price of $5.00 per share.
If
the Company defaults on payment, Mr. Abrams may at his option, extend all conversion rights, through and including the date the
Company tenders or attempts to tender payment in full of all amounts due under the Abrams Debenture. Any amount of principal or
interest, which is not paid when due shall bear interest at the rate of 12% per annum. Upon an Event of Default (as defined in
the Abrams Debenture), Mr. Abrams may (i) declare the entire principal amount and all accrued and unpaid interest under the Abrams
Debenture immediately due and payable, and (ii) exercise any and all rights, powers and remedies available to Mr. Abrams at law
or in equity or other appropriate proceeding, whether for the specific performance of any covenant or agreement contained in the
Abrams Debenture and proceed to enforce the payment thereof or any other legal or equitable right of Mr. Abrams.
On
March 1, 2018, the Company and Alan Abrams entered into a Reaffirmation Agreement whereby Mr. Abrams reaffirmed his personal guarantee
of his obligations under certain of the Company’s commercial leases. Additionally, Mr. Abrams affirmed that the principal
of the Abrams Debenture in the principal amount of $2,000,000 was acknowledged as collateral within the scope of the guaranty
included in the commercial lease agreements.
As
of December 31, 2020 and 2019, the principal balance due under the Abrams Debenture is $2,000,000.
As
of December 31, 2020 and 2019, accrued interest payable due under the Abrams Debenture was $30,000 which is included in accrued
expenses on the accompanying consolidated balance sheets.
For
the years ended December 31, 2020 and 2019, interest expense related to the Abrams Debenture amounted to $120,000.
F- 16
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
NOTE
8 – RELATED PARTY TRANSACTIONS
Convertible
notes payable – related parties
On
January 9, 2017, the Company issued a convertible debenture (the “McLaren Debenture”) in the principal amount of $20,000
in favor of Bryan McLaren, the Company’s Chief Executive Officer, President, Chief Financial Officer, and a member of the
Company’s Board of Directors, in exchange for cash from Mr. McLaren of $20,000. The McLaren Debenture accrues interest at
the rate of 6% per annum payable quarterly by the 1 st of each quarter and matures on January 9, 2022. The Company may
prepay the McLaren Debenture at any point after nine months, in whole or in part. Pursuant to the terms of the McLaren Debenture,
Mr. McLaren is entitled to convert all or a portion of the principal balance and all accrued and unpaid interest due under this
McLaren Debenture into shares of the Company’s common stock at a conversion price of $5.00 per share.
If
the Company defaults on payment, Mr. McLaren may at his option, extend all conversion rights, through and including the date the
Company tenders or attempts to tender payment in full of all amounts due under the McLaren Debenture. Any amount of principal
or interest, which is not paid when due shall bear interest at the rate of 12% per annum. Upon an Event of Default (as defined
in the McLaren Debenture), Mr. McLaren may (i) declare the entire principal amount and all accrued and unpaid interest under the
McLaren Debenture immediately due and payable, and (ii) exercise any and all rights, powers and remedies available to Mr. McLaren
at law or in equity or other appropriate proceeding, whether for the specific performance of any covenant or agreement contained
in the McLaren Debenture and proceed to enforce the
As
of December 31, 2020 and 2019, the principal balance due under the McLaren Debenture is $20,000.
As
of December 31, 2020 and 2019, accrued interest payable due under the McLaren Debenture was $4,200 and $3,000, respectively, which
is included in accrued expenses – related parties on the accompanying consolidated balance sheets.
For
the years ended December 31, 2020 and 2019, interest expense – related parties amounted to $1,200.
Stock
redemption agreement
Effective
January 1, 2019, the Company and certain beneficial shareholders entered into a Stock Redemption Agreement (See Note 3 and 9).
Pursuant to SEC rules, each of these beneficial shareholders was deemed to be a “related person” due solely to their
status as significant stockholders of the Company. Pursuant to the terms of the Stock Redemption Agreement, these beneficial shareholders
would no longer be significant stockholders of the Company and would no longer be deemed to be “related persons” under
SEC rules. Accordingly, as of January 1, 2019, the Company will no longer reflect transactions and balances related to these beneficial
shareholders as related party transactions. Prior to January 1, 2019, transactions with these beneficial shareholders were reflected
as related party transactions on the Company’s consolidated financial statements.
NOTE
9 – STOCKHOLDERS’ EQUITY
(A)
Preferred Stock
On
December 13, 2013, the Board of Directors of the Company authorized and approved the creation of a new class of Preferred Stock
consisting of 5,000,000 shares authorized, $.001 par value. The preferred stock is not convertible into any other class or series
of stock. The holders of the preferred stock are entitled to fifty (50) votes for each share held. Voting rights are not subject
to adjustment for splits that increase or decrease the common shares outstanding. Upon liquidation, the holders of the shares
will be entitled to receive $1.00 per share plus redemption provision before assets distributed to other shareholders. The holders
of the shares are entitled to dividends equal to common share dividends. Once any shares of Preferred Stock are outstanding, at
least 51% of the total number of shares of Preferred Stock outstanding must approve the following transactions:
a.
Alter
or change the rights, preferences or privileges of the Preferred Stock.
b.
Create
any new class of stock having preferences over the Preferred Stock.
c.
Repurchase
any of our common stock.
d.
Merge
or consolidate with any other company, except our wholly owned subsidiaries.
e.
Sell,
convey or otherwise dispose of, or create or incur any mortgage, lien, or charge or encumbrance or security interest in or
pledge of, or sell and leaseback, in all or substantially all of our property or business.
f.
Incur,
assume or guarantee any indebtedness maturing more than 18 months after the date on which it is incurred, assumed or guaranteed
by us, except for operating leases and obligations assumed as part of the purchase price of property.
F- 17
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
(B)
Common stock issued for services
2019
On
January 14, 2019, the Company issued an aggregate of 100,000 shares of common stock to the members of the Company’s board
of directors for services rendered. The shares were valued at their fair value of $31,100 using the quoted share price on the
date of grant of $0.311 per common share. In connection with these grants, in January 2019, the Company recorded stock-based compensation
expense of $31,100.
2020
On
January 6, 2020, the Company issued an aggregate of 110,000 shares of common stock to members of the Company’s board of
directors for services rendered. The shares were valued at their aggregate fair value of $24,200 using the quoted per share price
on the date of grant of $0.22. In connection with these grants, in January 2020, the Company recorded stock-based compensation
expense of $24,200 which is included in compensation and benefits on the consolidated statements of operations.
(C)
Equity incentive plans
On
August 9, 2016, the Company’s Board of Directors authorized the 2016 Equity Incentive Plan (the “2016 Plan”)
and reserved 10,000,000 shares of common stock for issuance thereunder. The 2016 Plan was approved by shareholders on November
21, 2016. The 2016 Plan’s purpose is to encourage ownership in the Company by employees, officers, directors and consultants
whose long-term service the Company considers essential to its continued progress and, thereby, encourage recipients to act in
the stockholders’ interest and share in the Company’s success. The 2016 Plan authorizes the grant of awards in the
form of options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended,
options that do not qualify (non-statutory stock options) and grants of restricted shares of common stock. Restricted shares granted
pursuant to the 2016 Plan are amortized to expense over the vesting period. Options vest and expire over a period not to exceed
seven years. If any share of common stock underlying a stock option that has been granted ceases to be subject to a stock option,
or if any shares of common stock that are subject to any other stock-based award granted are forfeited or terminate, such shares
shall again be available for distribution in connection with future grants and awards under the 2016 Plan. As of December 31,
2019, 40,000 stock option awards are outstanding and 40,000 options are exercisable under the 2016 Plan. As of December 31, 2020,
75,000 stock option awards are outstanding and 75,000 options are exercisable under the 2016 Plan. As of December 31, 2020 and
2019, 9,925,000 and 9,960,000 shares are available for future issuance.
The
Company also continues to maintain its 2014 Equity Compensation Plan (the “2014 Plan”), pursuant to which 1,250,000
previously awarded stock options are outstanding. The 2014 Plan has been superseded by the 2016 Plan. Accordingly, no additional
shares subject to the existing 2014 Plan will be issued and the 1,250,000 shares issuable upon exercise of stock options will
be issued pursuant to the 2014 Plan, if exercised. As of December 31, 2020 and 2019, options to purchase 1,250,000 shares of common
stock are outstanding and 1,150,000 options are exercisable pursuant to the 2014 Plan.
(D)
Stock options
On
January 6, 2020, the Company granted an employee an option, pursuant to the 2016 Plan, to purchase 125,000 of the Company’s
common stock at an exercise price of $1.00 per share. The grant date of the option was January 6, 2020 and the option expires
on January 6, 2030. The option vests as to (i) 35,000 of such shares on January 6, 2020; and (ii) as to 10,000 of such shares
on January 6, 2021 and each year thereafter through January 6, 2029. The fair value of this option grant was estimated on the
date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: dividend yield of
0%; expected volatility of 110%; risk-free interest rate of 1.81%; and an estimated holding period of 10 years. In connection
with these options, the Company valued these options at a fair value of $23,388 and will record stock-based compensation expense
over the vesting period. In July 2020, this employee was terminated and 90,000 unvested options were cancelled.
For
the years ended December 31, 2020 and 2019, in connection with the accretion of stock-based option expense, the Company recorded
stock-based compensation expense of $24,231 and $23,612, respectively. As of December 31, 2020, there were 1,325,000 options outstanding
and 1,225,000 options vested and exercisable. As of December 31, 2020, there was $34,582 of unvested stock-based compensation
expense to be recognized through December 2024. The aggregate intrinsic value on December 31, 2020 was nil and was calculated
based on the difference between the quoted share price on December 31, 2020 of $0.43 and the exercise price of the underlying
options.
F- 18
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Stock
option activities for the years ended December 31, 2020 and 2019 are summarized as follows:
Number of
Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Balance Outstanding December 31, 2018
1,290,000
$ 0.99
6.74
$ -
Granted
-
-
-
-
Balance Outstanding December 31, 2019
1,290,000
0.99
5.74
-
Granted
125,000
1.00
-
-
Forfeited
(90,000 )
1.00
-
-
Balance Outstanding December 31,
2020
1,325,000
$ 0.99
4.85
$ -
Exercisable, December 31, 2020
1,225,000
$ 0.99
4.76
-
Balance Non-vested at December 31, 2019
125,000
$ 1.00
-
$ -
Granted
125,000
1.00
-
-
Forfeited
(90,000 )
1.00
-
-
Vested during
the period
(60,000 )
1.00
-
-
Balance Non-vested at December 31,
2020
100,000
$ 1.00
6.00
$ -
(E)
Stock redemption agreement
Effective
January 1, 2019, the Company, Christopher Carra, Alan Abrams, Clayton Abrams Revocable Trust (the “Clayton Abrams Trust”),
and Kyle Abrams Revocable Trust (the “Kyle Abrams Trust” and together with the Clayton Abrams Trust, the “Trusts”)
entered into the Stock Redemption Agreement. Prior to entry into the Stock Redemption Agreement, (i) Mr. Carra was the owner 2,028,335
shares of the Company’s common stock, representing approximately 11.6% of the Company’s outstanding shares as of January
1, 2019, and (ii) Mr. Abrams, together with the Trusts (collectively, the “Abrams Affiliates”), owned 3,611,669 shares
of the Company’s common stock, representing approximately 20.7% of the Company’s outstanding common stock as of January
1, 2019. Pursuant to SEC rules, each of Messrs. Carra and Abrams was deemed to be a “related person” due solely to
their status as significant stockholders of the Company. Pursuant to the terms of the Stock Redemption Agreement, the parties
agreed that the Company would redeem an aggregate of 5,640,004 owned by Mr. Carra and the Abrams Affiliates (the “Stock
Redemption”) such that Messrs. Carra and Abrams would no longer be significant and stockholders of the Company and would
no longer be deemed to be “related persons” under SEC rules. In exchange for the Stock Redemption, the parties agreed
that:
●
The
Company and Broken Arrow, which was owned at the time of the transaction, in whole or in part, directly or indirectly, by
Messrs. Abrams and Carra, amended the Broken Arrow CASA to reduce the gross revenue fee payable by Broken Arrow from 10% of
gross revenue to 0% of gross revenue, and added a $250 an hour advisory fee.
●
The
Company and CJK, which is owned at the time of the transaction, in whole or in part, directly or indirectly, by Messrs. Abrams
and Carra, amended the CJK CASA to reduce the gross revenue fee payable by CJK from 10% of gross revenue to 0% of gross revenue,
and added a $250 an hour advisory fee.
●
The
Company and Mr. Abrams amended the convertible debenture dated January 9, 2017 (the “Abrams Debenture”) to extend
the maturity date of the Abrams Debenture from January 9, 2022 until January 9, 2030.
●
Chino
Valley and Broken Arrow amended the Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018
(the “New Chino Valley Lease”) to increase the monthly base rent payable by Broken Arrow from $35,000 to $40,000.
F- 19
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Following
effectiveness of the Stock Redemption and the transactions set forth above:
●
Messrs.
Carra and Abrams will no longer beneficially own any shares of the Company’s common stock. Accordingly, they will no
longer be significant stockholders of the Company or “related persons” under the SEC rules. Therefore,
transactions between the Company and Carra or Abrams or entities related in whole or in part, directly or indirectly, to Carra
and Abrams have not been reflected as related party transactions in these consolidated financial statements after the effectiveness
of the Stock Redemption.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between Chino Valley and Broken Arrow
will continue in full force and effect, except as amended by the Chino Valley Lease Amendment to increase the monthly base
rent payable by Broken Arrow from $35,000 to $40,000.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between Green Valley and Broken Arrow
will continue in full force and effect.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement (concerning the Company’s Tempe, Arizona property)
dated May 1, 2018 between Zoned Arizona and CJK will continue in full force and effect.
●
The
Licensed Medical Marijuana Facility Triple Net (NNN) Lease Agreement dated May 1, 2018 between Kingman and CJK will continue
in full force and effect.
NOTE
10 - INCOME TAXES
The
Company maintains deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying
amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The deferred
tax assets on December 31, 2020 and 2019 consist of net operating loss carryforwards. The net deferred tax asset has been fully
offset by a valuation allowance because of the uncertainty of the attainment of future taxable income.
The
items accounting for the difference between income taxes at the effective statutory rate and the provision for income taxes for
the years ended December 31, 2020 and 2019 were as follows:
Years
Ended
December 31,
2020
2019
Income
tax benefit at U.S. statutory rate
$ (16,311 )
$ (2,579 )
Income
tax benefit – state
(5,092 )
(798 )
Non-deductible
expenses
6,663
6,920
Change
in valuation allowance
14,740
(3,543 )
Total
provision for income tax
$ -
$ -
The
Company’s approximate net deferred tax asset as of December 31, 2020 and 2019 was as follows:
Deferred
Tax Asset:
December 31,
2020
December 31,
2019
Net
operating loss carryforward
$ 485,172
$ 470,432
Net
deferred tax assets before valuation allowance
485,172
470,432
Valuation
allowance
(485,172 )
(470,432 )
Net
deferred tax asset
$ -
$ -
F- 20
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
The
net operating loss carryforward was approximately $1,764,000 on December 31, 2020. The Company provided a valuation allowance
equal to the net deferred income tax asset as of December 31, 2020 and 2019 because it was not known whether future taxable income
will be sufficient to utilize the loss carryforward. Additionally, the future utilization of the net operating loss carryforward
to offset future taxable income is subject to an annual limitation as a result of ownership changes that occurred in 2014 and
may occur in the future. Based on the Company’s analysis to determine the limitation on the utilization of its net operating
loss carryforward amounts, in 2018, the deferred tax asset was reduced by any carryforward that cannot be utilized or expires
prior to utilization as a result of such limitations, with a corresponding reduction of the valuation allowance. In 2020, the
valuation allowance increased by $14,740. The potential tax benefit arising from the loss carryforward will expire in 2040.
The
Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2020,
2019 and 2018 Corporate Income Tax Returns are subject to Internal Revenue Service examination.
NOTE
11 – COMMITMENTS AND CONTINGENCIES
Rental
property acquisition
On
April 22, 2016, Zoned Colorado, a wholly owned subsidiary of the Company, entered into a Contract to Buy and Sell Real Estate
(the “Parachute Agreement”) with Parachute Development Corporation (“Seller”) pursuant to which Zoned
Colorado agreed to purchase, and Seller agreed to sell, property in Parachute, Colorado (the “Property”) for a purchase
price of $499,857. Of the total purchase price, $274,857, or 55%, will be paid in cash at closing and $225,000, or 45%, will be
financed by Seller at an interest rate of 6.5%, amortized over a five-year period, with a balloon payment at the end of the fifth
year. Payments will be made monthly and there will be no pre-payment penalty. Pursuant to the terms of the Parachute Agreement,
the parties will cooperate in good faith to complete due diligence during a period of 45 days following execution of the Parachute
Agreement. The closing is subject to certain contingencies, including that Zoned Colorado must obtain acceptable financing for
the purchase and development of the Property, the grant of a special use permit by the Town of Parachute, approval of a protected
development deal or equivalent agreement by the Town of Parachute, execution of a lease agreement by a prospective tenant and
the prospective tenant’s obtaining a license to cultivate on the Property.
Pursuant
to the terms of the Parachute Agreement, Zoned Colorado will have a right of first refusal on eleven additional lots owned by
Seller in Parachute, Colorado. In April 2016, the Company paid a refundable deposit of $45,000 into escrow in connection with
the Parachute Agreement which is included in prepaid expenses and other assets on the consolidated balance sheets as of December
31, 2020 and 2019. In January 2021, the Parachute Agreement was mutually terminated, and the refundable deposit was returned to
the Company (See Note 12).
Legal
matters
From
time to time, the Company may be involved in litigation related to claims arising out of its operations in the normal course of
business. As of December 31, 2020 and 2019, the Company is not involved in any pending or threatened legal proceedings that it
believes could reasonably be expected to have a material adverse effect on its financial condition, results of operations, or
cash flows.
Confidential
Advisory Services Agreements
On
May 1, 2018, the Company entered into that certain Confidential Advisory Services Agreement by and between the Company and Broken
Arrow (the “Broken Arrow CASA”), with a term expiring on April 30, 2040, unless earlier terminated as provided in
the Broken Arrow CASA. Additionally, on May 1, 2018, the Company entered into that certain Confidential Advisory Services Agreement
by and between the Company and CJK (the “CJK CASA” and together with the Broken Arrow CASA, the “CASAs”),
with a term expiring on April 30, 2040, unless earlier terminated as provided in the CJK CASA. The CASAs may be terminated prior
to the expiration of their respective term upon the occurrence of any of the following: (a) by the Company for any reason at any
time upon thirty calendar days’ written notice to the other party; (b) by either party immediately upon the mutual agreement
of the parties, evidenced by a writing signed by the parties; or (c) immediately by either party in the event of an actual finding,
by a court of competent jurisdiction, of fraud, gross negligence or willful misconduct of the other party in connection with the
CASAs. Pursuant to the terms of the CASAs, Broken Arrow and CJK engaged the Company to perform certain advisory services in exchange
for a fee equal to 10% of Broken Arrow’s and CJK’s gross revenues (the “Revenue Fee”). Effective January
1, 2019, the parties agreed to amend the May 1, 2018 leases to reduce the Revenue Fee payable pursuant to each of the CASAs from
10% of gross revenue to 0% of gross revenue.
F- 21
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
Effective
January 1, 2019, the Company and Messrs. Abrams and Carra or entities controlled by Messrs. Abrams and Carra entered into Stock
Redemption Agreements (see Note 9). Prior to entry into the Stock Redemption Agreement, pursuant to the terms of the Stock Redemption
Agreement, the parties agreed that the Company would redeem an aggregate of 5,640,004 owned by such related party shareholders’
in exchange for the Stock Redemption. In addition to other terms, the parties agreed to amend the May 1, 2018 leases to reduce
the gross revenue fee payable by these related party tenants from 10% of gross revenue to 0% of gross revenue (See Note 3).
Employment
and Related Golden Parachute Agreement
On
May 23, 2018, the Company and Mr. McLaren, the Company’s President, Chief Executive Officer, Chief Financial Officer and
Chairman of the Board, agreed to replace Mr. McLaren’s 2014 employment agreement with a new employment agreement dated May
23, 2018 (the “2018 Employment Agreement”). Pursuant to the terms of the 2018 Employment Agreement, the Company agreed
to continue to pay Mr. McLaren his then-current base annual salary of $215,000, and to award Mr. McLaren with an annual and/or
quarterly bonus payable in either cash and/or equity of no less than 2% of the Company’s net income for the associated period.
The
2018 Employment Agreement has a term of 10 years. The term and Mr. McLaren’s employment will terminate (a “Termination”)
in any of the following circumstances:
(i)
immediately,
if Mr. McLaren dies;
(ii)
immediately,
if Mr. McLaren receives benefits under the long-term disability insurance coverage then provided by the Company or, if no
such insurance is in effect, upon Mr. McLaren’s disability;
(iii)
on
the expiration date, as the same may be extended by the parties by written amendment to the 2018 Employment Agreement prior
to the occasion thereof;
(iv)
at
the option of the Company for Cause (as defined in the 2018 Employment Agreement) upon the Company’s provision of written
notice to Mr. McLaren of the basis for such Termination;
(v)
at
the option of the Company, without Cause;
(vi)
by
Mr. McLaren at any time with Good Reason (as defined in the 2018 Employment Agreement), upon 30 days’ prior written
notice to the Company delivered not later than within 90 days of the existence of the condition therefor; or
(vii)
by
Mr. McLaren at any time without Good Reason, upon not less than three months’ prior written notice to the Company.
In
the event of a Termination for any reason or for no reason whatsoever, or upon the expiration date of the 2018 Employment Agreement,
whichever comes first, all rights and obligations under the 2018 Employment Agreement shall cease (i) as to the Company, except
for the Company’s obligations for the payment of applicable severance benefits thereunder, and for indemnification thereunder,
and (ii) as to Mr. McLaren, except for his obligation under the restrictive covenants in the 2018 Employment Agreement.
The
Company and Mr. McLaren also entered into a Golden Parachute Agreement (the “Golden Parachute Agreement”) on May 23,
2018. No benefits shall be payable under the Golden Parachute Agreement unless there shall have been a change in control of the
Company, as set forth below. For purposes of the Golden Parachute Agreement, amongst other terms in the Golden Parachute Agreement,
a “change in control of the Company” shall mean a change of control of a nature that would be required to be reported
in response to Item 6(e) of Schedule 14A of Regulation 14A promulgated under the Securities Exchange Act of 1934, as amended.
For
purposes of the Golden Parachute Agreement, “Cause” means termination upon (a) the willful and continued failure to
substantially perform duties with the Company after a written demand for substantial performance is delivered by the Board, which
demand specifically identifies the manner in which the Board believes that duties have not substantially been performed, or (b)
the willful engaging in conduct, which is demonstrably and materially injurious to the Company, monetarily or otherwise.
For
purposes of the Golden Parachute Agreement, “Good Reason” means, without express written consent, the occurrence after
a change in control of the Company of any of the following circumstances unless, such circumstances are fully corrected prior
to the date of Termination specified in the notice of Termination:
(a)
a
material diminution in Mr. McLaren’s authority, duties or responsibility from those in effect immediately prior to the
change in control of the Company;
(b)
a
material diminution in Mr. McLaren’s base compensation;
(c)
a
material change in the geographic location at which Mr. McLaren performs his duties;
(d)
a
material diminution in the authority, duties, or responsibilities of the supervisor to whom Mr. McLaren is required to report,
including a requirement that Mr. McLaren report to a corporate officer or employee instead of reporting directly to the Board;
F- 22
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
(e)
a
material diminution in the budget over which Mr. McLaren retains authority;
(f)
a
material breach under any agreement with the Company to continue in effect any bonus to which Mr. McLaren was entitled, or
any compensation plan in which Mr. McLaren participates immediately prior to the change in control of the Company which is
material to Mr. McLaren’s total compensation;
(g)
a
material breach under any agreement with the Company to provide Mr. McLaren benefits substantially similar to those enjoyed
by him under any of the Company’s life insurance, medical, health and accident, or disability plans in which he was
participating at the time of the change in control of the Company, the failure to continue to provide Mr. McLaren with a Company
automobile or allowance in lieu of it, if Mr. McLaren was provided with such an automobile or allowance in lieu of it at the
time of the change of control of the Company, the taking of any action by the Company which would directly or indirectly materially
reduce any of such benefits or deprive him of any material fringe benefit enjoyed by him at the time of the change in control
of the Company, or the failure by the Company to provide him with the number of paid vacation days to which he is entitled
on the basis of years of service with the Company in accordance with the Company’s normal vacation policy in effect
at the time of the change in control of the Company;
Following
a change in control of the Company, upon termination of Mr. McLaren’s employment or during a period of disability, Mr. McLaren
will be entitled to the following benefits:
(i)
During
any period that he fails to perform his full-time duties with the Company as a result of incapacity due to physical or mental
illness, Mr. McLaren will continue to receive his base salary at the rate in effect at the commencement of any such period,
together with all amounts payable to him under any compensation plan of the Company during such period, until the Golden Parachute
Agreement is terminated.
(ii)
If
Mr. McLaren’s employment is terminated by the Company for Cause or by Mr. McLaren other than for Good Reason, disability,
death or retirement, the Company will pay Mr. McLaren his full base salary through the date of Termination at the rate in
effect at the time notice of Termination is given, plus all other amounts and benefits to which he is entitled under any compensation
plan of the Company at the time such payments are due.
(iii)
If
employment by the Company shall be terminated (a) by the Company other than for Cause, death or disability or (b) by Mr. McLaren
for Good Reason, Mr. McLaren will be entitled to benefits provided below:
a.
The
Company will pay Mr. McLaren his full base salary through the date of Termination at the rate in effect at the time notice
of Termination is given, plus all other amounts and benefits to which he is entitled under any compensation plan of the Company.
b.
In
lieu of any further salary payments to Mr. McLaren for periods subsequent to the date of Termination, the Company will pay
as severance pay to Mr. McLaren a lump sum severance payment (together with the payments provided in clauses (c) and (d) below)
equal to five times the sum of his annual base salary in effect immediately prior to the occurrence of the circumstance giving
rise to the notice of Termination given in respect of them.
c.
The
Company will pay to Mr. McLaren any deferred compensation allocated or credited to him or his account as of the date of Termination.
d.
In
lieu of shares of common stock of the Company issuable upon exercise of outstanding options, if any, granted to Mr. McLaren
under the Company’s stock option plans (which options shall be cancelled upon the making of the payment referred to
below), Mr. McLaren will receive an amount in cash equal to the product of (i) the excess of the closing price of the Company’s
common stock as reported on or nearest the date of Termination (or, if not so reported, on the basis of the average of the
lowest asked and highest bid prices on or nearest the date of Termination), over the per share exercise price of each option
held by Mr. McLaren (whether or not then fully exercisable) plus the amount of any applicable cash appreciation rights, times
(ii) the number of the Company’s common stock covered by each such option.
e.
The
Company will also pay to Mr. McLaren all legal fees and expenses incurred by him as a result of such Termination.
F- 23
ZONED
PROPERTIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2020 AND 2019
NOTE
12 – SUBSEQUENT EVENTS
On
January 1, 2021, the Company granted a consultant an option, pursuant to the 2016 Plan, to purchase 125,000 of the Company’s
common stock at an exercise price of $1.00 per share. The grant date of the option was January 1, 2021 and the option expires
on January 1, 2031. The option vests as to (i) 25,000 of such shares on January 1, 2021; and (ii) as to 10,000 of such shares
on January 1, 2022 and each year thereafter through January 1, 2031. The fair value of this option grant was estimated on the
date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: dividend yield of
0%; expected volatility of 117%; risk-free interest rate of 0.93%; and an estimated holding period of 10 years. In connection
with these options, the Company valued these options at a fair value of $48,677 and will record stock-based compensation expense
over the vesting period.
On
January 31, 2021, the Company issued an aggregate of 130,000 shares of common stock to members of the Company’s board of
directors for services rendered. The shares were valued at their aggregate fair value of $52,000 using the quoted per share price
on the date of grant of $0.40. In connection with these grants, in January 2021, the Company recorded stock-based compensation
expense of $52,000 which will be included in compensation and benefits on the consolidated statements of operations.
In
January 2021, the Parachute Agreement was mutually terminated, and the refundable deposit was returned to the Company (see Note
11).
On
February 19, 2021 (the “Amendment Date”), the Company made an additional investment of $100,000 into KCB (the “Additional
Investment”) (See Note 6). In exchange, KCB issued to the Company an amended and restated convertible debenture (the “A&R
Debenture”) on the Amendment Date. The A&R Debenture amends and restates in its entirety the KCB Debenture (see Note
6). Pursuant to the A&R Debenture, the Company and KCB agreed to certain new terms that did not exist in the KCB Debenture,
which are described below.
● Interest
Accrual Commencement : Pursuant to the A&R Debenture, interest on the Initial
Investment begins accruing as of March 19, 2020, while interest on the Additional Investment
begins accruing on February 19, 2021.
● Franchise
Fees . In the A&R Debenture, the parties acknowledge that each time that KCB sells
one of its franchise locations, KCB earns a fee (an “Initial Fee”), and that
KCB also earns a fee when one of its franchise locations renews its franchise with KCB
(a “Renewal Fee”). Pursuant to the A&R Debenture, the Company and KCB
agreed that, as additional consideration for the Additional Investment, KCB will pay
to the Company, in perpetuity, 5% of any Initial Fee received by KCB after the Amendment
Date, as well as 5% of any Renewal Fee received by KCB related to any franchise locations
sold after the Amendment Date, in each case to be paid within five (5) days of receipt
of KCB thereof.
In
addition, following the Amendment Date, KCB agreed not to decrease the amount it charges its franchise locations for an Initial
Fee or any Renewal Fee as in effect on the Amendment Date without the prior written consent of the Company, or to take any other
actions that would reduce the value of KCB’s obligation to the Company with respect to these franchise fee payments. KCB’s
obligation to pay the Company the franchise fees listed above will survive any termination, repayment or conversion of the A&R
Debenture. Failure by KCB to pay the Company the franchise fees in the manner described above will result in an event of default,
and, among other things, any due and unpaid franchise fees will accrue interest at 12% per year from the date the obligation was
due.
Apart
from the terms described above, the terms of the A&R Debenture are substantially identical to the terms of the KCB Debenture
(See Note 6).
On
March 3, 2021, Gilbert entered into that certain Commercial Lease Agreement (the “Lease”), dated as of February 26,
2021, between Gilbert and AZ2CAL Enterprises, LLC (the “Tenant”). Pursuant to the terms of the Lease, Gilbert agreed
to rent its vacant land in Gilbert, AZ (the “Property”) to the Tenant for a term of 24 months, from April 1, 2021
to March 31, 2023, for monthly rent of $2,750; provided, however, that no rent is due for the month of April 2021. In addition,
pursuant to the terms of the Lease, the Tenant has an option to purchase the Property (the “Option”) that can be exercised
any time after the fourth month of the lease term, but no later than the end of the 12 th month of the lease term. The
purchase price of the Property would be $335,000. If the Tenant exercises its Option, $750 of each lease payment made prior to
close of escrow, along with the security deposit will be credited toward the purchase price of the Property. If the Tenant exercises
its Option, close of escrow will occur no later than 30 days after opening of escrow. The parties agreed to make every reasonable
attempt to fully execute a purchase contract within seven business days of the Tenant’s notice of its desire to exercise
the Option.
On
March 17, 2021, the Company formed a new wholly-owned subsidiary, Zoned Brokerage, LLC. that was organized in the State of Arizona.
F- 24
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.